Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 617
Encontrada(s) 7 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

  • Payo Serafín, Tania
  • Méndez Blanco, Carolina
  • Fernández Palanca, Paula
  • Martínez Geijo, Jennifer
  • Reviejo, María
  • Ortiz de Urbina, Juan José
  • González Gallego, Javier
  • García Marín, José Juan
  • Mauriz Gutiérrez, José Luis
  • San Miguel de Vega, Beatriz
[EN]Although the treatment landscape has rapidly evolved over the last years, hepatocellular carcinoma (HCC) is one of the most lethal cancers. With recent advances, both immunotherapy and tyrosine kinase inhibitors (TKIs)-based chemotherapy constitute the standard treatment for advanced HCC. A systematic search of randomized clinical trials employing TKIs was performed in 17 databases, obtaining 25 studies evaluating the prognosis, tumor response, and presence of adverse events (AEs) related to TKIs in HCC. Overall effect sizes were estimated for the hazard ratios (HR) and odds ratios (OR) with 95% confidence interval (CI), either extracted or calculated with the Parmar method, employing STATA 16. Heterogeneity was assessed by Chi-square-based Q-test and inconsistency (I2) statistic; source of heterogeneity by meta-regression and subgroup analysis; and publication bias by funnel plot asymmetry and Egger's test. The research protocol was registered in PROSPERO (CRD42023397263). Meta-analysis revealed a correlation between survival and tumor response parameters and TKI treatment vs. placebo, despite detecting high heterogeneity. Combined TKI treatment showed a significantly better objective response rate (ORR) with no heterogeneity, whereas publication bias was only detected with time to progression (TTP). Few gastrointestinal and neurological disorders were associated with TKI treatment vs. placebo or with combined treatment. However, a higher number of serious AEs were related to TKI treatment vs. sorafenib alone. Results show positive clinical benefits from TKI treatment, supporting the approval and maintenance of TKI-based therapy for advanced HCC, while establishing appropriate strategies to maximize efficacy and minimize toxicity., SI, Publicación en abierto financiada por el Consorcio de Bibliotecas Universitarias de Castilla y León (BUCLE), con cargo al Programa Operativo 2014ES16RFOP009 FEDER 2014-2020 DE CASTILLA Y LEÓN, Actuación:20007-CL - Apoyo Consorcio BUCLE
Docta Complutense
Publicación Artículo científico (JournalArticle)

Antipsychotic medication influences the discriminative value of acylethanolamides as biomarkers of substance use disorder

  • Herrera-Imbroda, Jesús
  • Flores-López, María
  • Requena-Ocaña, Nerea
  • Araos, Pedro
  • Ropero, Jessica
  • García Marchena, Nuria
  • Bordallo, Antonio
  • Suarez, Juan
  • Pavón-Morón, Francisco Javier
  • Serrano, Antonia
  • Mayoral, Fermín
  • Rodríguez De Fonseca, Fernando Antonio
Plasma acylethanolamides (NAEs), including the endocannabinoid anandamide (AEA), have been proposed as circulating biomarkers of substance use disorders. However, the concentration of these lipid transmitters might be influenced by the use of drugs prescribed for either the treatment of addiction or the associated psychiatric co-morbidities such as psychosis. As an example, neuroleptics, used for attenuation of psychotic symptoms and sedation, might theoretically interfere with the monoamine-mediated production of NAEs, obstructing the interpretation of plasma NAEsasclinical biomarkers. To solve the lack of information on the impact of neuroleptics on the concentration of NAEs, we evaluated the concentrations of NAEs in a control group and compared them to those present in (a) substance use disorders (SUD) patients that are not prescribed with neuroleptics, and (b) SUD patients (both alcohol use disorder and cocaine use disorder patients) using neuroleptics. The results demonstrate that SUD patients exhibited greater concentrations of NAEsthan the control population, affecting all species with the exception of stearoylethanolamide (SEA) and palmitoleoylethanolamide (POEA). Neuroleptic treatment enhanced the concentrations of NAEs, especially those of AEA, linoleoylethanolamide (LEA), and oleoylethanolamide (OEA). This effect of neuroleptic treatment was observed independently of the drug addiction that motivated the demand for treatment (either alcohol or cocaine). This study remarks the need to control the current use of psychotropic medication as a potential confounding variable when considering the use of NAEsasbiomarkers in SUD.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Bicalutamide Enhances Conventional Chemotherapy in In Vitro and In Vivo Assays Using Human and Canine Inflammatory Mammary Cancer Cell Lines

  • Crespo, Belén
  • Illera Del Portal, Juan Carlos
  • Silván Granado, Gema
  • López Plaza, Paula
  • Herrera de la Muela, María
  • De la Puente Yagüe, Miriam
  • Díaz Del Arco, Cristina
  • Andrés Gamazo, Paloma Jimena de
  • Illera, María José
  • Cáceres Ramos, Sara Cristina
Human inflammatory breast cancer (IBC) and canine inflammatory mammary cancer (IMC) are highly aggressive neoplastic diseases that share numerous characteristics. In IBC and IMC, chemotherapy produces a limited pathological response and anti-androgen therapies have been of interest for breast cancer treatment. Therefore, the aim was to evaluate the effect of a therapy based on bicalutamide, a non-steroidal anti-androgen, with doxorubicin and docetaxel chemotherapy on cell proliferation, migration, tumor growth, and steroid-hormone secretion. An IMC-TN cell line, IPC-366, and an IBC-TN cell line, SUM149, were used. In vitro assays revealed that SUM149 exhibited greater sensitivity, reducing cell viability and migration with all tested drugs. In contrast, IPC-366 exhibited only significant in vitro reductions with docetaxel as a single agent or in different combinations. Decreased estrogen levels reduced in vitro tumor growth in both IMC and IBC. Curiously, doxorubicin resulted in low efficacy, especially in IMC. In addition, all drugs reduced the tumor volume in IBC and IMC by increasing intratumoral testosterone (T) levels, which have been related with reduced tumor progression. In conclusion, the addition of bicalutamide to doxorubicin and docetaxel combinations may represent a potential treatment for IMC and IBC.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Dihydropyrimidinase-Related Protein 2 Is a New Partner in the Binding between 4E-BP2 and eIF4E Related to Neuronal Death after Cerebral Ischemia

  • Martínez-Alonso, Emma
  • Escobar-Peso, Alejandro
  • Guerra Pérez, Natalia
  • Roca, Marcel
  • Masjuan, Jaime
  • Alcázar, Alberto
Transient cerebral ischemia induces neuronal degeneration, followed in time by secondary delayed neuronal death that is strongly correlated with a permanent inhibition of protein synthesis in vulnerable brain regions, while protein translational rates are recovered in resistant areas. In the translation-regulation initiation step, the eukaryotic initiation factor (eIF) 4E is a key player regulated by its association with eIF4E-binding proteins (4E-BPs), mostly 4E-BP2 in brain tissue. In a previous work, we identified dihydropyrimidinase-related protein 2 (DRP2) as a 4E-BP2-interacting protein. Here, using a proteomic approach in a model of transient cerebral ischemia, a detailed study of DRP2 was performed in order to address the challenge of translation restoration in vulnerable regions. In this report, several DRP2 isoforms that have a specific interaction with both 4E-BP2 and eIF4E were identified, showing significant and opposite differences in this association, and being differentially detected in resistant and vulnerable regions in response to ischemia reperfusion. Our results provide the first evidence of DRP2 isoforms as potential regulators of the 4E-BP2–eIF4E association that would have consequences in the delayed neuronal death under ischemic-reperfusion stress. The new knowledge reported here identifies DRP2 as a new target to promote neuronal survival after cerebral ischemia.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Microfluidic-assisted synthesis of integrin-targeting cRGD liposomes as a scalable strategy for theranostic applications in triple-negative breast cancer

  • Ovejero Paredes, Karina
  • Giovanni Bisbano
  • Inge Flier
  • Alejandro Gonzalez-Simon
  • Marciello, Marzia
  • Sabrina Oliveira
  • Marco Zupi
  • Davide Rubes
  • Fatima Ayash
  • Filippo Doria
  • Valentina Pirota
  • Marco Terreni
  • Massimo Serra
  • Filice, Marco
Triple negative breast cancer (TNBC) represents one of the most aggressive types of cancer, with a difficult treatment leading to poor prognosis of the disease. Herein we report the synthesis of a custom-made cyclic RGD peptide (cRGD), and its use in decorating liposomes for targeted drug delivery of doxorubicin to TNBC cells overexpressing integrin receptor αvβ3. Liposomes carrying dibenzocyclooctine groups on their surface were produced using an optimized large scale microfluidic-assisted approach and subsequently conjugated with cRGD bearing an acyl azide group by means of a click chemistry reaction. This functionalization promotes enhanced cellular uptake via integrin-mediated endocytosis. In vitro assessments confirm enhanced selectivity and cytotoxicity of cRGD-liposomes against triple-negative cancer cells, in addition to dual imaging capabilities by fluorescence and magnetic resonance techniques due to the incorporation of a fluorescent dye and gadolinium complex, respectively. These features support the potential of cRGD-liposomes as a promising platform for targeted drug delivery to specific cancer cell populations, establishing them as viable theranostic agents for precision medicine applications.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables

  • Wicke, Pablo Delgado
  • Fernández de Córdoba Oñate, Sara
  • Roy Vallejo, Emilia
  • Alegría Carrasco, Estibaliz
  • Rodríguez Serrano, Diego A.
  • Lamana Domínguez, Amalia
  • Montes, Nuria
  • Nicolao Gómez, Ana
  • Carracedo Rodríguez, Rosa
  • Marcos Jiménez, Ana
  • Díaz Fernández, Paula
  • Galván Román, José M.
  • Rabes Rodríguez, Laura
  • Sanz Alba, Marta
  • Álvarez Rodríguez, Jesús
  • Villa Martí, Almudena
  • Rodríguez Franco, Carlos
  • Villapalos García, Gonzalo
  • Zubiaur, Pablo
  • Abad Santos, Francisco
  • De los Santos, Ignacio
  • Pérez Gomáriz, Rosa María
  • García Vicuña, Rosario
  • Muñoz Calleja, Cecilia
  • González Álvaro, Isidoro
  • Fernández Ruiz, Elena
  • Suárez Fernández, Carmen
  • Barrios, Ana
  • Sanz, Jesús
  • Casado, Pedro
  • Gutiérrez, Ángela
  • Bautista, Azucena
  • Hernández, Pilar
  • Ruiz Giménez, Nuria
  • Moyano, Berta
  • Gil, Paloma
  • Delgado, María Jesús
  • Parra, Pedro
  • Sánchez, Beatriz
  • Sáez, Carmen
  • Fernández Rico, Marta
  • Arévalo Román, Cristina
  • Ciudad, Marianela
  • Castañeda, Santos
  • Llorente, Irene
  • Tomero, Eva G.
  • García Castañeda, Noelia
  • Uriarte, Miren
  • Cardeñoso, Laura
  • Fontán García-Rodrigo, Leticia
  • Domingo García, Diego
  • Alarcón Cavero, Teresa
  • Semiglia Chong, María Auxiliadora
  • Gutiérrez Cobos, Ainhoa
  • Zurita Cruz, Nelly D.
  • Sánchez Madrid, Francisco
  • Martín Gayo, Enrique
  • Sánchez Cerrillo, Ildefonso
  • Martínez Fleta, Pedro
  • López Sanz, Celia
  • Gabrie, Ligia
  • Del Campo Guerola, Luciana
  • Tejedor, Reyes
  • Ancochea, Julio
  • García Castillo, Elena
  • Ávalos, Elena
  • Sánchez Azofra, Ana
  • Alonso, Tamara
  • Cisneros, Carolina
  • Valenzuela, Claudia
  • García Pérez, Francisco J.
  • Girón, Rosa M.
  • Aspa, Javier
  • Marcos, Celeste
  • Socorro Churruca, M. del Perpetuo
  • Zamora, Enrique
  • Martínez, Adrián
  • Barrio Mayo, Mar
  • Henares Espi, Rosalina
  • Méndez, Rosa
  • Arribas, David
  • Chicot Llano, Marta
  • González, Begoña
  • Quicios, Begoña
  • Patiño, Pablo
  • Trigueros, Marina
  • Dominguez Peña, Cristina
  • Jiménez Jiménez, David
  • Villamayor, Pablo
  • Canabal, Alfonso
  • De la Cámara, Rafael
  • Ortiz, Javier
  • Iturrate, Isabel
The characteristics of the host are crucial in the final outcome of COVID-19. Herein, the influence of genetic and clinical variants in COVID-19 severity was investigated in a total of 1350 patients. Twenty-one single nucleotide polymorphisms of genes involved in SARS-CoV-2 sensing as Toll-like-Receptor 7, antiviral immunity as the type I interferon signalling pathway (TYK2, STAT1, STAT4, OAS1, SOCS) and the vasoactive intestinal peptide and its receptors (VIP/VIPR1,2) were studied. To analyse the association between polymorphisms and severity, a model adjusted by age, sex and different comorbidities was generated by ordinal logistic regression. The genotypes rs8108236-AA (OR 0.12 [95% CI 0.02–0.53]; p = 0.007) and rs280519-AG (OR 0.74 [95% CI 0.56–0.99]; p = 0.03) in TYK2, and rs688136-CC (OR 0.7 [95% CI 0.5–0.99]; p = 0.046) in VIP, were associated with lower severity; in contrast, rs3853839-GG in TLR7 (OR 1.44 [95% CI 1.07–1.94]; p = 0.016), rs280500-AG (OR 1.33 [95% CI 0.97–1.82]; p = 0.078) in TYK2 and rs1131454-AA in OAS1 (OR 1.29 [95% CI 0.95–1.75]; p = 0.110) were associated with higher severity. Therefore, these variants could influence the risk of severe COVID-19.
Docta Complutense
Publicación Artículo científico (JournalArticle)

BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury

  • Saiz, M. L.
  • Lozano-Chamizo, L.
  • Florez, A. B.
  • Marciello, Marzia
  • Diaz-Bulnes, P.
  • Corte-Iglesias, V.
  • Bernet, C. R.
  • Rodrigues-Diez, R. R.
  • Martin-Martin, C.
  • Rodriguez-Santamaria, M.
  • Fernandez-Vega, I.
  • Rodriguez, R. M.
  • Diaz-Corte, C.
  • Suarez-Alvarez, B.
  • Filice, Marco
  • Lopez-Larrea, C.
Targeting epigenetic mechanisms has emerged as a potential therapeutic approach for the treatment of kidney diseases. Specifically, inhibiting the bromodomain and extra-terminal (BET) domain proteins using the small molecule inhibitor JQ1 has shown promise in preclinical models of acute kidney injury (AKI) and chronic kidney disease (CKD). However, its clinical translation faces challenges due to issues with poor pharmacokinetics and side effects. Here, we developed engineered liposomes loaded with JQ1 with the aim of enhancing kidney drug delivery and reducing the required minimum effective dose by leveraging cargo protection. These liposomes efficiently encapsulated JQ1 in both the membrane and core, demonstrating superior therapeutic efficacy compared to freely delivered JQ1 in a mouse model of kidney ischemia-reperfusion injury. JQ1-loaded liposomes (JQ1-NPs) effectively targeted the kidneys and only one administration, one-hour after injury, was enough to decrease the immune cell (neutrophils and monocytes) infiltration to the kidney—an early and pivotal step to prevent damage progression. By inhibiting BRD4, JQ1-NPs suppress the transcription of pro-inflammatory genes, such as cytokines (il-6) and chemokines (ccl2, ccl5). This success not only improved early the kidney function, as evidenced by decreased serum levels of BUN and creatinine in JQ1-NPs-treated mice, along with reduced tissue expression of the damage marker, NGAL, but also halted the production of extracellular matrix proteins (Fsp-1, Fn-1, α-SMA and Col1a1) and the fibrosis development. In summary, this work presents a promising nanotherapeutic strategy for AKI treatment and its progression and provides new insights into renal drug delivery.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Comprehensive analysis of GDF15 as a biomarker in primary mitochondrial myopathies

  • Martín-Jiménez, Paloma
  • Bermejo-Guerrero, Laura
  • Navarro-Riquelme, María
  • Serrano-Lorenzo, Pablo
  • Garrido-Moraga, Rocío
  • Hernández-Laín, Aurelio
  • Hernández-Voth, Ana
  • Lora Pablos, David
  • Morales Conejo, Montserrat
  • Arenas Barbero, Joaquín
  • Blázquez, Alberto
  • Martín, Miguel Ángel
  • Domínguez-González, Cristina
Background and objectives: Mitochondrial diseases are caused by defects in oxidative phosphorylation, with primary mitochondrial myopathies (PMM) being a subset where muscle involvement is predominant. PMM presents symptoms ranging from exercise intolerance to progressive muscle weakness, often involving ocular muscles, leading to ptosis and progressive external ophthalmoplegia (PEO). PMM can be due to variants in mitochondrial or nuclear DNA. Growth differentiation factor 15 (GDF15) has been identified as an accurate biomarker for mitochondrial dysfunction. This study evaluates the utility of GDF15 as a biomarker for monitoring PMM. Methods: This observational study involved 50 adult PMM patients. Clinical data were collected alongside functional motor outcomes measured by the Motor Research Council scale, 6-min walk test, North Star Ambulatory Assessment, and 100-m run test (100MRT). Biomarkers including serum lactate, creatine kinase (CK), creatinine, and plasma GDF15 were assessed. Results: Patients exhibited diverse phenotypes, including exercise intolerance (8 %), progressive myopathy (22 %), isolated PEO (24 %), and PEO plus (42 %). Significant correlations were found among motor function tests, with 100MRT being particularly sensitive. Biomarker analysis showed elevated lactate in 32 %, elevated CK in 54 %, reduced creatinine in 76 %, and elevated GDF15 in 86 % of cases. GDF15 levels correlated with motor performance, lactate levels, and mtDNA mutation load in muscle. Creatinine levels were strongly linked to disease severity. Discussion: This study underscores the heterogeneity of PMM and the importance of reliable biomarkers. GDF15 was consistently elevated across all PMM phenotypes and genotypes, correlating well with disease severity. Reduced creatinine also emerged as a potential prognostic marker.
Docta Complutense
Publicación Artículo científico (JournalArticle)

High enhancement of sensitivity and reproducibility in label-free SARS-CoV-2 detection with graphene field-effect transistor sensors through precise surface biofunctionalization control

  • Lozano-Chamizo, L.
  • Márquez, C.
  • Marciello, Marzia
  • Galdon, J. C.
  • de la Fuente-Zapico, E.
  • Martinez-Mazón, P.
  • Gonzalez-Rumayor, V.
  • Filice, Marco
  • Gamiz, F.
The COVID-19 pandemic has taught us valuable lessons, especially the urgent need for a widespread, rapid and sensitive diagnostic tool. To this, the integration of bidimensional nanomaterials, particularly graphene, into point-of-care biomedical devices is a groundbreaking strategy able to potentially revolutionize the diagnostic landscape. Despite advancements in the fabrication of these biosensors, the relationship between their surface biofunctionalization and sensing performance remains unclear. Here, we demonstrate that the combination of careful sensor fabrication and its precise surface biofunctionalization is crucial for exalting the sensing performances of 2D biosensors. Specifically, we have biofunctionalized Graphene Field-Effect Transistor (GFET) sensors surface through different biochemical reactions to promote either random/heterogeneous or oriented/homogeneous immobilization of the Anti-SARS-CoV-2 spike protein antibody. Each strategy was thoroughly characterized by in-silico simulations, physicochemical and biochemical techniques and electrical characterization. Subsequently, both biosensors were tested in the label-free direct titration of SARS-CoV-2 virus in simulated clinical samples, avoiding sample preprocessing and within short timeframes. Remarkably, the oriented GFET biosensor exhibited significantly enhanced reproducibility and responsiveness, surpassing the detection sensitivity of conventional non-oriented GFET by more than twofold. This breakthrough not only involves direct implications for COVID-19 surveillance and next pandemic preparedness but also clarify an unexplored mechanistic dimension of biosensor research utilizing 2D-nanomaterials.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Inherited human ezrin deficiency impairs adaptive immunity

  • García-Solís, Blanca et al.
  • Rebeca Pérez de Diego
  • Martínez Martínez, Laura María
  • Recio Hoyas, María José
  • Fernández Arquero, Miguel
  • Sánchez Ramón, Silvia María
Background Inborn errors of immunity (IEI) are a group of monogenic diseases that confer susceptibility to infection, autoimmunity, and cancer. Despite the life-threatening consequences of some IEI, their genetic cause remains unknown in many patients. Objective We investigated a patient with an IEI of unknown genetic etiology. Methods Whole-exome sequencing identified a homozygous missense mutation of the gene encoding ezrin (EZR), substituting a threonine for an alanine at position 129. Results Ezrin is one of the subunits of the ezrin, radixin, and moesin (ERM) complex. The ERM complex links the plasma membrane to the cytoskeleton and is crucial for the assembly of an efficient immune response. The A129T mutation abolishes basal phosphorylation and decreases calcium signaling, leading to complete loss of function. Consistent with the pleiotropic function of ezrin in myriad immune cells, multidimensional immunophenotyping by mass and flow cytometry revealed that in addition to hypogammaglobulinemia, the patient had low frequencies of switched memory B cells, CD4+ and CD8+ T cells, MAIT, γδ T cells, and centralnaive CD4+ cells. Conclusions Autosomal-recessive human ezrin deficiency is a newly recognized genetic cause of B-cell deficiency affecting cellular and humoral immunity.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy

  • Martín Giménez, Virna Margarita
  • Modrego, Javier
  • Gómez Garre, María Dulce Nombre
  • Manucha, Walter
  • Heras Jiménez, Natalia De Las
<jats:p>Inflammation and oxidative stress are critical underlying mechanisms associated with COVID-19 that contribute to the complications and clinical deterioration of patients. Additionally, COVID-19 has the potential to alter the composition of patients’ gut microbiota, characterized by a decreased abundance of bacteria with probiotic effects. Interestingly, certain strains of these bacteria produce metabolites that can target the S protein of other coronaviruses, thereby preventing their transmission and harmful effects. At the same time, the presence of gut dysbiosis can exacerbate inflammation and oxidative stress, creating a vicious cycle that perpetuates the disease. Furthermore, it is widely recognized that the gut microbiota can metabolize various foods and drugs, producing by-products that may have either beneficial or detrimental effects. In this regard, a decrease in short-chain fatty acid (SCFA), such as acetate, propionate, and butyrate, can influence the overall inflammatory and oxidative state, affecting the prevention, treatment, or worsening of COVID-19. This review aims to explore the current evidence regarding gut dysbiosis in patients with COVID-19, its association with inflammation and oxidative stress, the molecular mechanisms involved, and the potential of gut microbiota modulation in preventing and treating SARS-CoV-2 infection. Given that gut microbiota has demonstrated high adaptability, exploring ways and strategies to maintain good intestinal health, as well as an appropriate diversity and composition of the gut microbiome, becomes crucial in the battle against COVID-19.</jats:p>
Docta Complutense
Publicación Artículo científico (JournalArticle)

Exercise Intolerance in McArdle Disease: A Role for Cardiac Impairment? A Preliminary Study in Humans and Mice.

  • Santos Lozano, Alejandro
  • Boraita, Araceli
  • Valenzuela, Pedro L.
  • Santalla, Alfredo
  • Villareal Salazar, Mónica
  • Bustos, Asunción
  • Brea Alejo, Lidia
  • Barranco Gil, David
  • Millán Parlanti, Daniela
  • López Ortiz, Susana
  • Peñín Grandes, Saúl
  • Naranjo Orellana, José
  • Fiuza Luces, Carmen
  • González Gálvez, Beatriz
  • García Fernández, Miguel Ángel
  • Pinós, Tomàs
  • Lucia, Alejandro
INTRODUCTION: Whether cardiac impairment can be fully discarded in McArdle disease-the paradigm of "exercise intolerance," caused by inherited deficiency of the skeletal muscle-specific glycogen phosphorylase isoform ("myophosphorylase")-remains to be determined. METHODS: Eight patients with McArdle disease and seven age/sex-matched controls performed a 15-min moderate, constant-load cycle-ergometer exercise bout followed by a maximal ramp test. Electrocardiographic and two-dimensional transthoracic (for cardiac dimension's assessment) and speckle tracking (for left ventricular global longitudinal strain (GLS) assessments) echocardiographic evaluations were performed at baseline. Electrocardiographic and GLS assessments were also performed during constant-load exercise and immediately upon maximal exertion. Four human heart biopsies were obtained in individuals without McArdle disease, and in-depth histological/molecular analyses were performed in McArdle and wild-type mouse hearts. RESULTS: Exercise intolerance was confirmed in patients ("second wind" during constant-load exercise, -55% peak power output vs controls). As opposed to controls, patients showed a decrease in GLS during constant-load exercise, especially upon second wind occurrence, but with no other between-group difference in cardiac structure/function. Human cardiac biopsies showed that all three glycogen phosphorylase-myophosphorylase, but also liver and especially brain-isoforms are expressed in the normal adult heart, thereby theoretically compensating for eventual myophosphorylase deficiency. No overall histological (including glycogen depots), cytoskeleton, metabolic, or mitochondrial (morphology/network/distribution) differences were found between McArdle and wild-type mouse hearts, except for lower levels of pyruvate kinase M2 and translocase of outer-membrane 20-kDa subunit in the former. CONCLUSIONS: This study provides preliminary evidence that cardiac structure and function seem to be preserved in patients with McArdle disease. However, the role for an impaired cardiac contractility associated with the second wind phenomenon should be further explored.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Improved antitumor activity through a tyramidyl maslinic acid derivative. Design and validation as drug-loaded electrospun polymeric nanofibers

  • Luque, C.
  • de la Cabeza Fernández, M
  • Fuentes-Rios, D.
  • Cepero, A.
  • Contreras-Cáceres, R.
  • Doña, M.
  • Perazzoli, G.
  • Lozano-Chamizo, L.
  • Filice, Marco
  • Marciello, Marzia
  • Gonzalez-Rumayor, V.
  • López-Romero, J. M.
  • Cabeza, L.
  • Melguizo, C.
  • Prados, J.
Among the most harmful tumors detected in the human body, such as breast, colon, brain or pancreas, breast (BC) and colorectal cancer (CRC) are the first and third most frequent cancer worldwide, respectively. The current existing chemotherapeutic treatments present serious side effects due to their intravenous administration can induce cytotoxicity in healthy cells. Thus, new treatment methods based on drug-loaded polymeric nanofibers (NFs) have gained significant potential for their use in localized cancer chemotherapy. Here, a deep in vitro comparative analysis between maslinic acid (MA) and a tyramine-maslinic acid (TMA) derivative is initially performed. This analysis includes a proliferation, and a cell cycle assay, and a genotoxicity, antiangiogenic and apoptosis study. Then, the TMA derivative has been incorporated into electrospun polymeric NFs obtaining an implantable dressing material with antitumor activity. Two types of patches containing TMA-loaded polymeric NFs of poly(caprolactone) (PCL), and a mixture of polylactic acid/poly(4-vinylpyridine) (PLA/PVP) were fabricated by the electrospinning technique. The characterization of the drug-loaded NFs showed an encapsulation capacity of 0.027 mg TMA/mg PCL and 0.024 mg TMA/mg PLA/PVP. Then, the cytotoxic activity of both polymeric systems was tested in CRC (T84), BC (MCF-7) and a no tumor (L929) cell lines exposed to TMA-loaded NFs and blank NFs for 48 h. Moreover, cell cycle assay, genotoxicity, angiogenesis and apoptosis tests were carried out to study the mechanism of action of TMA. Blank NFs showed no-toxicity in all cell lines tested and both drug-loaded NFs significantly reduced cell proliferation (relative proliferation of ≈44 % and ≈25 % respectively). Therefore, TMA was less genotoxic than maslinic acid (MA), and reduced VEGFA expression in MCF-7 cells (1.32 and 2.12-fold for MA and TMA respectively). These results showed that TMA-loaded NFs could constitute a promising biocompatible and biodegradable nanoplatform for the local treatment of solid tumors such as CRC or BC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients

  • Solé Font, Laura|||0000-0002-3195-0565
  • Lobo-Jarne, Teresa|||0000-0002-1632-438X
  • Cabré-Romans, Júlia-Jié
  • González, Antón
  • Fernández, Lierni
  • Marruecos, Laura|||0000-0002-4206-709X
  • Guix, Marta|||0000-0002-2143-0697
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • López, Sandra
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Torres, Ferran|||0000-0002-7355-7913
  • Iglesias, Mar|||0000-0002-2274-4671
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Espinosa, Lluis|||0000-0002-2897-4099
Background: We have previously shown that non-curative chemotherapy imposes fetal conversion and high metastatic capacity to cancer cells. From the set of genes differentially expressed in Chemotherapy Resistant Cells, we obtained a characteristic fetal intestinal cell signature that is present in a group of untreated tumors and is sufficient to predict patient prognosis. A feature of this fetal signature is the loss of CDX1. Methods: We have analyzed transcriptomic data in public datasets and performed immunohistochemistry analysis of paraffin embedded tumor samples from two cohorts of colorectal cancer patients. Results: We demonstrated that low levels of CDX1 are sufficient to identify patients with poorest outcome at the early tumor stages II and III. Presence tumor areas that are negative for CDX1 staining in stage I cancers is associated with tumor relapse. Conclusions: Our results reveal the actual possibility of incorporating CDX1 immunostaining as a valuable biomarker for CRC patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development and Evaluation of an NTM-IGRA to Guide Pediatric Lymphadenitis Diagnosis

  • Villar-Hernández, Raquel|||0000-0002-2249-0579
  • Latorre, Irene|||0000-0001-8159-2455
  • Noguera-Julian, Antoni|||0000-0001-7485-0583
  • Martínez-Planas, Aina
  • Minguell Domingo, Laura
  • Vallmanya, Teresa
  • Méndez Hernández, Maria|||0000-0001-5697-2763
  • Soriano-Arandes, Antoni|||0000-0001-9613-7228
  • Baquero-Artigao, Fernando|||0000-0002-6903-3826
  • Rodríguez-Molino, Paula
  • Guillén-Martín, Sara
  • Toro Rueda, Carlos
  • De Souza Galvão, Maria Luiza|||0000-0001-9703-989X
  • Jiménez-Fuentes, María Ángeles|||0000-0001-5181-4192
  • Stojanovic, Zoran|||0000-0001-5082-0750
  • Sabriá, Josefina
  • Santos, José Ramón|||0000-0002-0886-7114
  • Puig, Jordi|||0000-0002-4075-0346
  • Domínguez-Álvarez, Marisol
  • Millet, Joan Pau|||0000-0003-0200-2459
  • Altet, Neus
  • Galea, Yolanda
  • Muriel-Moreno, Beatriz|||0000-0002-6683-9082
  • García-García, Esther
  • Bach Griera, Marc|||0000-0001-9845-7225
  • Prat i Aymerich, Cristina|||0000-0001-6974-9165
  • Julián, Esther|||0000-0002-6558-3978
  • Torrelles, Jordi B.|||0000-0001-7702-5941
  • Rodrigo Gonzalo de Líria, Carlos|||0000-0003-1140-2585
  • Domínguez, José|||0000-0001-7888-0309
Background: Diagnosis of nontuberculous mycobacteria (NTM) infections remains a challenge. In this study, we describe the evaluation of an immunological NTM-interferon (IFN)-γ release assay (IGRA) that we developed using glycopeptidolipids (GPLs) as NTM-specific antigens. Methods: We tested the NTM-IGRA in 99 samples from pediatric patients. Seventy-five were patients with lymphadenitis: 25 were NTM confirmed, 45 were of unknown etiology but compatible with mycobacterial infection and 5 had lymphadenitis caused by an etiologic agent other than NTM. The remaining 24 samples were from control individuals without lymphadenitis (latently infected with M.Tuberculosis, uninfected controls and active tuberculosis patients). Peripheral blood mononuclear cells were stimulated overnight with GPLs. Detection of IFN-γ producing cells was evaluated by enzyme-linked immunospot assay. Results: NTM culture-confirmed lymphadenitis patient samples had a significantly higher response to GPLs than the patients with lymphadenitis of unknown etiology but compatible with mycobacterial infection (P < 0.001) and lymphadenitis not caused by NTM (P < 0.01). We analyzed the response against GPLs in samples from unknown etiology lymphadenitis but compatible with mycobacterial infection cases according to the tuberculin skin test (TST) response, and although not statistically significant, those with a TST ≥5 mm had a higher response to GPLs when compared with the TST <5 mm group. Conclusions: Stimulation with GPLs yielded promising results in detecting NTM infection in pediatric patients with lymphadenitis. Our results indicate that the test could be useful to guide the diagnosis of pediatric lymphadenitis. This new NTM-IGRA could improve the clinical handling of NTM-infected patients and avoid unnecessary misdiagnosis and treatments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology

  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Vidal-Fernández, Núria|||0009-0008-3749-6448
  • Tejada-Illa, Clara|||0009-0008-2856-7179
  • Collet Vidiella, Roger|||0000-0003-1668-1018
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
  • Vesperinas-Castro, Ana|||0000-0003-1919-9382
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Llansó, Laura|||0000-0003-4950-7657
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Shock, Anthony|||0000-0002-9971-8789
  • Christodoulou, Louis
  • Dizier, Benjamin
  • Freeth, Jim
  • Soden, Jo
  • Dawson, Sarah
  • Querol, Luis|||0000-0002-4289-8264
Background and Objectives Autoantibody discovery in complex autoimmune diseases is challenging. Diverse successful antigen identification strategies are available, but, so far, have often been unsuccessful, especially in the discovery of protein antigens in which conformational and post-translational modification are critical. Our study assesses the utility of a human membrane and secreted protein microarray technology to detect autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods A cell microarray consisting of human embryonic kidney-293 cells expressing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Rituximab treatment in myasthenia gravis

  • Vesperinas-Castro, Ana|||0000-0003-1919-9382
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
Myasthenia gravis (MG) is a chronic autoimmune disease mediated by antibodies against post-synaptic proteins of the neuromuscular junction. Up to 10%-30% of patients are refractory to conventional treatments. For these patients, rituximab has been used off-label in the recent decades. Rituximab is a monoclonal antibody against the CD20 protein that leads to B cell depletion and to the synthesis of new antibody-secreting plasma cells. Although rituximab was created to treat B-cell lymphoma, its use has widely increased to treat autoimmune diseases. In MG, the benefit of rituximab treatment in MuSK-positive patients seems clear, but a high variability in the results of observational studies and even clinical trials has been reported for AChR-positive patients. Moreover, few evidence has been reported in seronegative MG and juvenile MG and some questions about regimen of administration or monitoring strategies, remains open. In this review, we intend to revise the available literature on this topic and resume the current evidence of effectiveness of Rituximab in MG, with special attention to results on every MG subtype, as well as the administration protocols, monitoring strategies and safety profile of the drug.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Artificial intelligence, a new field of knowledge for nephrologists

  • Fayos de Arizón, Leonor|||0000-0002-9277-645X
  • R. Viera, Elizabeth
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Perera Lluna, Alexandre|||0000-0001-6427-851X
  • De Maeztu, Gabriel
  • Nicolau, Anna
  • Furlano, Monica|||0000-0003-1025-3901
  • Torra Balcells, Roser|||0000-0001-8714-2332
Artificial intelligence (AI) is a science that involves creating machines that can imitate human intelligence and learn. AI is ubiquitous in our daily lives, from search engines like Google to home assistants like Alexa and, more recently, OpenAI with its chatbot. AI can improve clinical care and research, but its use requires a solid understanding of its fundamentals, the promises and perils of algorithmic fairness, the barriers and solutions to its clinical implementation, and the pathways to developing an AI-competent workforce. The potential of AI in the field of nephrology is vast, particularly in the areas of diagnosis, treatment and prediction. One of the most significant advantages of AI is the ability to improve diagnostic accuracy. Machine learning algorithms can be trained to recognize patterns in patient data, including lab results, imaging and medical history, in order to identify early signs of kidney disease and thereby allow timely diagnoses and prompt initiation of treatment plans that can improve outcomes for patients. In short, AI holds the promise of advancing personalized medicine to new levels. While AI has tremendous potential, there are also significant challenges to its implementation, including data access and quality, data privacy and security, bias, trustworthiness, computing power, AI integration and legal issues. The European Commission's proposed regulatory framework for AI technology will play a significant role in ensuring the safe and ethical implementation of these technologies in the healthcare industry. Training nephrologists in the fundamentals of AI is imperative because traditionally, decision-making pertaining to the diagnosis, prognosis and treatment of renal patients has relied on ingrained practices, whereas AI serves as a powerful tool for swiftly and confidently synthesizing this information. plans, leading to better patient outcomes. However, the implementation of AI in healthcare faces several challenges. The European Commission's proposed regulatory framework aims to promote the safe and ethical use of AI in healthcare. To fully leverage the benefits of AI, nephrologists and other healthcare professionals need to be educated about its fundamentals and its potential applications in routine patient care. This will enable them to effectively utilize AI technologies and provide better care for kidney patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic study in young patients with chronic kidney disease stage G5 from unknown etiology. The GENSEN study design Estudio genético en pacientes jóvenes con enfermedad renal crónica avanzada de etiología no filiada. Diseño del estudio GENSEN

  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Quiroga, Borja|||0000-0001-5730-1929
  • García-Aznar, José M.
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ortiz, Alberto|||0000-0002-9805-9523
  • de Sequera, Patricia|||0000-0001-7705-9228
Introduction: Chronic kidney disease (CKD) of unknown etiology is one of the main causes of renal replacement therapy in our environment. Previous studies in other territories suggest that hereditary diseases could be one of the potential causes of this pathology, especially in younger patients. The GENSEN study will evaluate the presence of pathogenic genetic variants in subjects who have developed CKD category G5 before the age of 46, of unknown etiology. Methods: Observational, prospective and multicenter study, which evaluates the diagnostic usefulness of massive high-throughput sequencing (HTS) directed at a set of genes, in identifying the cause of CKD. Patients from all over Spain will be included, from whom a blood or saliva sample will be extracted, subsequently analyzing a panel of 529 genes associated with hereditary kidney disease. This publication communicates the study protocol and design. Conclusion: The GENSEN study will allow to evaluate the diagnostic performance of a gene panel study in young subjects from our environment with the development of category G5 CKD without a clear cause. An etiological diagnosis would offer potential benefits for patients and relatives (targeted therapies, clinical trials, detection of extrarenal manifestations, evaluation of relatives for living kidney donation, estimation of the risk of recurrence in the kidney graft, genetic counseling, among others) and would allow genetic study to be brought closer to nephrology in our country.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genotyping Hepatitis B virus by Next-Generation Sequencing, Detection of Mixed Infections and Analysis of Sequence Conservation

  • Dopico, Eva|||0000-0002-5306-3035
  • Vila, Marta|||0000-0001-9303-5189
  • Tabernero, David|||0000-0002-1146-4084
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Pacín Ruiz, Beatriz|||0000-0001-8718-6589
  • Guerrero, Laura|||0000-0003-1978-9067
  • Ubillos, Itziar|||0000-0002-0993-0058
  • Martínez, Miguel J.|||0000-0002-0682-1075
  • Costa, Josep|||0000-0001-7978-0748
  • Quer, Josep|||0000-0003-0014-084X
  • Pérez Garreta, Javier
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Ferrer Costa, Roser|||0000-0002-8925-3172
  • Buti, Maria|||0000-0002-0732-3078
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Cortese, Maria Francesca|||0000-0002-4318-532X
Our aim was to develop an accurate, highly sensitive method for HBV genotype determination and detection of genotype mixtures. We examined the preS and 5' end of the HBV X gene (5X) regions of the HBV genome using next-generation sequencing (NGS). The 1852 haplotypes obtained were subjected to genotyping via the Distance-Based discrimination method (DB Rule) using two sets of 95 reference sequences of genotypes A-H. In clinical samples from 125 patients, the main genotypes were A, D, F and H in Caucasian, B and C in Asian and A and E in Sub-Saharan patients. Genotype mixtures were identified in 28 (22.40%) cases, and potential intergenotypic recombination was observed in 29 (23.20%) cases. Furthermore, we evaluated sequence conservation among haplotypes classified into genotypes A, C, D, and E by computing the information content. The preS haplotypes exhibited limited shared conserved regions, whereas the 5X haplotypes revealed two groups of conserved regions across the genotypes assessed. In conclusion, we developed an NGS-based HBV genotyping method utilizing the DB Rule for genotype classification. We identified two regions conserved across different genotypes at 5X, offering promising targets for RNA interference-based antiviral therapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Association of Liver Damage and Quasispecies Maturity in Chronic HCV Patients, The Fate of a Quasispecies

  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • Campos, Carolina|||0000-0002-0132-7027
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Quer, Josep|||0000-0003-0014-084X
Viral diversity and disease progression in chronic infections, and particularly how quasispecies structure affects antiviral treatment, remain key unresolved issues. Previous studies show that advanced liver fibrosis in long-term viral infections is linked to higher rates of antiviral treatment failures. Additionally, treatment failure is associated with high quasispecies fitness, which indicates greater viral diversity and adaptability. As a result, resistant variants may emerge, reducing retreatment effectiveness and increasing the chances of viral relapse. Additionally, using a mutagenic agent in monotherapy can accelerate virus evolution towards a flat-like quasispecies structure. This study examines 19 chronic HCV patients who failed direct-acting antiviral (DAA) treatments, using NGS to analyze quasispecies structure in relation to fibrosis as a marker of infection duration. Results show that HCV evolves towards a flat-like quasispecies structure over time, leading also to advanced liver damage (fibrosis F3 and F4/cirrhosis). Based on our findings and previous research, we propose that the flat-like fitness quasispecies structure is the final stage of any quasispecies in chronic infections unless eradicated. The longer the infection persists, the lower the chances of achieving a cure. Interestingly, this finding may also be applicable to other chronic infection and drug resistance in cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term, protocol of the PE37 study

  • Llurba, Elisa|||0000-0003-4048-6407
  • Crispi, Fatima|||0000-0002-7422-5240
  • Crovetto, Francesca|||0000-0003-0140-7411
  • Youssef, Lina|||0000-0002-0554-5507
  • Delgado, Juan Luis
  • Puig, Isabel
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • Krofta, Ladislav
  • Mackova, Katerina
  • Martinez-Varea, Alicia
  • Tubau Navarra, Albert|||0000-0001-5460-0763
  • Ruiz, Aina
  • Paya, Antoni
  • Prat Grau, Maria|||0000-0002-3811-9205
  • Chantraine, Frederic
  • Comas, Carmina|||0000-0001-6631-0165
  • Kajdy, Anna
  • Lopez-Tinajero, Maria Fernanda|||0000-0002-3999-2620
  • Figueras, Francesc|||0000-0003-4403-1274
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Castillo, Heidi
  • Casas, Irene
  • Campos, Rafael José
  • Timmermans, Marie
  • Parriego, Vanessa
  • Sys, Dorota
  • Modzelewski, Jan
Pre-eclampsia affects ~5%-7% of pregnancies. Although improved obstetric care has significantly diminished its associated maternal mortality, it remains a leading cause of maternal morbidity and mortality in the world. Term pre-eclampsia accounts for 70% of all cases and a large proportion of maternal-fetal morbidity related to this condition. Unlike in preterm pre-eclampsia, the prediction and prevention of term pre-eclampsia remain unsolved. Previously proposed approaches are based on combined third-trimester screening and/or prophylactic drugs, but these policies are unlikely to be widely implementable in many world settings. Recent evidence shows that the soluble fms-like tyrosine kinase-1 (s-Flt-1) to placental growth factor (PlGF) ratio measured at 35-37 weeks' gestation predicts term pre-eclampsia with an 80% detection rate. Likewise, recent studies demonstrate that induction of labour beyond 37 weeks is safe and well accepted by women. We hypothesise that a single-step universal screening for term pre-eclampsia based on sFlt1/PlGF ratio at 35-37 weeks followed by planned delivery beyond 37 weeks reduces the prevalence of term pre-eclampsia without increasing the caesarean section rates or worsening the neonatal outcomes. We propose an open-label randomised clinical trial to evaluate the impact of a screening of term pre-eclampsia with the sFlt-1/PlGF ratio followed by planned delivery in asymptomatic nulliparous women at 35-37 weeks. Women will be assigned 1:1 to revealed (sFlt-1/PlGF known to clinicians) versus concealed (unknown) arms. A cut-off of.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synaptic and extrasynaptic distribution of NMDA receptors in the cortex of Alzheimer's disease patients

  • Escamilla, Sergio
  • Badillos Rodríguez, Raquel|||0000-0002-8257-1784
  • Comella i Carnicé, Joan Xavier|||0000-0002-6218-0786
  • Solé Piñol, Montserrat|||0000-0003-4240-6562
  • Pérez-Otaño, Isabel
  • Sánchez-Mut, José Vicente|||0000-0002-9292-8521
  • Sáez-Valero, Javier
  • Cuchillo-Ibáñez, Inmaculada|||0000-0002-3689-5518
Synaptic and extrasynaptic distribution of N-methyl-D-aspartate receptors (NMDARs) has not been addressed in the brain from Alzheimer's disease (AD) subjects, despite their contribution to neurodegeneration. We have developed a protocol to isolate synaptic and extrasynaptic membranes from controls and AD frontal cortex. We characterized the distribution of the NMDAR subunits GluN2B, GluN2A, GluN1, and GluN3A, as well as post-translational modifications, such as phosphorylation and glycosylation. Lower levels of synaptic GluN2B and GluN2A were found in AD fractions, while extrasynaptic GluN2B and GluN1 levels were significantly higher; GluN3A distribution remained unaffected in AD. We also identified different glycoforms of GluN2B and GluN2A in extrasynaptic membranes. Synaptic Tyr1472 GluN2B phosphorylation was significantly lower in AD fractions. Reduction of synaptic NMDAR subunits, particularly for GluN2B, is likely to contribute to synaptic transmission failure in AD. Additionally, the increment of extrasynaptic NMDAR subunits could favor the activation of excitotoxicity in AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Survival Outcomes in Sinonasal Mucosal Melanoma, Systematic Review and Meta-Analysis

  • Rojas-Lechuga, María Jesús|||0000-0002-1402-5167
  • Jubés, Sara
  • Molina-García, Manuel|||0000-0003-4218-9756
  • da Silva-Júnior, Rui Milton Patricio
  • Sampieri, Claudio
  • Langdon, Cristóbal
  • Gras Cabrerizo, Juan Ramón|||0000-0001-9674-1783
  • Bernal Sprekelsen, Manuel
  • Puig, Susana|||0000-0003-1337-9745
  • Alobid, Isam|||0000-0001-7204-5599
Background/Objectives : Sinonasal mucosal melanomas (SNMMs) are rare and aggressive malignancies with poor survival outcomes. Our systematic review and meta-analysis aim to evaluate overall survival (OS) rates in patients with SNMM; Methods : We conducted a systematic search, following PRISMA guidelines across PubMed, Web of Science (WOS), and citation searching for studies reporting survival and prognosis outcomes for SNMMs. Inclusion criteria included studies with 5-year OS rates. Studies were excluded if they included tumor sites other than the paranasal sinuses or nasal cavity, were published in languages other than English and Spanish, or had a sample size of fewer than 15 patients. Two reviewers independently screened studies, extracted data, and assessed study quality using the Joanna Briggs Institute (JBI) critical appraisal checklist. Analyses of survival probabilities were conducted. Meta-analyses were performed using a random-effects model. PROSPERO ID CRD42024565137; Results : A total of 515 articles were identified after removing duplicates, and 99 reports were assessed for eligibility. Of these, 35 studies were included in the meta-analysis, encompassing a total of 2383 SNMM patients, of whom 1192 (50%) were female, with a weighted mean age of 65.4 years (SD = 5.4). Fifteen studies were from Europe (42.9%), six (17.1%) were from America, eleven (31.4%) were from Asia, two (5.7%) were from Australia, and one (2.9%) combined European, United Kingdom, and American populations. The 5-year OS was 34.8 [95% CI = 30.6-39.5], with the highest OS in America at 40.5 [95% CI = 34.1-48.1], followed by Europe at 36.6 [95% CI = 30.6-43.7], Australia at 32.3 [95% CI = 12.5-83.8], and Asia at 28.1 [95% CI = 19.5-40.7]. The age-standardized incidence rate (ASIR) for SNMM ranges was between 0.07 and 0.14 per 100,000 persons/year, with a slightly higher incidence in women than in men; Conclusions : This meta-analysis, one of the largest to date on SNMM, confirms the aggressive nature of this melanoma subtype with poor survival outcomes. Despite geographic differences in survival rates, the overall 5-year survival remains low, highlighting the urgent need for improved treatment strategies and more research to improve patient outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Implementation of a virtual community of practice to promote the empowerment of middle-aged people with multimorbidity, study protocol of a randomised controlled trial

  • Campillejo, Alba
  • Gefaell-Larrondo, Ileana
  • Ramos-García, Vanesa|||0000-0002-9106-2420
  • Koatz, Débora|||0000-0002-8178-7540
  • Santos-Álvarez, Anthea
  • Barrio-Cortes, Jaime
  • Gómez-Rueda, Sara
  • Calderón-Larrañaga, Amaia|||0000-0001-9064-9222
  • Cifuentes, Patricia
  • Company-Sancho, Consuelo
  • Domínguez-Coello, Santiago
  • García-García, Francisco Javier
  • Garrido-Elustondo, Sofía
  • González de León, Beatriz
  • Vázquez, José Ramón
  • Martín, Candelaria
  • Suárez-Fernández, Carmen
  • Parra-Caballero, Pedro
  • Vicente-Rabaneda, Esther F.
  • Quiroga-Colina, Patricia
  • Ramírez-Puerta, Ana Belén
  • Ruíz-López, Marta
  • Tello-Bernabé, María-Eugenia
  • Sanchez-Gamborino, Estrella
  • Ugalde-Abiega, Beatriz
  • Vall Roqué, Helena|||0000-0003-4235-0810
  • Duarte-Díaz, Andrea|||0000-0003-1171-9945
  • Abt-Sacks, Analía
  • Hernández-Yumar, Aránzazu
  • Torres-Castaño, Alezandra|||0000-0003-4690-1421
  • Álvarez-Pérez, Yolanda|||0000-0002-6414-2863
  • Muth, Christiane
  • van den Akker, Marjan|||0000-0002-1022-8637
  • Montori, Victor M.|||0000-0003-0595-2898
  • Orrego, Carola|||0000-0002-2978-6268
  • Perestelo-Pérez, Lilisbeth|||0000-0002-6113-7313
  • González González, Ana Isabel|||0000-0001-7167-4211
Empowering people living with multimorbidity (multiple chronic conditions) to gain greater confidence in managing their health can enhance their quality of life. Education focused on self-management is a key tool for fostering patient empowerment and is mostly provided on an individual basis. Virtual communities of practice (VCoP) present a unique opportunity for online education in chronic condition self-management within a social context. This research aims to evaluate the effectiveness/cost-effectiveness of individualised, online self-management education compared with VCoP among middle-aged individuals living with multiple chronic conditions. People aged 30-60, living with ≥2 chronic conditions and receiving care in primary care (PC) centres and outpatient hospital-based clinics in Madrid and Canary Islands will enrol in an 18-month parallel-design, blinded (intervention assessment and data analysts), pragmatic (adhering to the intention-to-treat principle), individually randomised trial. The trial will compare two 12-month web-based educational offers of identical content; one delivered individually (control) and the other with online social interaction (VCoP, intervention). Using repeated measures mixed linear models, with the patient as random effect and allocation groups and time per group as fixed effects, we will estimate between-arm differences in the change in Patient Activation Measure from baseline to 12 months (primary endpoint), including measurements at 6-month and 18-month follow-up. Other outcomes will include measures of depression and anxiety, treatment burden, quality of life. In addition to a process evaluation of the VCoP, we will conduct an economic evaluation estimating the relative cost-effectiveness of the VCoP from the perspectives of both the National Health System and the Community. The trial was approved by Clinical Research Ethics Committees of Gregorio Marañón University Hospital in Madrid/Nuestra Señora Candelaria University Hospital in Santa Cruz de Tenerife. The results will be disseminated through workshops, policy briefs, peer-reviewed publications and local/international conferences.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cortical microinfarcts in adults with Down syndrome assessed with 3T-MRI

  • Aranha, Mateus|||0000-0001-9594-292X
  • Montal, Victor|||0000-0002-5714-9282
  • van den Brink, Hilde
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Benejam, Bessy|||0000-0002-6789-8615
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Ribas, Laia
  • Alcolea, Daniel|||0000-0002-3819-3245
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Bargalló, Núria|||0000-0001-6284-5402
  • Biessels, Geert Jan|||0000-0001-6862-2496
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Coutinho, Artur Martins|||0000-0002-5555-4583
  • Leite, Cláudia Costa
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Fortea, Juan|||0000-0002-1340-638X
Cortical microinfarcts (CMI) were attributed to cerebrovascular disease and cerebral amyloid angiopathy (CAA). CAA is frequent in Down syndrome (DS) while hypertension is rare, yet no studies have assessed CMI in DS. We included 195 adults with DS, 63 with symptomatic sporadic Alzheimer's disease (AD), and 106 controls with 3T magnetic resonance imaging. We assessed CMI prevalence in each group and CMI association with age, AD clinical continuum, vascular risk factors, vascular neuroimaging findings, amyloid/tau/neurodegeneration biomarkers, and cognition in DS. CMI prevalence was 11.8% in DS, 4.7% in controls, and 17.5% in sporadic AD. In DS, CMI increased in prevalence with age and the AD clinical continuum, was clustered in the parietal lobes, and was associated with lacunes and cortico-subcortical infarcts, but not hemorrhagic lesions. In DS, CMI are posteriorly distributed and related to ischemic but not hemorrhagic findings suggesting they might be associated with a specific ischemic CAA phenotype. This is the first study to assess cortical microinfarcts (assessed with 3T magnetic resonance imaging) in adults with Down syndrome (DS). We studied the prevalence of cortical microinfarcts in DS and its relationship with age, the Alzheimer's disease (AD) clinical continuum, vascular risk factors, vascular neuroimaging findings, amyloid/tau/neurodegeneration biomarkers, and cognition. The prevalence of cortical microinfarcts was 11.8% in DS and increased with age and along the AD clinical continuum. Cortical microinfarcts were clustered in the parietal lobes, and were associated with lacunes and cortico-subcortical infarcts, but not hemorrhagic lesions. In DS, cortical microinfarcts are posteriorly distributed and related to ischemic but not hemorrhagic findings suggesting they might be associated with a specific ischemic phenotype of cerebral amyloid angiopathy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

RET Fusion Testing in Patients With NSCLC, The RETING Study

  • Conde, Esther
  • Hernandez, Susana
  • Rodriguez Carrillo, Jose Luis
  • Martinez, Rebeca
  • Alonso, Marta
  • Curto, Daniel
  • Jimenez, Beatriz
  • Caminoa, Alejandra
  • Benito, Amparo
  • Garrido, Pilar|||0000-0002-5899-6125
  • Clavé, Sergi|||0000-0002-9435-8454
  • Arriola, Edurne|||0000-0001-8960-7519
  • Esteban Rodríguez, Isabel|||0000-0003-1576-7215
  • Castro, Javier de|||0000-0002-3622-6306
  • Sansano, Irene|||0000-0003-0188-5210
  • Felip, Enriqueta|||0000-0002-7620-0098
  • Rojo, Federico|||0000-0001-9989-0290
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Abdulkader, Ihab
  • Garcia-Gonzalez, Jorge
  • Teixidó, Cristina|||0000-0002-7226-6567
  • Reguart, Noemi|||0000-0001-8190-499X
  • Compañ, Desamparados
  • Insa, Amelia|||0000-0002-3438-6170
  • Mancheño, Nuria
  • Palanca, Sarai
  • Juan, Óscar|||0000-0002-7772-9030
  • Baixeras, Nuria|||0000-0001-6127-0475
  • Nadal, Ernest|||0000-0002-9674-5554
  • Cebollero, Maria
  • Calles, Antonio
  • Martin, Paloma
  • Salas, Clara
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Aranda, Ignacio
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • López Vilaró, Laura|||0000-0002-5428-8017
  • Majem Tarruella, Margarita|||0000-0002-9919-7485
  • Paz-Ares, Luis|||0000-0002-3327-3246
  • Lopez-Rios, Fernando
RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RET fusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencing (NGS), or alternatively, fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-PCR) when NGS is not possible or available. Taken together, the suboptimal performance of single-analyte assays to detect RET fusions, although consistent with the notion of encouraging universal NGS, is currently widening some of the clinical practice gaps in the implementation of predictive biomarkers in patients with advanced NSCLC. This situation prompted us to evaluate several RET assays in a large multicenter cohort of RET fusion-positive NSCLC (n = 38) to obtain real-world data. In addition to RNA-based NGS (the criterion standard method), all positive specimens underwent break-apart RET FISH with two different assays and were also tested by an RT-PCR assay. The most common RET partners were KIF5B (78.9%), followed by CCDC6 (15.8%). The two RET NGS-positive but FISH-negative samples contained a KIF5B(15)-RET(12) fusion. The three RET fusions not identified with RT-PCR were AKAP13(35)-RET(12), KIF5B(24)-RET(9) and KIF5B(24)-RET(11). All three false-negative RT-PCR cases were FISH-positive, exhibited a typical break-apart pattern, and contained a very high number of positive tumor cells with both FISH assays. Signet ring cells, psammoma bodies, and pleomorphic features were frequently observed (in 34.2%, 39.5%, and 39.5% of tumors, respectively). In-depth knowledge of the advantages and disadvantages of the different RET testing methodologies could help clinical and molecular tumor boards implement and maintain sensible algorithms for the rapid and effective detection of RET fusions in patients with NSCLC. The likelihood of RET false-negative results with both FISH and RT-PCR reinforces the need for upfront NGS in patients with NSCLC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Mild Presentation of X-Linked Hypophosphatemia Caused by a Non-Canonical Splice Site Variant in the PHEX Gene

  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • Herreros García, Alba|||0009-0003-0451-7568
  • Pybus, Marc|||0000-0002-6195-5738
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Pilco-Teran, Melissa|||0000-0002-1311-0896
  • Furlano, Monica|||0000-0003-1025-3901
  • Garcia Borau, Maria José|||0000-0002-8223-8033
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ars, Elisabet|||0000-0002-4118-4358
X-linked hypophosphatemia (XLH) is a rare inherited disorder of renal phosphate wasting with a highly variable phenotype caused by loss-of-function variants in the PHEX gene. The diagnosis of individuals with mild phenotypes can be challenging and often delayed. Here, we describe a three-generation family with a very mild clinical presentation of XLH. The diagnosis was unexpectedly found in a 39-year-old woman who was referred for genetic testing due to an unclear childhood diagnosis of a tubulopathy. Genetic testing performed by next-generation sequencing using a kidney disease gene panel identified a novel non-canonical splice site variant in the PHEX gene. Segregation analysis detected that the consultand's father, who presented with hypophosphatemia and decreased tubular phosphate reabsorption, and the consultand's son also carried this variant. RNA studies demonstrated that the non-canonical splice site variant partially altered the splicing of the PHEX gene, as both wild-type and aberrant splicing transcripts were detected in the two male members with only one copy of the PHEX gene. In conclusion, this case contributes to the understanding of the relationship between splicing variants and the variable expressivity of XLH disease. The mild phenotype of this family can be explained by the coexistence of PHEX transcripts with aberrant and wild-type splicing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

  • Torres Esquius, Sara|||0000-0001-7540-7284
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Romey, Marcel
  • Teule, Alex|||0000-0003-0028-7200
  • Llort, Gemma|||0000-0001-9987-7862
  • Herrero, Ana
  • Sánchez-Henarejos, Pilar
  • Vallmajó, Anna
  • González-Santiago, Santiago|||0000-0002-4787-0236
  • Chirivella, Isabel|||0000-0002-0733-3276
  • Cano, Juana María|||0000-0002-2493-0988
  • Graña, Begoña|||0000-0003-2008-8188
  • Simonetti, Sara|||0000-0003-2406-030X
  • Díaz de Corcuera, Isabel
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Sanz, Judit
  • Serrano, Sara
  • Otero, Andrea
  • Churruca, Cristina
  • Sánchez-Heras, Ana Beatriz|||0000-0003-1742-5374
  • Servitja, Sonia|||0000-0001-6988-4519
  • Guillén-Ponce, Carmen
  • Brunet, Joan|||0000-0003-1945-3512
  • Denkert, Carsten
  • Serra, Violeta|||0000-0001-6620-1065
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
IMPORTANCE RAD51C and RAD51D are involved in DNA repair by homologous recombination. Germline pathogenic variants (PVs) in these genes are associated with an increased risk of ovarian and breast cancer. Understanding the homologous recombination deficiency (HRD) status of tumors from patients with germline PVs in RAD51C/D could guide therapeutic decision-making and improve survival. OBJECTIVE To characterize the clinical and tumor characteristics of germline RAD51C/D PV carriers, including the evaluation of HRD status. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study included 91 index patients plus 90 relatives carrying germline RAD51C/D PV (n = 181) in Spanish hospitals from January 1, 2014, to December 31, 2021. Genomic and functional HRD biomarkers were assessed in untreated breast and ovarian tumor samples (n = 45) from June 2022 to February 2023. MAIN OUTCOMES AND MEASURES Clinical and pathologic characteristics were assessed using descriptive statistics. Genomic HRD by genomic instability scores, functional HRD by RAD51, and gene-specific loss of heterozygosity were analyzed. Associations between HRD status and tumor subtype, age at diagnosis, and gene-specific loss of heterozygosity in RAD51C/D were investigated using logistic regression or the t test. RESULTS A total of 9507 index patients were reviewed, and 91 patients (1.0%) were found to carry a PV in RAD51C/D; 90 family members with a germline PV in RAD51C/D were also included. A total of 157 of carriers (86.7%) were women and 181 (55.8%) had received a diagnosis of cancer, mainly breast cancer or ovarian cancer. The most prevalent PVs were c.1026+5_1026+7del (11 of 56 [19.6%]) and c.709C.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity

  • Cuyàs, Elisabet|||0000-0001-5353-440X
  • Pedarra, Stefano
  • Verdura, Sara|||0000-0001-8980-0423
  • Pardo-Cea, Miguel Ángel|||0000-0003-4823-6613
  • Espin Garcia, Roderic|||0000-0003-2494-0964
  • Serrano-Hervás, Eila|||0000-0002-9477-0350
  • Llop-Hernández, Àngela
  • Teixidor, Eduard
  • Bosch-Barrera, J.|||0000-0002-0893-7821
  • López-Bonet, Eugeni
  • Martin-Castillo, Begoña
  • Lupu, Ruth|||0000-0002-5564-3172
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Sardanyés, Josep|||0000-0001-7225-5158
  • Alarcón Cor, Tomás|||0000-0002-8566-3676
  • Menéndez, Javier A.|||0000-0001-8733-4561
Fatty acid synthase (FASN)-catalyzed endogenous lipogenesis is a hallmark of cancer metabolism. However, whether FASN is an intrinsic mechanism of tumor cell defense against T cell immunity remains unexplored. To test this hypothesis, here we combined bioinformatic analysis of the FASN-related immune cell landscape, real-time assessment of cell-based immunotherapy efficacy in CRISPR/Cas9-based FASN gene knockout (FASN KO) cell models, and mathematical and mechanistic evaluation of FASN-driven immunoresistance. FASN expression negatively correlates with infiltrating immune cells associated with cancer suppression, cytolytic activity signatures, and HLA-I expression. Cancer cells engineered to carry a loss-of-function mutation in FASN exhibit an enhanced cytolytic response and an accelerated extinction kinetics upon interaction with cytokine-activated T cells. Depletion of FASN results in reduced carrying capacity, accompanied by the suppression of mitochondrial OXPHOS and strong downregulation of electron transport chain complexes. Targeted FASN depletion primes cancer cells for mitochondrial apoptosis as it synergizes with BCL-2/BCL-X-targeting BH3 mimetics to render cancer cells more susceptible to T-cell-mediated killing. FASN depletion prevents adaptive induction of PD-L1 in response to interferon-gamma and reduces constitutive overexpression of PD-L1 by abolishing PD-L1 post-translational palmitoylation. FASN is a novel tumor cell-intrinsic metabolic checkpoint that restricts T cell immunity and may be exploited to improve the efficacy of T cell-based immunotherapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A phenome-wide association and Mendelian randomisation study of alcohol use variants in a diverse cohort comprising over 3 million individuals

  • Jennings, Mariela V.
  • Martínez-Magaña, José Jaime
  • Courchesne-Krak, Natasia S.
  • Cupertino , Renata B.
  • Vilar-Ribó, L.|||0000-0001-8758-523X
  • Bianchi, Sevim B.
  • Hatoum, Alexander S.
  • Atkinson, Elizabeth G.
  • Giusti-Rodriguez, Paola
  • Montalvo-Ortiz, Janitza L.|||0000-0002-7657-8365
  • Gelernter, Joel|||0000-0002-4067-1859
  • Soler Artigas, María|||0000-0002-3213-1107
  • Elson, Sarah L.
  • Edenberg, Howard J.|||0000-0003-0344-9690
  • Fontanillas, Pierre
  • Palmer, Abraham A.
  • Sánchez Roige, Sandra|||0000-0001-6137-5699
Alcohol consumption is associated with numerous negative social and health outcomes. These associations may be direct consequences of drinking, or they may reflect common genetic factors that influence both alcohol consumption and other outcomes. We performed exploratory phenome-wide association studies (PheWAS) of three of the best studied protective single nucleotide polymorphisms (SNPs) in genes encoding ethanol metabolising enzymes (ADH1B : rs1229984-T, rs2066702-A; ADH1C : rs698-T) using up to 1109 health outcomes across 28 phenotypic categories (e.g., substance-use, mental health, sleep, immune, cardiovascular, metabolic) from a diverse 23andMe cohort, including European (N ≤ 2,619,939), Latin American (N ≤ 446,646) and African American (N ≤ 146,776) populations to uncover new and perhaps unexpected associations. These SNPs have been consistently implicated by both candidate gene studies and genome-wide association studies of alcohol-related behaviours but have not been investigated in detail for other relevant phenotypes in a hypothesis-free approach in such a large cohort of multiple ancestries. To provide insight into potential causal effects of alcohol consumption on the outcomes significant in the PheWAS, we performed univariable two-sample and one-sample Mendelian randomisation (MR) analyses. The minor allele rs1229984-T, which is protective against alcohol behaviours, showed the highest number of PheWAS associations across the three cohorts (N = 232, European; N = 29, Latin American; N = 7, African American). rs1229984-T influenced multiple domains of health. We replicated associations with alcohol-related behaviours, mental and sleep conditions, and cardio-metabolic health. We also found associations with understudied traits related to neurological (migraines, epilepsy), immune (allergies), musculoskeletal (fibromyalgia), and reproductive health (preeclampsia). MR analyses identified evidence of causal effects of alcohol consumption on liability for 35 of these outcomes in the European cohort. Our work demonstrates that polymorphisms in genes encoding alcohol metabolising enzymes affect multiple domains of health beyond alcohol-related behaviours. Understanding the underlying mechanisms of these effects could have implications for treatments and preventative medicine. MVJ, NCK, SBB, SSR and AAP were supported by T32IR5226 and 28IR-0070. SSR was also supported by DP1DA054394. NCK and RBC were also supported by R25MH081482. ASH was supported by funds from NIAAA K01AA030083. JLMO was supported by VA 1IK2CX002095. JLMO and JJMM were also supported by R21DA050160. JJMM was also supported by the for Academic Diversity. EGA was supported by K01MH121659 from the /, the and the at . MSA was supported by the and co-funded by the : (FSE+) (P19/01224, PI22/00464 and CP22/00128).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Premature Death, Suicide, and Nonlethal Intentional Self-Harm After Psychiatric Discharge

  • Mortier, Philippe|||0000-0003-2113-6241
  • Conde, Susana
  • Alayo, Itxaso|||0000-0002-7333-3450
  • Amigo, Franco|||0000-0002-3602-5168
  • Ballester, Laura
  • Cirici Amell, Roser
  • Guinart, Daniel
  • Contaldo, Salvatore Fabrizio
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Leis, Angela
  • Mayer, Miguel Angel|||0000-0003-0362-6298
  • Portillo-Van Diest, Ana|||0000-0001-7199-8339
  • Puértolas-Gracia, Beatriz
  • Ramírez-Anguita, Juan Manuel|||0000-0002-8509-0927
  • Peña-Salazar, Carlos
  • Sanz, Ferran|||0000-0002-7534-7661
  • Kessler, Ronald|||0000-0003-4831-2305
  • Palao, Diego|||0000-0002-3323-6568
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Mehlum, Lars|||0000-0003-2813-0045
  • Qin, Ping
  • Vilagut, Gemma|||0000-0002-3714-226X
  • Alonso, Jordi|||0000-0001-8627-9636
This cohort study estimates rates of all-cause premature death, suicide, and nonlethal intentional self-harm after discharge from a psychiatric hospitalization among patients in Spain and investigates associations of these outcomes with variables including sex and mental disorders. What is the risk for premature death, suicide, and nonlethal intentional self-harm following discharge from psychiatric hospitalization? In this cohort study including 49 108 patients, risk for postdischarge premature death (age <70 years) and suicide was significantly higher compared with the general population. Premature death was associated with cognitive disorders and alcohol-related disorders in both sexes; suicide was associated with postdischarge nonlethal intentional self-harm in both sexes, with depressive and adjustment disorders in males, and with bipolar disorder in females. The findings suggest individuals discharged from psychiatric inpatient care constitute a vulnerable population for premature death and suicidal behavior. There is a need for representative research on serious adverse outcomes following discharge from psychiatric hospitalization. To compare rates of premature death, suicide, and nonlethal intentional self-harm after psychiatric discharge with rates in the general population and investigate associations of these outcomes with relevant variables associated with the index psychiatric hospitalization. This retrospective cohort study included all residents from Catalonia, Spain (7.6 million population), who had psychiatric hospitalizations between January 1, 2014, and December 31, 2018, and were older than 10 years at the index (first) hospitalization. Follow-up was until December 31, 2019. Statistical analysis was performed from December 1, 2022, through April 11, 2024. Socioeconomic status, psychiatric diagnoses, duration of index hospitalization, and number of previous psychiatric hospitalizations. Postdischarge premature death (ie, all-cause death before age 70 years) and suicide (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision [ICD-10] code range X60-X84), identified using mortality data, and postdischarge nonlethal intentional self-harm, identified using electronic health record and self-harm case register data. Standardized mortality ratios (SMRs) compared rates of premature death and suicide between the cohort and the general population. Fully adjusted, multivariable, cause-specific Cox proportional hazards regression models for the 3 outcomes were fitted. A total of 49 108 patients discharged from psychiatric hospitalization were included (25 833 males [52.6%]; mean [SD] age at discharge, 44.2 [18.2] years). During follow-up, 2260 patients (4.6%) died prematurely, 437 (0.9%) died by suicide, and 4752 (9.7%) had an episode of nonlethal intentional self-harm. The overall SMR for premature death was 7.5 (95% CI, 7.2-7.9). For suicide, SMR was 32.9 (95% CI, 29.9-36.0) overall and was especially high among females (47.6 [95% CI, 40.2-54.9]). In fully adjusted sex-stratified hazard models, postdischarge premature death was associated with cognitive disorders (adjusted hazard ratio [AHR], 2.89 [95% CI, 2.24-3.74] for females; 2.59 [95% CI, 2.17-3.08] for males) and alcohol-related disorders (AHR, 1.41 [95% CI, 1.18-1.70] for females; 1.22 [95% CI, 1.09-1.37] for males). Postdischarge suicide was associated with postdischarge intentional self-harm (AHR, 2.83 [95% CI, 1.97-4.05] for females; 3.29 [95% CI, 2.47-4.40] for males), with depressive disorders (AHR, 2.13 [95% CI, 1.52-2.97]) and adjustment disorders (AHR, 1.94 [95% CI, 1.32-2.83]) among males, and with bipolar disorder among females (AHR, 1.94 [95% CI, 1.21-3.09]). Postdischarge intentional self-harm was associated with index admissions for intentional self-harm (AHR, 1.95 [95% CI, 1.73-2.21] for females; 2.62 [95% CI, 2.20-3.13] for males) as well as for adjustment disorders (AHR, 1.48 [95% CI, 1.33-1.65] for females; 1.99 [95% CI, 1.74-2.27] for males), anxiety disorders (AHR, 1.24 [95% CI, 1.10-1.39] for females; 1.36 [95% CI, 1.18-1.58] for males), depressive disorders (AHR, 1.54 [95% CI, 1.40-1.69] for females; 1.80 [95% CI, 1.58-2.04] for males), and personality disorders (AHR, 1.59 [95% CI, 1.46-1.73] for females; 1.43 [95% CI, 1.28-1.60] for males). In this cohort study of patients discharged from psychiatric hospitalization, risk for premature death and suicide was significantly higher compared with the general population, suggesting individuals discharged from psychiatric inpatient care are a vulnerable population for premature death and suicidal behavior.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Women's neuroplasticity during gestation, childbirth and postpartum

  • Paternina-Die, María|||0000-0002-5100-4955
  • Martínez-García, Magdalena|||0000-0002-5054-9427
  • Martín de Blas, Daniel|||0000-0001-6985-9460
  • Noguero, Inés
  • Servin-Barthet, Camila|||0000-0002-4771-898X
  • Pretus, Clara|||0000-0003-2172-1184
  • Soler, Anna
  • López-Montoya, Gonzalo
  • Desco, Manuel|||0000-0003-0989-3231
  • Carmona Cañabate, Susana|||0000-0001-5853-6527
Pregnancy is a unique neuroplastic period in adult life. This longitudinal study tracked brain cortical changes during the peripartum period and explored how the type of childbirth affects these changes. We collected neuroanatomic, obstetric and neuropsychological data from 110 first-time mothers during late pregnancy and early postpartum, as well as from 34 nulliparous women evaluated at similar time points. During late pregnancy, mothers showed lower cortical volume than controls across all functional networks. These cortical differences attenuated in the early postpartum session. Default mode and frontoparietal networks showed below-expected volume increases during peripartum, suggesting that their reductions may persist longer. Results also pointed to different cortical trajectories in mothers who delivered by scheduled C-section. The main findings were replicated in an independent sample of 29 mothers and 24 nulliparous women. These data suggest a dynamic trajectory of cortical decreases during pregnancy that attenuates in the postpartum period, at a different rate depending on the brain network and childbirth type. This longitudinal study tracked the brains of 139 first-time mothers. Mothers showed lower cortical volume before childbirth that attenuated during the postpartum, with a distinct recovery rate as a function of the brain network and birth type.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dissecting the polygenic contribution of attention-deficit/hyperactivity disorder and autism spectrum disorder on school performance by their relationship with educational attainment

  • Cabana-Domínguez, Judit|||0000-0002-4732-7284
  • Bosch, Rosa|||0000-0002-7596-183X
  • Soler Artigas, María|||0000-0002-3213-1107
  • Alemany Sierra, Silvia|||0000-0002-7925-6767
  • Llonga, Natalia|||0000-0003-4325-6201
  • Vilar-Ribó, L.|||0000-0001-8758-523X
  • Carabí-Gassol, Pau
  • Arribas, Lorena|||0000-0002-9683-9999
  • Macias-Chimborazo, Valeria
  • Español-Martín, Gemma|||0000-0002-2362-8189
  • del Castillo, Clara
  • Martínez, Laura
  • Pagerols, Mireia|||0000-0003-0856-6247
  • Pagespetit, Èlia
  • Prat, Raquel|||0000-0001-8097-6617
  • Puigbó, Julia
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Ribasés Haro, Marta|||0000-0003-1039-1116
Attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorders (ASD) are strongly associated with educational attainment (EA), but little is known about their genetic relationship with school performance and whether these links are explained, in part, by the genetic liability of EA. Here, we aim to dissect the polygenic contribution of ADHD and ASD to school performance, early manifestation of psychopathology and other psychiatric disorders and related traits by their relationship with EA. To do so, we tested the association of polygenic scores for EA, ADHD and ASD with school performance, assessed whether the contribution of the genetic liability of ADHD and ASD to school performance is influenced by the genetic liability of EA, and evaluated the role of EA in the genetic overlap between ADHD and ASD with early manifestation of psychopathology and other psychiatric disorders and related traits in a sample of 4,278 school-age children. The genetic liability for ADHD and ASD dissected by their relationship with EA show differences in their association with school performance and early manifestation of psychopathology, partly mediated by ADHD and ASD symptoms. Genetic variation with concordant effects in ASD and EA contributes to better school performance, while the genetic variation with discordant effects in ADHD or ASD and EA is associated with poor school performance and higher rates of emotional and behavioral problems. Our results strongly support the usage of the genetic load for EA to dissect the genetic and phenotypic heterogeneity of ADHD and ASD, which could help to fill the gap of knowledge of mechanisms underlying educational outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A founder variant in the RYR1 gene is associated with hyperCKemia, myalgia and muscle cramps

  • Segarra Casas, Alba|||0000-0001-5185-5031
  • Iruzubieta, Pablo
  • Kapetanovic, Solange
  • Hernández-Laín, Aurelio
  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Fernández-Torrón, Roberto
  • Maneiro, Miren
  • Marco-Moreno, Pablo|||0000-0002-0302-9031
  • Zelaya-Huerta, M. Victoria
  • Rodriguez Santiago, Benjamin|||0000-0003-1167-3852
  • Calafell, Francesc|||0000-0002-1083-9438
  • Töpf, Ana
  • Straub, Volker|||0000-0001-9046-3540
  • Vallejo-Illarramendi, Ainara
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • Gallano, Pia|||0000-0001-8104-2197
  • González Quereda, Lidia|||0000-0003-0715-6414
Background and purpose: Pathogenic variants in the RYR1 gene have been associated with a variety of conditions, ranging from congenital myopathy to adult manifestations. Our aim was to characterize the p.Leu2286Val variant in 17 Basque patients, to accurately determine its correlation with clinical features and to explore the possible founder effect of the variant. Methods: Families harbouring the p.Leu2286 RYR1 variant underwent a detailed clinical evaluation, including muscle magnetic resonance imaging, electromyography and muscle biopsy. Haplotypes were analysed in available patients and their relatives. Results: Individuals carrying the p.Leu2286Val shared a common haplotype, suggesting a founder event in the Basque Country population. The most prevalent features were exertional myalgia, high creatine kinase (CK) levels, cramps and muscle hypertrophy. None of the patients carrying only the p.Leu2286Val showed progression to severe muscle weakness and muscle magnetic resonance imaging showed a heterogeneous muscle involvement. Muscle biopsy revealed non-specific findings in two patients and features associated with central core disease in one patient carrying only the p.Leu2286Val and two patients harbouring an additional RYR1 variant. Three individuals carrying an in trans RYR1 variant presented with an earlier onset and more severe phenotype. Conclusion: Here, it is shown that the dominantly inherited p.Leu2286Val RYR1 founder variant is associated with a milder phenotype of exercise intolerance, myalgia and hyperCKemia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biomarkers for Psychosis, Are We There Yet? Umbrella Review of 1478 Biomarkers

  • Fuentes-Claramonte, Paola|||0000-0002-1428-7976
  • Estradé, Andrés|||0000-0001-6871-5932
  • Solanes, Aleix|||0000-0002-2491-200X
  • Ramella-Cravaro, Valentina
  • Garcia-Leon, Maria Angeles
  • Diego-Adeliño, Javier de|||0000-0001-9708-2441
  • Molins, Conrad
  • Fung, Eric
  • Valentí, Marc
  • Anmella, Gerard|||0000-0002-6798-4054
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Oliver, Dominic|||0000-0002-8920-3407
  • Vieta, Eduard|||0000-0002-0548-0053
  • Radua, Joaquim|||0000-0003-1240-5438
  • Fusar-Poli, Paolo|||0000-0003-3582-6788
This umbrella review aims to comprehensively synthesize the evidence of association between peripheral, electrophysiological, neuroimaging, neuropathological, and other biomarkers and diagnosis of psychotic disorders. We selected systematic reviews and meta-analyses of observational studies on diagnostic biomarkers for psychotic disorders, published until February 1, 2018. Data extraction was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Evidence of association between biomarkers and psychotic disorders was classified as convincing, highly suggestive, suggestive, weak, or non-significant, using a standardized classification. Quality analyses used the Assessment of Multiple Systematic Reviews (AMSTAR) tool. The umbrella review included 110 meta-analyses or systematic reviews corresponding to 3892 individual studies, 1478 biomarkers, and 392 210 participants. No factor showed a convincing level of evidence. Highly suggestive evidence was observed for transglutaminase autoantibodies levels (odds ratio [OR] = 7.32; 95% CI: 3.36, 15.94), mismatch negativity in auditory event-related potentials (standardized mean difference [SMD] = 0.73; 95% CI: 0.5, 0.96), P300 component latency (SMD = -0.6; 95% CI: -0.83, -0.38), ventricle-brain ratio (SMD = 0.61; 95% CI: 0.5, 0.71), and minor physical anomalies (SMD = 0.99; 95% CI: 0.64, 1.34). Suggestive evidence was observed for folate, malondialdehyde, brain-derived neurotrophic factor, homocysteine, P50 sensory gating (P50 S2/S1 ratio), frontal N -acetyl-aspartate, and high-frequency heart rate variability. Among the remaining biomarkers, weak evidence was found for 626 and a non-significant association for 833 factors. While several biomarkers present highly suggestive or suggestive evidence of association with psychotic disorders, methodological biases, and underpowered studies call for future higher-quality research.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility

  • de la Fuente-Vivas, Dalia
  • Cappitelli, Vincenzo
  • García-Gómez, Rocío
  • Valero-Díaz, Sara
  • Amato, Camilla
  • Rodriguéz, Javier
  • Duro Sánchez, Santiago|||0000-0002-3829-7562
  • von Kriegsheim, Alexander
  • Grusch, Michael|||0000-0001-5486-9340
  • Lozano, José
  • Arribas, Joaquín V|||0000-0002-0504-0664
  • Casar, Berta|||0000-0002-3058-5631
  • Crespo, Piero|||0000-0003-2825-7783
ERK1/2 mitogen-activated protein kinases (ERK) are key regulators of basic cellular processes, including proliferation, survival, and migration. Upon phosphorylation, ERK becomes activated and a portion of it dimerizes. The importance of ERK activation in specific cellular events is generally well documented, but the role played by dimerization is largely unknown. Here, we demonstrate that impeding ERK dimerization precludes cellular movement by interfering with the molecular machinery that executes the rearrangements of the actin cytoskeleton. We also show that a constitutively dimeric ERK mutant can drive cell motility per se, demonstrating that ERK dimerization is both necessary and sufficient for inducing cellular migration. Importantly, we unveil that the scaffold protein kinase suppressor of Ras 1 (KSR1) is a critical element for endowing external agonists, acting through tyrosine kinase receptors, with the capacity to induce ERK dimerization and, subsequently, to unleash cellular motion. In agreement, clinical data disclose that high KSR1 expression levels correlate with greater metastatic potential and adverse evolution of mammary tumors. Overall, our results portray both ERK dimerization and KSR1 as essential factors for the regulation of cell motility and mammary tumor dissemination. In mammary tumor cells, ERK dimerization is both necessary and sufficient for inducing cellular migration. The scaffold protein KSR1 is a critical element for endowing external agonists, acting through tyrosine kinase receptors, with the capacity to induce ERK dimerization and, subsequently, unleashing cellular motion, as a consequence of which tumor cell migration and metastatic dissemination are promoted.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice

  • Verberk, I.M.W.
  • Jutte, J.
  • Kingma, M.Y.
  • Vigneswaran, S.
  • Gouda, M.M.T.E.E.
  • van Engelen, M.P.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Chevalier, C.
  • Marizzoni, M.
  • van de Giessen, E.M.
  • Lemstra, A.W.
  • Pijnenburg, Y.A.L.
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • den Braber, A.
  • Wilson, D.
  • Schut, M.C.
  • van Harten, A.C.
  • Teunissen, C.E.
INTRODUCTION: We developed a multimarker blood test result interpretation tool for the clinical dementia practice, including phosphorylated (P-)tau181, amyloid-beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). METHODS: We measured the plasma biomarkers with Simoa (n = 1199), applied LASSO regression for biomarker selection and receiver operating characteristics (ROC) analyses to determine diagnostic accuracy. We validated our findings in two independent cohorts and constructed a visualization approach. RESULTS: P-tau181, GFAP, and NfL were selected. This combination had area under the curve (AUC) = 83% to identify amyloid positivity in pre-dementia stages, AUC = 87%-89% to differentiate Alzheimer's or controls from frontotemporal dementia, AUC = 74%-76% to differentiate Alzheimer's or controls from dementia with Lewy bodies. Highly reproducible AUCs were obtained in independent cohorts. The resulting visualization tool includes UpSet plots to visualize the stand-alone biomarker results and density plots to visualize the biomarker results combined. DISCUSSION: Our multimarker blood test interpretation tool is ready for testing in real-world clinical dementia settings. Highlights: We developed a multimarker blood test interpretation tool for clinical dementia practice. Our interpretation tool includes plasma biomarkers P-tau, GFAP, and NfL. Our tool is particularly useful for Alzheimer's and frontotemporal dementia diagnosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of white matter hyperintensities in Down syndrome

  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Aranha, Mateus|||0000-0001-9594-292X
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Padilla, Concepción|||0000-0003-4102-6787
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernandez, S.
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Giménez, Sandra|||0000-0001-8031-2319
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Bargalló, Núria|||0000-0001-6284-5402
  • Ribas, Laia
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Belbin, Olivia|||0000-0002-6109-6371
  • Camacho, Valle|||0000-0003-0748-0847
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Bejanin, Alexandre|||0000-0002-9958-0951
INTRODUCTION: In Down syndrome (DS), white matter hyperintensities (WMHs) are highly prevalent, yet their topography and association with sociodemographic data and Alzheimer's disease (AD) biomarkers remain largely unexplored. METHODS: In 261 DS adults and 131 euploid controls, fluid-attenuated inversion recovery magnetic resonance imaging scans were segmented and WMHs were extracted in concentric white matter layers and lobar regions. We tested associations with AD clinical stages, sociodemographic data, cerebrospinal fluid (CSF) AD biomarkers, and gray matter (GM) volume. RESULTS: In DS, total WMHs arose at age 43 and showed stronger associations with age than in controls. WMH volume increased along the AD continuum, particularly in periventricular regions, and frontal, parietal, and occipital lobes. Associations were found with CSF biomarkers and temporo-parietal GM volumes. DISCUSSION: WMHs increase 10 years before AD symptom onset in DS and are closely linked with AD biomarkers and neurodegeneration. This suggests a direct connection to AD pathophysiology, independent of vascular risks. Highlights: White matter hyperintensities (WMHs) increased 10 years before Alzheimer's disease symptom onset in Down syndrome (DS). WMHs were strongly associated in DS with the neurofilament light chain biomarker. WMHs were more associated in DS with gray matter volume in parieto-temporal areas.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL), GELLC-7 trial from the Spanish group of CLL (GELLC)

  • Abrisqueta, Pau|||0000-0001-9625-7422
  • González Barca, Eva|||0000-0002-1323-1508
  • Ferrá, Christelle|||0000-0003-4571-5125
  • Ríos-Herranz, Eduardo
  • Fernández de la Mata, Margarita
  • Delgado, Julio|||0000-0002-5157-4376
  • Andreu, Rafael|||0000-0002-9220-3352
  • Hernández-Rivas, José Ángel
  • Terol, María José
  • Navarro, Almudena
  • Vidriales, M. Belén
  • Baltasar, Patricia
  • De La Serna, Javier|||0000-0003-3904-1101
  • Ramírez, Á.ngel
  • Ballester, C.
  • Moreno, Carol|||0000-0003-3275-0271
  • García-Marco, J.A.|||0000-0002-8993-5982
  • Córdoba, Raúl|||0000-0002-7654-8836
  • Yáñez, Lucrecia|||0000-0001-9925-3048
  • Casado, Luis Felipe
  • González, Marcos
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
BTK inhibitors have been concurrently administered with anti-CD20 monoclonal antibodies (mAbs) in chronic lymphocytic leukemia (CLL). However, the optimal regimen for combining these two drugs remains pending. Methods: This multi-center phase 2 study aimed to analyze whether consolidation with ofatumumab improved the response in patients with CLL receiving front-line treatment with ibrutinib. Patients received 12 cycles of ibrutinib monotherapy. Those who achieved CR after this induction were maintained on ibrutinib. Conversely, those who did not attain CR continued with ibrutinib in addition to a consolidation, which involved 7 doses of ofatumumab. The primary objective was the complete response (CR) rate at cycle 20. This study is registered within the EU Clinical Trials Register (EudraCT 2016-004937-26). Findings: Between September 8, 2017, and May 21, 2018, 84 patients (median age, 69 years) were included. After completion of 12 cycles of ibrutinib (n = 80), 4 patients (5%) were in CR, 67 (84%) in partial response (PR), and 6 patients (7%) had a PR with lymphocytosis (PRL). After consolidation with ofatumumab, 20 patients improved the response from PR to CR and 6 patients with PRL obtained a PR. Seventy-one patients (85%) completed 20 cycles of treatment, with a CR rate of 24/71 (34%). According to the intention-to-treat analysis at cycle 20, the ORR was 69/84 (82.2%), with a CRR of 24/84 (28.6%). Progression-free survival and overall survival at 48-months were 89.9% (CI: 82.4-95.5) and 92.2% (CI: 85.3-97.1), respectively. Interpretation: These findings underscore the potential for a consolidation strategy in CLL, wherein the addition of a mAb in patients with low tumor burden might enhance the quality of the response. Funding: The study was funded by Janssen that also supplied ibrutinib, whereas ofatumumab was supplied by Novartis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality

  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
  • Martí-Aguado, D.|||0000-0002-4266-6076
  • Gómez-Medina, C.|||0000-0002-4788-5630
  • Ferrero-Gregori, Andreu|||0000-0001-6492-2416
  • Szafranska, Justyna|||0000-0003-0467-8479
  • Brujats Rubirola, Anna|||0000-0003-3317-0295
  • Osuna Gómez, Rubén|||0000-0003-2875-4405
  • Alfaro-Cervelló, C.|||0000-0002-3737-4028
  • Pose, Elisa|||0000-0002-0224-7686
  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Fernández-Carrillo, C.|||0000-0002-1326-5142
  • Cabezas González, Joaquín|||0000-0003-0012-484X
  • López-Pelayo, Hugo|||0000-0002-3850-8374
  • Arab, Juan Pablo|||0000-0002-8561-396X
  • Argemi, J.|||0000-0003-1696-7753
  • Bataller, Ramon|||0000-0002-1119-7799
  • Guinart Cuadra, Albert|||0000-0003-0233-5595
  • Clemente-Sanchez, Ana
  • Contreras, Cynthia
Background and Aims: Alcohol use disorder has been reported in patients undergoing bariatric procedures, but the pattern of alcohol consumption has not been evaluated. We investigated the prevalence, risk factors, and impact of binge drinking (BD) at the time of surgery and during follow-up. Methods: A prospective, longitudinal study of subjects undergoing bariatric surgery was included in the LABS-2 registry between 2006 and 2009. Participants with AUDIT questionnaire at the time of surgery and a minimum of 12 months follow-up were included. BD was defined as consuming ≥5 drinks on at least 1 occasion in the previous month. Liver biopsies were obtained during bariatric procedures in not all cases. Survival analysis was performed with the adjusted Cox regression model and competing risk. Results: A total of 2257 subjects were included, with a median follow-up of 79 months. The prevalence of BD at time of surgery was 12%, and it raised up to 23% during follow-up. Patients with BD predominantly had a binge eating disorder (OR=1.35 [95% CI: 1.04-1.76]), regularly consumed fast food [OR=1.4 (95% CI: 1.07-1.85)] and used other drugs (OR=2.65 [95% CI: 1.74-4.04]). Within liver biopsies evaluation, BD showed higher hepatic iron deposits (OR=3.00 [95% CI: 1.25-7.21]). BD at the time of surgery was associated with a higher risk of BD during follow-up (OR=10.49 [95% CI: 7.86-14.00]) and long-term mortality (HR: 3.21 [95% CI: 1.67-6.18]). Specific causes of death in these patients with BD were liver disease (p=0.020), suicide (p=0.015), neoplasms (p=0.034), and respiratory (p=0.025). Conclusions: The prevalence of BD in patients undergoing bariatric surgery is high and increases the risk of postoperative liver disease, suicides, and long-term mortality.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A nationwide Guillain-Barré syndrome epidemiological study in Spain during the COVID-19 years

  • Blanco-Ruiz, M.
  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Collet Vidiella, Roger|||0000-0003-1668-1018
  • Tejada-Illa, Clara|||0009-0008-2856-7179
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Llansó, Laura|||0000-0003-4950-7657
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Amaya Pascasio, L.
  • Querol, Luis|||0000-0002-4289-8264
Background and purpose: The purpose was to perform a nationwide epidemiological study of Guillain-Barré syndrome (GBS) in Spain, analysing background incidences and seasonal variation and trying to identify incidence changes during the coronavirus disease 2019 (COVID-19) years. Methods: This was an observational study collecting all GBS diagnoses from the National Epidemiological Surveillance Network collected by the Ministry of Health. Patients discharged with GBS as the main diagnosis and admitted during 2018-2021 were included. Data on the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were obtained from the National Epidemiology Centre. Results: In total, 3147 cases were included, 832 in 2018, 861 in 2019, 670 in 2020 and 784 in 2021. Nationwide hospital incidence was 1.78 in 2018, 1.71 in 2019, 1.41 in 2020 and 1.66 in 2021, with an increased frequency in males, the elderly population and in the winter season. Eleven per cent of GBS patients needed ventilatory support. GBS and SARS-CoV-2 incidences did not correlate with one another (r = -0.29, p = 0.36). GBS incidence decreased during 2020 and during the COVID-19 lockdown period in comparison to the same months of 2018-2019. Conclusions: The incidence of GBS in Spain is similar to that of other countries. Despite prior reports describing a significant increase in COVID-19-associated GBS in Spain, a significant drop of GBS incidence during the SARS-CoV-2 pandemic was detected, probably due to prevention measures.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease

  • Seguí, Elia|||0000-0001-7770-9825
  • Torres Canizales, Juan|||0000-0002-7138-5732
  • Auclin, E.
  • Casadevall, David|||0000-0002-3986-2084
  • Peiro Carmona, Sara
  • Aguilar Company, Juan|||0000-0002-9838-1950
  • García de Herreros, Marta|||0000-0001-8010-3584
  • Gorría, Teresa
  • Laguna, Juan Carlos|||0000-0002-2357-1186
  • Rodríguez, Marta
  • González, Azucena
  • Epaillard, N.|||0000-0001-7543-491X
  • Gavira, Javier|||0000-0001-6385-3519
  • Bolaño, Victor
  • Tapia, Jose C.|||0000-0001-6545-8862
  • Tagliamento, M.
  • Teixidó, C.
  • Arasanz, Hugo|||0000-0001-6838-6702
  • Pilotto, S.|||0000-0003-2229-4874
  • Lopez Castro, Rafael|||0000-0003-4770-4710
  • Mielgo-Rubio, Xabier|||0000-0002-0985-6150
  • Urbano, C.
  • Recondo, G.
  • Diaz Pavon, Mar|||0009-0001-2378-5432
  • Bluthgen, M.V.
  • Minatta, J.N.|||0000-0002-3531-1920
  • Lupinacci, L.
  • Brasó-Maristany, F.
  • Prat, A.
  • Vlagea, Alexandru|||0000-0003-3169-4597
  • Mezquita, Laura|||0000-0003-0936-7338
Inflammation and neutrophils play a central role in both COVID-19 disease and cancer. We aimed to assess the impact of pre-existing tumor-related inflammation on COVID-19 outcomes in patients with cancer and to elucidate the role of circulating neutrophil subpopulations. We conducted a multicenter retrospective analysis of 524 patients with cancer and SARS-CoV-2 infection, assessing the relationship between clinical outcomes and circulating inflammatory biomarkers collected before and during COVID-19 infection. Additionally, a single-center prospective cohort study provided data for an exploratory analysis, assessing the immunophenotype of circulating neutrophils and inflammatory cytokines. The primary endpoints were 30-day mortality and the severity of COVID-19 disease. Prior to COVID-19, 25% of patients with cancer exhibited elevated dNLR, which increased to 55% at the time of COVID-19 diagnosis. We developed the FLARE score, incorporating both tumor- and infection-induced inflammation, which categorized patients into four prognostic groups. The poor prognostic group had a 30-day mortality rate of 68%, significantly higher than the 23% in the favorable group (p < 0.0001). This score proved to be an independent predictor of early mortality. This prospective analysis revealed a shift towards immature forms of neutrophils and higher IL-6 levels in patients with cancer and severe COVID-19 infection. A pre-existing tumor-induced pro-inflammatory state significantly impacts COVID-19 outcomes in patients with cancer. The FLARE score, derived from circulating inflammatory markers, emerges as an easy-to-use, globally accessible, effective tool for clinicians to identify patients with cancer at heightened risk of severe COVID-19 complications and early mortality who might benefit most from immediate and intensive treatment strategies. Furthermore, our findings underscore the significance of immature neutrophils in the progression of COVID-19 in patients with cancer, advocating for further investigation into how these cells contribute to both cancer and COVID-19 disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical value of plasma pTau181 to predict Alzheimer's disease pathology in a large real-world cohort of a memory clinic

  • Cano, Amanda|||0000-0001-9567-4283
  • Capdevila, María
  • Puerta, Raquel|||0000-0002-1191-5893
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • García-González, Pablo|||0000-0003-0125-5403
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • García-Gutiérrez, Fernando
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Aguilera, Nuria
  • Ramis, Maribel
  • Rosende-Roca, Maite
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Tartari, Juan Pablo
  • Lafuente, Asunción
  • Vargas, Liliana|||0000-0001-5685-5903
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Muñoz, Nathalia
  • Sanabria, Ángela|||0000-0002-7501-9895
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Morató, Xavier|||0000-0002-3012-2864
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Fernández, Victoria
  • Marquié, Marta|||0000-0002-0660-0950
  • Valero, Sergi|||0000-0002-6599-948X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
The identification of patients with an elevated risk of developing Alzheimer's disease (AD) dementia and eligible for the disease-modifying treatments (DMTs) in the earliest stages is one of the greatest challenges in the clinical practice. Plasma biomarkers has the potential to predict these issues, but further research is still needed to translate them to clinical practice. Here we evaluated the clinical applicability of plasma pTau181 as a predictive marker of AD pathology in a large real-world cohort of a memory clinic. Methods: Three independent cohorts (modelling [n = 991, 59.7% female], testing [n = 642, 56.2% female] and validation [n = 441, 55.1% female]) of real-world patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD dementia, and other dementias were included. Paired cerebrospinal fluid (CSF) and plasma samples were used to measure AT(N) CSF biomarkers and plasma pTau181. CSF and plasma pTau181 showed correlation in all phenotypes except in SCD and other dementias. Age significantly influenced the biomarker's performance. The general Aβ(+) vs Aβ(-) ROC curve showed an AUC = 0.77 [0.74-0.80], whereas the specific ROC curve of MCI due to AD vs non-AD MCI showed an AUC = 0.89 [0.85-0.93]. A cut-off value of 1.30 pg/ml of plasma pTau181 exhibited a sensitivity of 93.57% [88.72-96.52], specificity of 72.38% [62.51-79.01], VPP of 77.85% [70.61-83.54], and 8.30% false negatives in the subjects with MCI of the testing cohort. The HR of cox regression showed that patients with MCI up to this cut-off value exhibited a HR = 1.84 [1.05-3.22] higher risk to convert to AD dementia than patients with MCI below the cut-off value. Plasma pTau181 has the potential to be used in the memory clinics as a screening biomarker of AD pathology in subjects with MCI, presenting a valuable prognostic utility in predicting the MCI conversion to AD dementia. In the context of a real-world population, a confirmatory test employing gold-standard procedures is still advisable. This study has been mainly funded by Ace Alzheimer Center Barcelona, Instituto de Salud Carlos III (ISCIII), Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Spanish Ministry of Science and Innovation, Fundación ADEY, Fundación Echevarne and Grífols S.A.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

NADPH Oxidase 5 (NOX5) Upregulates MMP-10 Production and Cell Migration in Human Endothelial Cells

  • Marqués, J.
  • Ainzúa, E.
  • Orbe, J.
  • Martínez-Azcona, M.
  • Martínez-González, José|||0000-0002-3894-7166
  • Zalba, G.
NADPH oxidases (NOXs) have been described as critical players in vascular remodeling, a mechanism modulated by matrix metalloproteinases. In this study, we describe for the first time the upregulation of MMP-10 through the activation of NOX5 in endothelial cells. In a chronic NOX5 overexpression model in human endothelial cells, MMP-10 production was measured at different levels: extracellular secretion, gene expression (mRNA and protein levels), and promoter activity. Effects on cell migration were quantified using wound healing assays. NOX5 overexpression increased MMP-10 production, favoring cell migration. In fact, NOX5 and MMP-10 silencing prevented this promigratory effect. We showed that NOX5-mediated MMP-10 upregulation involves the redox-sensitive JNK/AP-1 signaling pathway. All these NOX5-dependent effects were enhanced by angiotensin II (Ang II). Interestingly, MMP-10 protein levels were found to be increased in the hearts of NOX5-expressing mice. In conclusion, we described that NOX5-generated ROS may modulate the MMP-10 expression in endothelial cells, which leads to endothelial cell migration and may play a key role in vascular remodeling.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pregnancy entails a U-shaped trajectory in human brain structure linked to hormones and maternal attachment

  • Servin-Barthet, Camila|||0000-0002-4771-898X
  • Martínez-García, Magdalena|||0000-0002-5054-9427
  • Paternina-Die, María|||0000-0002-5100-4955
  • Marcos-Vidal, Luis|||0000-0003-2135-1478
  • Martín de Blas, Daniel|||0000-0001-6985-9460
  • Soler, Anna
  • Khymenets, Olha|||0000-0002-8668-580X
  • Bergé Baquero, Daniel|||0000-0003-2544-1016
  • Casals, Gemma
  • Prats Rodriguez, Pilar|||0000-0001-9216-9118
  • Pozo, Oscar J.|||0000-0002-1735-9728
  • Pretus, Clara|||0000-0003-2172-1184
  • Carmona Cañabate, Susana|||0000-0001-5853-6527
  • Vilarroya Oliver, Óscar|||0000-0001-8285-5624
Growing evidence places the gestational period as a unique moment of heightened neuroplasticity in adult life. In this longitudinal study spanning pre, during, and post pregnancy, we unveil a U-shaped trajectory in gray matter (GM) volume, which dips in late pregnancy and partially recovers during postpartum. These changes are most prominent in brain regions associated with the Default Mode and Frontoparietal Network. The U-shaped trajectory is predominantly linked to gestational factors, as it only presents in gestational mothers and correlates with fluctuations in estrogens over time. Finally, the mother's mental health status mediates the relationship between postpartum GM volume recovery and maternal attachment at 6 months postpartum. This research sheds light on the complex interplay between hormones, brain development, and behavior during the transition to motherhood. It addresses a significant knowledge gap in the neuroscience of human pregnancy and opens new possibilities for interventions aimed at enhancing maternal health and well-being.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The transition to motherhood, linking hormones, brain and behaviour

  • Servin-Barthet, Camila|||0000-0002-4771-898X
  • Martínez-García, Magdalena|||0000-0002-5054-9427
  • Pretus, Clara|||0000-0003-2172-1184
  • Paternina-Die, María|||0000-0002-5100-4955
  • Soler Campillo, Anna
  • Khymenets, Olha|||0000-0002-8668-580X
  • Pozo, Oscar J.|||0000-0002-1735-9728
  • Leuner, Benedetta|||0000-0002-8919-6892
  • Vilarroya Oliver, Óscar|||0000-0001-8285-5624
  • Carmona Cañabate, Susana|||0000-0001-5853-6527
We are witnessing a stark increase in scientific interest in the neurobiological processes associated with pregnancy and maternity. Convergent evidence suggests that around the time of labour, first-time mothers experience a specific pattern of neuroanatomical changes that are associated with maternal behaviour. Here we provide an overview of the human neurobiological adaptations of motherhood, focusing on the interplay between pregnancy-related steroid and peptide hormones, and neuroplasticity in the brain. We discuss which brain plasticity mechanisms might underlie the structural changes detected by MRI, which hormonal systems are likely to contribute to such neuroanatomical changes and how these brain mechanisms may be linked to maternal behaviour. This Review offers an overarching framework that can serve as a roadmap for future investigations.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Patritumab deruxtecan in HER2-negative breast cancer, part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response

  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Ferrero-Cafiero, Juan Manuel|||0000-0001-8796-8812
  • Falato, Claudette
  • Martínez-Sáez, Olga|||0000-0001-8686-0236
  • Cejalvo, Juan Miguel|||0000-0002-8755-8626
  • Margelí, Mireia|||0000-0003-3594-4530
  • Tolosa, Pablo|||0000-0002-3747-4766
  • Salvador-Bofill, Francisco Javier
  • Cruz, Josefina
  • González Farré, Blanca|||0000-0002-1796-7248
  • Sanfeliu, Esther|||0000-0002-7974-3346
  • Òdena, Andreu|||0000-0003-1529-880X
  • Serra, Violeta|||0000-0001-6620-1065
  • Pardo, Francisco|||0000-0002-3067-0166
  • Luna Barrera, Ana María
  • Arumi, Miriam|||0000-0003-3329-4941
  • Guerra, Juan Antonio
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Sánchez-Bayona, Rodrigo
  • Ciruelos, Eva|||0000-0002-2796-1042
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Izarzugaza, Yann
  • Galván, Patricia
  • Matito, Judit|||0000-0001-7560-7737
  • Pernas, Sonia|||0000-0002-1485-5080
  • Vidal Losada, Maria|||0000-0003-1992-5727
  • Santhanagopal, Anu
  • Sellami, Dalila
  • Esker, Stephen
  • Fan, Pang-Dian
  • Suto, Fumitaka
  • Vivancos, Ana|||0000-0003-2888-6512
  • Pascual, Tomás|||0000-0001-8431-3183
  • Prat, Aleix|||0000-0003-2377-540X
  • Oliveira, Mafalda|||0000-0001-9152-8799
Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3/HER3 levels. This research investigates the genetic factors affecting HER3-DXd's response in women with early-stage hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer. In the SOLTI-1805 TOT-HER3 trial, a single HER3-DXd dose was administered to 98 patients across two parts: 78 patients received 6.4 mg/kg (Part A), and 44 received a lower 5.6 mg/kg dose (Part B). The CelTIL score, measuring tumor cellularity and infiltrating lymphocytes from baseline to day 21, was used to assess drug activity. Part A demonstrated increased CelTIL score after one dose of HER3-DXd. Here we report CelTIL score and safety for Part B. In addition, the exploratory analyses of part A involve a comprehensive study of gene expression, somatic mutations, copy-number segments, and DNA-based subtypes, while Part B focuses on validating gene expression. RNA analyses show significant correlations between CelTIL responses, high proliferation genes (e.g., CCNE1, MKI67), and low expression of luminal genes (e.g., NAT1, SLC39A6). DNA findings indicate that CelTIL response is significantly associated with TP53 mutations, proliferation, non-luminal signatures, and a distinct DNA-based subtype (DNADX cluster-3). Critically, low HER2DX ERBB2 mRNA, correlates with increased HER3-DXd activity, which is validated through in vivo patient-derived xenograft models. This study proposes chemosensitivity determinants, DNA-based subtype classification, and low ERBB2 expression as potential markers for HER3-DXd activity in HER2-negative breast cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Treatment and Monitoring of Eosinophilic Fasciitis

  • Selva O'Callaghan, Albert|||0000-0003-2823-9761
  • Trallero Araguás, Ernesto|||0000-0003-3365-4521
  • Gil Vila, Albert|||0000-0003-2786-2009
  • Guillén-Del-Castillo, Alfredo|||0000-0003-0626-507X
  • Matas-Garcia, Ana|||0000-0002-9184-8079
  • Milisenda, José César|||0000-0003-0151-7872
  • Simeón-Aznar, Carmen Pilar|||0000-0003-3390-9029
  • Pinal Fernandez, Iago|||0000-0001-6338-9218
Purpose of Review Eosinophilic fasciitis (EF) is a rare infammatory disease characterized by skin induration. Although some guidelines from scientifc societies exist, standard recommendations on monitoring and therapy are lacking. Recent Findings Current therapy for patients diagnosed with EF includes glucocorticoids plus at least one immunosuppressive drug in cases of relapse or refractory disease. Methotrexate and mycophenolate mofetil are the most recommended, although recently a myriad of case reports or small series reporting the efectivity of biological agents or JAK inhibitors for treating relapses or refractory disease have been published. Anti-IL5 may have a role in those rare refractory cases with persistent eosinophilia. Intravenous immunoglobulins and photopheresis (in those centers with experience) may act as adjuvant therapies. Monitoring the disease activity is a cornerstone to ascertain if the treatment is useful or not. MRI, PET/TC, and more specifcally POCUS have recently demonstrated their value for assessing therapy response. Summary High-quality data focused on therapy and monitoring is lacking in EF. Strategies for improving scientifc quality of observational studies and consensus about "activity", "sequela", "relapse" or "refractoriness" terms in EF patients are necessary to implement prospective clinical trials and generate evidence-based medicine. Meanwhile we have to deal with the available information.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Staniszewska, Anna D.
  • Domènech-Vivó, Joanna|||0000-0002-8049-7488
  • García-Galea, Eduardo|||0000-0003-4699-0786
  • Moles-Fernández, Alejandro|||0000-0003-0252-6084
  • Pedretti, Flaminia
  • Domènech, Heura
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Guzmán, Marta|||0000-0002-0924-9887
  • Arenas, Enrique
  • Verdaguer, Helena|||0000-0001-6163-382X
  • Calero-Nieto, Fernando|||0000-0003-3358-8253
  • Talbot, Sara
  • Tobalina, Luis
  • Leo, Elisabetta
  • Lau, Alan|||0000-0003-1055-9812
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Macarulla Mercadé, Teresa|||0000-0002-5856-4082
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Diez, Orland|||0000-0001-7339-0570
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Forment, Josep V.|||0000-0002-7797-2583
  • O'Connor, Mark J.|||0000-0003-1823-625X
  • Albertella, Mark Robert
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Serra, Violeta|||0000-0001-6620-1065
Background: Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors (PARPi) are targeted therapies approved for homologous recombination repair (HRR)-deficient breast, ovarian, pancreatic, and prostate cancers. Since inhibition of PARP1 is sufficient to cause synthetic lethality in tumors with homologous recombination deficiency (HRD), PARP1 selective inhibitors such as saruparib (AZD5305) are being developed. It is expected that selective PARP1 inhibition leads to a safer profile that facilitates its combination with other DNA damage repair inhibitors. Here, we aimed to characterize the antitumor activity of AZD5305 in patient-derived preclinical models compared to the first-generation PARP1/2 inhibitor olaparib and to identify mechanisms of resistance. Methods: Thirteen previously characterized patient-derived tumor xenograft (PDX) models from breast, ovarian, and pancreatic cancer patients harboring germline pathogenic alterations in BRCA1, BRCA2, or PALB2 were used to evaluate the efficacy of AZD5305 alone or in combination with carboplatin or an ataxia telangiectasia and Rad3 related (ATR) inhibitor (ceralasertib) and compared it to the first-generation PARPi olaparib. We performed DNA and RNA sequencing as well as protein-based assays to identify mechanisms of acquired resistance to either PARPi. Results: AZD5305 showed superior antitumor activity than the first-generation PARPi in terms of preclinical complete response rate (75% vs. 37%). The median preclinical progression-free survival was significantly longer in the AZD5305-treated group compared to the olaparib-treated group (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

  • Martinez-Verbo, Laura
  • Veselinova, Yoana|||0000-0003-4124-9788
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Noguera Castells, Aleix|||0000-0001-7436-6513
  • Pato, Miguel L.|||0000-0001-8840-7259
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Villanueva, Lorea|||0000-0003-1858-7076
  • Oliver-Caldés, Aina|||0000-0002-7921-5420
  • Cardus, Oriol|||0000-0002-5446-5423
  • Salsench, Sergi V.|||0000-0002-4390-6887
  • García-Ortiz, Almudena
  • Valeri, Antonio
  • Rojas, Elizabeta A.
  • Barrena, Naroa|||0000-0003-4324-3371
  • Gutiérrez, Norma C.
  • Prósper, Felipe
  • Agirre, Xabier|||0000-0002-6558-9560
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Esteller, M|||0000-0003-4490-6093
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action

  • Cerro-Herreros, E.
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Naldaiz-Gastesi, N.
  • Carrascosa-Sàez, M.
  • García-Rey, A.
  • Losilla, D.P.
  • González-Martínez, I.
  • Espinosa-Espinosa, J.
  • Moreno, K.
  • Poyatos-García, J.
  • Vilchez, J.J.
  • López de Munain, A.
  • Suelves, Mònica|||0000-0001-7095-5804
  • Nogales, Gisela|||0000-0002-7414-212X
  • Llamusí, B.
  • Artero, R.
This study evaluated therapeutic antimiRs in primary myoblasts from patients with myotonic dystrophy type 1 (DM1). DM1 results from unstable CTG repeat expansions in the DMPK gene, leading to variable clinical manifestations by depleting muscleblind-like splicing regulator protein MBNL1. AntimiRs targeting natural repressors miR-23b and miR-218 boost MBNL1 expression but must be optimized for a better pharmacological profile in humans. In untreated cells, miR-23b and miR-218 were up-regulated, which correlated with CTG repeat size, supporting that active MBNL1 protein repression synergizes with the sequestration by CUG expansions in DMPK. AntimiR treatment improved RNA toxicity readouts and corrected regulated exon inclusions and myoblast defects such as fusion index and myotube area across CTG expansions. Unexpectedly, the treatment also reduced DMPK transcripts and ribonuclear foci. A leading antimiR reversed 68% of dysregulated genes. This study highlights the potential of antimiRs to treat various DM1 forms across a range of repeat sizes and genetic backgrounds by mitigating MBNL1 sequestration and enhancing protein synthesis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL

  • Rivas Delgado, Alfredo|||0000-0003-0385-3415
  • López, Cristina
  • Clot, Guillem|||0000-0003-2588-7413
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Grau Vorster, Marta|||0000-0003-3779-0387
  • Frigola, Gerard|||0000-0001-6794-6456
  • Bosch-Schips, Jan
  • Radke, Josefine
  • Ishaque, Naveed|||0000-0002-8426-901X
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Luizaga Velasco, Luis|||0000-0001-9314-5783
  • Barcena, Carmen
  • Kelleher, Nicholas|||0000-0003-4610-2718
  • Villamor, Neus|||0000-0001-6538-4111
  • Baumann, Tycho|||0000-0003-4421-0088
  • Muntañola, Ana|||0000-0001-7839-6648
  • Sancho-Cia, Juan M.
  • Martín García-Sancho, Alejandro|||0000-0001-6330-1028
  • González Barca, Eva|||0000-0002-1323-1508
  • Matutes, Estella|||0000-0001-6745-7046
  • Brito, Jordi A.
  • Karube, Kennosuke
  • Salaverria Frigola, Itziar|||0000-0002-2427-9822
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Wiemann, Stefan|||0000-0003-4683-3174
  • Heppner, Frank L.
  • Siebert, Reiner
  • Climent, Fina|||0000-0002-4360-8388
  • Campo, Elias|||0000-0001-9850-9793
  • Giné, Eva|||0000-0002-0532-1204
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Bea, Sílvia|||0000-0001-7192-2385
Testicular large B-cell lymphoma (TLBCL) is an infrequent and aggressive lymphoma arising in an immune-privileged site and has recently been recognized as a distinct entity from diffuse large B-cell lymphoma (DLBCL). We describe the genetic features of TLBCL and compare them with published series of nodal DLBCL and primary large B-cell lymphomas of the CNS (PCNSL). We collected 61 patients with TLBCL. We performed targeted next-generation sequencing, copy number arrays, and fluorescent in situ hybridization to assess chromosomal rearrangements in 40 cases with available material. Seventy percent of the cases showed localized stages. BCL6 rearrangements were detected in 36% of cases, and no concomitant BCL2 and MYC rearrangements were found. TLBCL had fewer copy number alterations (p < 0.04) but more somatic variants (p < 0.02) than nodal DLBCL and had more frequent 18q21.32-q23 (BCL2) gains and 6q and 9p21.3 (CDKN2A/B) deletions. PIM1, MYD88, CD79B, TBL1XR1, MEF2B, CIITA, EP300, and ETV6 mutations were more frequent in TLBCL, and BCL10 mutations in nodal DLBCL. There were no major genetic differences between TLBCL and PCNSL. Localized or disseminated TLBCL displayed similar genomic profiles. Using LymphGen, the majority of cases were classified as MCD. However, we observed a subgroup of patients classified as BN2, both in localized and disseminated TLBCL, suggesting a degree of genetic heterogeneity in the TLBCL genetic profile. TLBCL has a distinctive genetic profile similar to PCNSL, supporting its recognition as a separate entity from DLBCL and might provide information to devise targeted therapeutic approaches.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Amyloid deposition in adults with drug-resistant temporal lobe epilepsy

  • Fonseca, Elena|||0000-0002-3895-1237
  • Lallana, Sofía|||0000-0002-5999-9889
  • Ortega, Gemma
  • Cano, Amanda|||0000-0001-9567-4283
  • Sarria Estrada, Silvana|||0000-0003-0083-362X
  • Pareto, Deborah|||0000-0001-7356-3769
  • Quintana, Manuel|||0000-0003-0288-9088
  • Lorenzo Bosquet, Carles|||0000-0002-8824-4602
  • López Maza, Samuel|||0000-0003-3660-2604
  • Gifreu, Ariadna
  • Campos Fernández, Daniel|||0000-0003-4795-5309
  • Abraira del Fresno, Laura|||0000-0002-5119-7929
  • Santamarina Perez, Estevo|||0000-0003-1915-0335
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Puerta, Raquel|||0000-0002-1191-5893
  • Aguilera, Núria
  • Ramis, Maribel
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Rovira, Alex|||0000-0002-2132-6750
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Toledo, Manuel|||0000-0003-1550-3316
Objective: Pathological amyloid-β (Aβ) accumulation and hyperphosphorylated tau proteins have been described in resected temporal lobe specimens of epilepsy patients. We aimed to determine cerebrospinal fluid (CSF) Aβ1-42 and p181-tau levels and cerebral Aβ deposits on positron emission tomography (Aβ PET) and correlate these findings with cognitive performance in adults with drug-resistant temporal lobe epilepsy (TLE). Methods: In this cross-sectional study, we enrolled individuals with drug-resistant TLE who were 25-55 years old. Each participant underwent F-flutemetamol PET, determination of CSF Aβ1-42, p181-tau, and total tau, and a comprehensive neuropsychological assessment. We evaluated normalized standard uptake value ratios (SUVRs) for different brain regions on Aβ PET. Results: Thirty patients (mean age = 41.9 ± SD 8.1 years, 57% men) were included. The median disease duration was 9.5 (interquartile range = 4-24) years. Twenty-six patients (87%) had a clinically significant cognitive impairment on neuropsychological evaluation, 18 (69%) of the amnesic type. On Aβ PET, high uptake was observed in both mesial temporal regions (ipsilateral: SUVR z-score =.90, 95% confidence interval [CI] =.60-1.20; contralateral: SUVR z-score =.92, 95% CI =.57-1.27; p <.001), which was higher when compared to SUVR z-scores in all the remaining regions (p <.001) and in the ipsilateral anterior cingulate (SUVR z-score =.27, 95% CI =.04-.49, p =.020). No significant deposition was observed in other regions. Seven patients (23%) had low Aβ1-42 levels, and two (7%) had elevated p181-tau levels in CSF. Higher p181-tau levels correlated with poorer verbal fluency (R = -.427, p =.044). Significance: Our findings reveal a considerable Aβ deposition in mesial temporal regions and ipsilateral anterior cingulate among adults with drug-resistant TLE. Additionally, abnormal CSF Aβ1-42 levels were observed in a significant proportion of patients, and p181-tau levels were associated with verbal fluency. These results suggest that markers of neuronal damage can be observed in adults with TLE, warranting further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Primary Cilia as a Tumor Marker in Pituitary Neuroendocrine Tumors

  • Martínez-Hernández, Rebeca
  • Serrano-Somavilla, Ana
  • Fernández-Contreras, Raul
  • Sanchez-Guerrero, Cristina
  • Sánchez de la Blanca, Nuria
  • Sacristán-Gómez, Pedro
  • Sebastian-Valles, Fernando|||0000-0002-4127-0483
  • Sampedro Núñez, Miguel Antonio
  • Fraga, Javier
  • Calatayud, María|||0000-0002-6737-7289
  • Vicente, Almudena
  • García-de-Casasola, G.|||0000-0002-5171-7373
  • Sanz-García, Ancor
  • Araujo-Castro, Marta|||0000-0002-0519-0072
  • Ruz-Caracuel, Ignacio|||0000-0002-2298-4683
  • Puig Domingo, Manuel|||0000-0002-6744-7195
  • Marazuela, Mónica|||0000-0003-1158-9618
Pituitary neuroendocrine tumors (PitNETs) account for approximately 15% of all intracranial neoplasms. Although they usually appear to be benign, some tumors display worse behavior, displaying rapid growth, invasion, refractoriness to treatment, and recurrence. Increasing evidence supports the role of primary cilia (PC) in regulating cancer development. Here, we showed that PC are significantly increased in PitNETs and are associated with increased tumor invasion and recurrence. Serial electron micrographs of PITNETs demonstrated different ciliation phenotypes (dot-like versus normal-like cilia) that represented PC at different stages of ciliogenesis. Molecular findings demonstrated that 123 ciliary-associated genes (eg, doublecortin domain containing protein 2, Sintaxin-3, and centriolar coiled-coil protein 110) were dysregulated in PitNETs, representing the upregulation of markers at different stages of intracellular ciliogenesis. Our results demonstrate, for the first time, that ciliogenesis is increased in PitNETs, suggesting that this process might be used as a potential target for therapy in the future.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Predictors of biochemical response to somatostatin receptor ligands in acromegaly

  • Marazuela, Mónica|||0000-0003-1158-9618
  • Martínez-Hernández, Rebeca
  • Marques-Pamies, Manuel
  • Biagetti, Betina|||0000-0002-8837-4343
  • Araujo-Castro, Marta|||0000-0002-0519-0072
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Although predictors of response to first-generation somatostatin receptor ligands (fg-SRLs), and to a lesser extent to pasireotide, have been studied in acromegaly for many years, their use is still not recommended in clinical guidelines. Is there insufficient evidence to use them? Numerous biomarkers including various clinical, functional, radiological and molecular markers have been identified. The first ones are applicable pre-surgery, while the molecular predictors are utilized for patients not cured after surgery. In this regard, factors predicting a good response to fg-SRLs are specifically: low basal GH, a low GH nadir in the acute octreotide test, T2 MRI hypointensity, a densely granulated pattern, high immunohistochemistry staining for somatostatin receptor 2 (SSTR2), and E-cadherin. However, there is still a lack of consensus regarding which of these biomarkers is more useful or how to integrate them into clinical practice. With classical statistical methods, it is complex to define reliable and generalizable cut-off values for a single biomarker. The potential solution to the limitations of traditional methods involves combining systems biology with artificial intelligence, which is currently providing answers to such long-standing questions that may eventually be finally included into the clinical guidelines and make personalized medicine a reality. The aim of this review is to describe the current knowledge of the main fg-SRLs and pasireotide response predictors, discuss their current usefulness, and point to future directions in the research of this field.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size

  • Jimenez-Leon, Maria Reyes|||0000-0003-2723-319X
  • Gasca-Capote, Carmen|||0000-0002-7211-8599
  • Roca-Oporto, Cristina|||0000-0003-0079-5491
  • Espinosa, Nuria|||0000-0003-2249-2352
  • Sobrino, Salvador
  • Fontillon-Alberdi, Maria|||0000-0003-4031-8067
  • Gao, Ce
  • Roseto, Isabelle
  • Gladkov, Gregory
  • Rivas-Jeremias, Inmaculada
  • Neukam, Karin
  • Sánchez Hernández, José Germán
  • Rigo Bonnin, Raül|||0000-0001-5511-074X
  • Cervera-Barajas, Antonio J.
  • Mesones, Rosario
  • García, Federico
  • Alvarez-Rios, Ana Isabel
  • Bachiller, Sara
  • Vitalle, Joana
  • Perez-Gomez, Alberto
  • Camacho-Sojo, María Inés
  • Gallego, Isabel
  • Brander, Christian|||0000-0002-0548-5778
  • McGowan, Ian
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Viciana, Pompeyo|||0000-0001-5606-0166
  • Yu, Xu
  • Lichterfeld, Mathias
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
BACKGROUND. We evaluated the safety and viral rebound, after analytical treatment interruption (ATI), of vedolizumab and ART in recent HIV-1 infection. We used this model to analyze the effect of α4β7 on the HIV-1 reservoir size. METHODS. Participants started ART with monthly vedolizumab infusions, and ATI was performed at week 24. Biopsies were obtained from ileum and cecum at baseline and week 24. Vedolizumab levels, HIV-1 reservoir, flow cytometry, and cell-sorting and antibody competition experiments were assayed. RESULTS. Vedolizumab was safe and well tolerated. No participant achieved undetectable viremia off ART 24 weeks after ATI. Only a modest effect on the time to achieve more than 1,000 HIV-1 RNA copies/mL and the proportion of participants off ART was observed, being higher in the vedolizumab group compared with historical controls. Just before ATI, α4β7 expression was associated with HIV-1 DNA and RNA in peripheral blood and with PD1 and TIGIT levels. Importantly, a complete blocking of α4β7 was observed on peripheral CD4 T cells but not in gut (ileum and cecum), where α4β7 blockade and vedolizumab levels were inversely associated with HIV-1 DNA. CONCLUSION. Our findings support α4β7 as an important determinant in HIV-1 reservoir size, suggesting the complete α4β7 blockade in tissue as a promising tool for HIV-cure combination strategies. TRIAL REGISTRATION. ClinicalTrials.gov NCT03577782. FUNDING. This work was supported by the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, "a way to make Europe," research contracts FI17/00186 and FI19/00083 and research projects PI18/01532, PI19/01127, PI22/01796), Conserjería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (research projects P20/00906), the Red Temática de Investigación Cooperativa en SIDA (RD16/0025/0020), and the Spanish National Research Council.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Validation of a pregnancy-adapted Mediterranean Diet Adherence Screener (preg-MEDAS), a validation study nested in the Improving Mothers for a better PrenAtal Care Trial BarCeloNa (IMPACT BCN) trial

  • Castro Barquero, Sara|||0000-0002-6876-5443
  • Crovetto, Francesca|||0000-0003-0140-7411
  • Estruch, Ramón|||0000-0003-1260-4445
  • Ruiz-León, Ana María
  • Larroya, Marta|||0000-0001-7929-6630
  • Sacanella, Emilio|||0000-0001-8018-1523
  • Casanovas-Garriga, Francesc
  • Casas, Irene
  • Nakaki, Ayako|||0000-0002-4395-3878
  • Youssef, Lina|||0000-0002-0554-5507
  • Trejo-Domínguez, Alejandra|||0000-0002-5448-275X
  • Benitez, Leticia|||0000-0002-4950-036X
  • Genero, Mariona
  • Vieta, Eduard|||0000-0002-0548-0053
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Crispi, Fatima|||0000-0002-7422-5240
  • Casas, Rosa|||0000-0002-0211-9166
Background: Non-time-consuming and easy-to-administer dietary assessment tools specific for pregnancy are needed. Objectives: The aim of this validation study nested in the IMPACT BCN (Improving Mothers for a better PrenAtal Care Trial BarCeloNa) trial is to determine the concurrent validity of the 17-item pregnancy-adapted Mediterranean diet score (preg-MEDAS) and to analyze whether changes in the preg-MEDAS score were associated with maternal favorable dietary and cardiometabolic changes after 3 mo of intervention in pregnant women. Methods: Dietary data was collected in 812 participants using the preg-MEDAS and a 151-item validated food frequency questionnaire (FFQ) at baseline (19-23 wk gestation) and final visit (31-34 wk gestation). Concurrent preg-MEDAS validity was evaluated by Pearson and intraclass correlation coefficients, κ statistic, and Bland-Altman methods. Results: The preg-MEDAS had a good correlation with the FFQ (r = 0.76 and intraclass correlation coefficient 0.75). The agreement of each of the preg-MEDAS items ranged from 40.9% to 93.8% with a substantial agreement mean concordance (κ = 0.61). A 2-point increase in preg-MEDAS was associated with a decrease in maternal mean and systolic blood pressure (β: -0.51 mmHg; 95% confidence interval [CI]: -0.97, -0.04 mmHg and -0.87 mmHg; 95% CI: -1.48, -0.26 mmHg, respectively). Conclusions: The preg-MEDAS displays good validity for assessing adherence to the Mediterranean diet, allowing detection of dietary changes over time. In addition, changes observed in preg-MEDAS are significantly associated with a decrease in maternal blood pressure. Therefore, we propose preg-MEDAS as a rapid and simple dietary assessment tool during pregnancy. This trial was registered at clinicaltrials.gov as NCT03166332.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effect of Mediterranean diet or mindfulness-based stress reduction during pregnancy on placental volume and perfusion, A subanalysis of the IMPACT BCN randomized clinical trial

  • Nakaki, Ayako|||0000-0002-4395-3878
  • Denaro, Eugenio
  • Crimella, Maddalena
  • Castellani, Roberta
  • Vellvé, Kilian|||0000-0002-2376-7664
  • Izquierdo, Nora
  • Basso, Annachiara
  • Paules, Cristina|||0000-0001-6795-0367
  • Casas, Rosa|||0000-0002-0211-9166
  • Benitez, Leticia|||0000-0002-4950-036X
  • Casas, Irene
  • Larroya, Marta|||0000-0001-7929-6630
  • Genero, Mariona
  • Castro Barquero, Sara|||0000-0002-6876-5443
  • Gomez-Gomez, A|||0000-0001-8172-1827
  • Pozo, Oscar J|||0000-0002-1735-9728
  • Vieta, Eduard|||0000-0002-0548-0053
  • Estruch, Ramón|||0000-0003-1260-4445
  • Nadal, Alfons
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Crovetto, Francesca|||0000-0003-0140-7411
  • Crispi, Fatima|||0000-0002-7422-5240
  • Youssef, Lina|||0000-0002-0554-5507
Introduction: The IMPACT BCN trial-a parallel-group randomized clinical trial where 1221 pregnant women at high risk for small-for-gestational age (SGA) newborns were randomly allocated at 19- to 23-week gestation into three groups: Mediterranean diet, Mindfulness-based Stress reduction or non-intervention-has demonstrated a positive effect of Mediterranean diet and Stress reduction in the prevention of SGA. However, the mechanism of action of these interventions remains still unclear. The aim of this study is to investigate the effect of Mediterranean diet and Stress reduction on placental volume and perfusion. Material and Methods: Participants in the Mediterranean diet group received monthly individual and group educational sessions, and free provision of extra-virgin olive oil and walnuts. Women in the Stress reduction group underwent an 8-week Stress reduction program adapted for pregnancy, consisting of weekly 2.5-h and one full-day sessions. Non-intervention group was based on usual care. Placental volume and perfusion were assessed in a subgroup of randomly selected women (n = 165) using magnetic resonance (MR) at 36-week gestation. Small placental volume was defined as MR estimated volume <10th centile. Perfusion was assessed by intravoxel incoherent motion. Results: While mean MR placental volume was similar among the study groups, both interventions were associated with a lower prevalence of small placental volume (3.9% Mediterranean diet and 5% stress reduction vs. 17% non-intervention; p = 0.03 and p = 0.04, respectively). Logistic regression showed that small placental volume was significantly associated with higher risk of SGA in both study groups (OR 7.48 [1.99-28.09] in Mediterranean diet and 20.44 [5.13-81.4] in Stress reduction). Mediation analysis showed that the effect of Mediterranean diet on SGA can be decomposed by a direct effect and an indirect effect (56.6%) mediated by a small placental volume. Similarly, the effect of Stress reduction on SGA is partially mediated (45.3%) by a small placental volume. Results on placental intravoxel incoherent motion perfusion fraction and diffusion coefficient were similar among the study groups. Conclusions: Structured interventions during pregnancy based on Mediterranean diet or Stress reduction are associated with a lower proportion of small placentas, which is consistent with the previously observed beneficial effects of these interventions on fetal growth.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Mediterranean Diet in Pregnancy, Implications for Maternal Brain Morphometry in a Secondary Analysis of the IMPACT BCN Randomized Clinical Trial

  • Nakaki, Ayako|||0000-0002-4395-3878
  • Gomez, Yvan|||0000-0003-0794-7750
  • Castro Barquero, Sara|||0000-0002-6876-5443
  • Conti, Allegra|||0000-0003-4210-5065
  • Vellvé, Kilian|||0000-0002-2376-7664
  • Casas, Irene
  • Genero, Mariona
  • Youssef, Lina|||0000-0002-0554-5507
  • Segalés Tañà, Laura|||0000-0002-8583-8835
  • Benitez, Leticia|||0000-0002-4950-036X
  • Casas, Rosa|||0000-0002-0211-9166
  • Vieta, Eduard|||0000-0002-0548-0053
  • Bargalló, Núria|||0000-0001-6284-5402
  • Toschi, Nicola
  • Estruch, Ramón|||0000-0003-1260-4445
  • Crispi, Fatima|||0000-0002-7422-5240
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Crovetto, Francesca|||0000-0003-0140-7411
INTRODUCTION: A Mediterranean diet has positive effects on the brain in mid-older adults; however, there is scarce information on pregnant individuals. We aimed to evaluate the effect of a structured Mediterranean diet intervention on the cortical structure of the maternal brain during pregnancy. METHODS: This study was a secondary analysis of the IMPACT BCN, a randomized clinical trial with 1221 high-risk pregnant women randomly allocated into three groups at 19-23 weeks of gestation: Mediterranean diet intervention, a mindfulness-based stress reduction program, or usual care. Maternal brain magnetic resonance imaging was performed during the third trimester of pregnancy in a random subgroup of participants. For this study, data from the Mediterranean diet and usual groups were analyzed. Maternal dietary intake, adherence to the Mediterranean diet and metabolite biomarkers were evaluated using a food frequency questionnaire, a 17-item dietary screener and plasma/urine samples, respectively. RESULTS: The cluster-wise analysis showed that the Mediterranean diet group participants (n = 34) had significantly larger surface areas in the right precuneus (90%CI: <0.0001-0.0004, p < 0.001) and left superior parietal (90%CI: 0.026-0.033, p = 0.03) lobules compared to the usual care group participants (n = 37). A larger right precuneus area was associated with high improvements in adherence to the Mediterranean diet, a high intake of walnuts and high concentrations of urinary hydroxytyrosol. A larger left superior parietal area was associated with a high intake of walnuts and high concentrations of urinary hydroxytyrosol. CONCLUSIONS: The promotion of a Mediterranean diet during pregnancy has a significant effect on maternal brain structure.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immortalized human myotonic dystrophy type 1 muscle cell lines to address patient heterogeneity

  • Núñez-Manchón, Judith
  • Capó, Júlia
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Juanola, Eduard
  • Pesovic, Jovan
  • Mosqueira-Martín, Laura
  • González-Imaz, Klaudia
  • Maestre-Mora, P.
  • Odria, Renato|||0000-0002-3420-797X
  • Savic-Pavicevic, Dusanka
  • Vallejo-Illarramendi, Ainara
  • Mamchaoui, Kamel
  • Bigot, Anne|||0000-0003-0337-5425
  • Mouly, Vicent
  • Suelves, Mònica|||0000-0001-7095-5804
  • Nogales, Gisela|||0000-0002-7414-212X
Historically, cellular models have been used as a tool to study myotonic dystrophy type 1 (DM1) and the validation of therapies in said pathology. However, there is a need for in vitro models that represent the clinical heterogeneity observed in patients with DM1 that is lacking in classical models. In this study, we immortalized three DM1 muscle lines derived from patients with different DM1 subtypes and clinical backgrounds and characterized them at the genetic, epigenetic, and molecular levels. All three cell lines display DM1 hallmarks, such as the accumulation of RNA foci, MBNL1 sequestration, splicing alterations, and reduced fusion. In addition, alterations in early myogenic markers, myotube diameter and CTCF1 DNA methylation were also found in DM1 cells. Notably, the new lines show a high level of heterogeneity in both the size of the CTG expansion and the aforementioned molecular alterations. Importantly, these immortalized cells also responded to previously tested therapeutics. Altogether, our results show that these three human DM1 cellular models are suitable to study the pathophysiological heterogeneity of DM1 and to test future therapeutic options.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis, data from the prospective INNOVA4TB cohort study in Ukraine

  • Dudnyk, Andrii|||0000-0002-8780-9480
  • Hempel, M.
  • Lytvyniuk, O.
  • Liudkevych, H.
  • Matsera, V.
  • Nikitchenko, T.
  • Blyzniuk, S.
  • Molina-Moya, Barbara|||0000-0001-5144-2165
  • Preyer, R.
  • Domínguez, José|||0000-0001-7888-0309
Background: Ukraine remains a high World Health Organization priority country for drug-resistant tuberculosis (TB). Rifampicin-resistant TB (RR-TB) has a more protracted, more complicated, and more expensive treatment. In 2021, Ukraine reported 4025 RR-TB cases - 5.4 times more (751) than all 30 European Union/ European Economic Area countries together. Objectives: The objective of the study was to determine the diagnostic accuracy of line probe assay (LPA), AID Autoimmun Diagnostika GmbH, for detecting resistance to anti-TB drugs and its clinical application for selecting treatment regimens. Design: A prospective observational cohort study. Methods: From May 2019 to June 2020, we consecutively enrolled patients with active TB hospitalized at the Regional Phthisiopulmonology Center (Vinnytsia, Ukraine), aged between 18 and 82 years. The LPA was performed in the Genetic Research Laboratory at National Pirogov Memorial Medical University, Vinnytsia, Ukraine. Results: A total of 84 clinical specimens and 97 culture isolates from 126 TB patients were tested during the study. Accuracy (95% confidence interval) of LPA for clinical samples in comparison with phenotypic drug susceptibility test (DST) was 80.1 (68.5-89.0) for isoniazid (H), 74.7 (62.4-84.6) for rifampicin (R), 74.4 (62.5-84.1) for ethambutol, 71.4 (41.9-91.6) for streptomycin, 84.6 (62.4-96.5) for prothionamide/ethionamide, and 84.6 (73.6-92.3) for levofloxacin (Lfx), respectively. We found a significantly higher sensitivity of LPA for H, R, and Lfx for the culture isolates compared to clinical specimens (p < 0.05). LPA detected different mutations in 6 out of 17 (35.5%) patients susceptible to R by Xpert. A shorter treatment regimen with an injectable agent demonstrated a low suitability rate of 5% (8/156) in a cohort of RR-TB patients from Ukraine. Conclusion: Initial LPA testing accurately identifies resistance to anti-TB drugs and facilitates the selection of an appropriate treatment regimen, minimizing exposure to empirical therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Complications of oropharyngeal dysphagia in older individuals and patients with neurological disorders, insights from Mataró hospital, Catalonia, Spain

  • Karunaratne, Tennekoon B.|||0000-0002-5918-5738
  • Clavé i Civit, Pere|||0000-0002-0696-8560
  • Ortega, Omar|||0000-0001-6178-3748
Background: Oropharyngeal dysphagia (OD) significantly impacts older individuals and neurologically compromised patients, hindering safe ingestion of food and liquids. Despite its prevalence, OD remains underdiagnosed and undertreated, leading to severe complications such as malnutrition, dehydration, respiratory infections, and aspiration pneumonia (AP), and increases hospital readmissions. Objectives: This study analyzes the intricate relationship between OD and various clinical complications in older individuals and patients with neurological disorders. Methods: Utilizing retrospective analysis and narrative review, our work consolidates findings from prior studies on Hospital de Mataro's dysphagia patient cohort. Revisiting OD's intricate association with clinical complications, it presents data via odds ratios (OR), incidence ratios (IR), and hazard ratios (HR) from univariate and multivariate analyses. Results: Five studies (2001-2014) involving 3,328 patients were scrutinized. OD exhibited independent and significant associations with various complications among older patients. Older individuals with OD faced heightened 1-month (ODDS 3.28) and 1-year (OR 3.42) mortality risks post-pneumonia diagnosis. OD correlated with a 2.72-fold risk of malnutrition, 2.39-fold risk of lower respiratory tract infections, 1.82-fold pneumonia readmissions (IR), and 5.07-fold AP readmissions (IR). Post-stroke OD is linked to neurological impairment (OR 3.38) and respiratory (OR 9.54) and urinary infections (OR 7.77), alongside extended hospital stays (beta coefficient 2.11). Conclusion: Oropharyngeal dysphagia causes and significantly exacerbates diverse clinical complications in older and post-stroke patients, emphasizing the urgent need for proactive identification, comprehensive assessment, and tailored management. Acknowledging OD's broader implications in general medical practice is pivotal to improving patient outcomes and healthcare quality.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Translating Muscle RNAseq Into the Clinic for the Diagnosis of Muscle Diseases

  • Segarra Casas, Alba|||0000-0001-5185-5031
  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Natera-de Benito, Daniel|||0000-0001-7764-2085
  • Kapetanovic, Solange
  • Hernández-Laín, Aurelio
  • Estévez-Arias, Berta|||0000-0002-1711-7489
  • Llansó, Laura|||0000-0003-4950-7657
  • Ortez, Carlos
  • Jou, Cristina|||0000-0002-2223-7880
  • Martí-Carrera, Itxaso
  • López-Márquez, Arístides
  • Rodríguez, Maria José
  • González Mera, Laura
  • Nedkova, Velina
  • Fernández-Torrón, Roberto
  • Rodriguez Santiago, Benjamin|||0000-0003-1167-3852
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
  • Juntas Morales, Raúl|||0000-0003-2205-1741
  • López-de Munain, Adolfo
  • Surralles, Jordi|||0000-0002-4041-7519
  • Nascimento, Andrés
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
  • Gallano, Pia|||0000-0001-8104-2197
  • González Quereda, Lidia|||0000-0003-0715-6414
Objective: Approximately half of patients with hereditary myopathies remain without a definitive genetic diagnosis after DNA next-generation sequencing (NGS). Here, we implemented transcriptome analysis of muscle biopsies as a complementary diagnostic tool for patients with muscle disease but no definitive genetic diagnosis after exome sequencing. Methods: In total, 70 undiagnosed cases with suspected genetic muscular dystrophies or congenital myopathies were included in the study. Muscle RNAseq comprised the analysis of aberrant splicing, aberrant expression, and monoallelic expression. In addition, existing NGS data or variant calling from RNAseq were reanalyzed, and genome sequencing was performed in selected cases. Four aberrant splicing open-source tools were compared and assessed. Results: RNAseq established a diagnosis in 10/70 patients (14.3%) by identifying aberrant transcripts produced by single nucleotide variants (7/10) or copy number variants (3/10). Reanalysis of NGS data allowed the diagnosis in 9/70 individuals (12.9%). Based on this cohort, FRASER was the tool that reported more splicing outlier events per sample while showing the highest accuracy (81.26%). Conclusions: We demonstrate the utility of RNAseq in identifying causative variants in muscle diseases. Evaluation of four aberrant splicing tools allowed efficient identification of most pathogenic splicing events, obtaining a manageable number of candidate events for manual inspection, demonstrating feasibility for translation into a clinical setting. We also show how the integration of omic technologies reduces the turnaround time to identify causative variants.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mitochondrial priming and response to BH3 mimetics in "one-two punch" senogenic-senolytic strategies

  • López, Júlia
  • Llop-Hernández, Àngela
  • Verdura, Sara|||0000-0001-8980-0423
  • Serrano-Hervás, Eila|||0000-0002-9477-0350
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
  • Bosch-Barrera, J.|||0000-0002-0893-7821
  • Teixidor, Eduard
  • López-Bonet, Eugeni
  • Martin-Castillo, Begoña
  • Sardanyés, Josep|||0000-0001-7225-5158
  • Alarcón Cor, Tomás|||0000-0002-8566-3676
  • Lupu, Ruth|||0000-0002-5564-3172
  • Cuyàs, Elisabet|||0000-0001-5353-440X
  • Menéndez, Javier A.|||0000-0001-8733-4561
A one-two punch sequential regimen of senescence-inducing agents followed by senolytic drugs has emerged as a novel therapeutic strategy in cancer. Unfortunately, cancer cells undergoing therapy-induced senescence (TIS) vary widely in their sensitivity to senotherapeutics, and companion diagnostics to predict the response of TIS cancer cells to a specific senolytic drug are lacking. Here, we hypothesized that the ability of the BH3 profiling assay to functionally measure the mitochondrial priming state-the proximity to the apoptotic threshold-and the dependencies on pro-survival BCL-2 family proteins can be exploited to inform the sensitivity of TIS cancer cells to BH3-mimetics. Replicative, mitotic, oxidative, and genotoxic forms of TIS were induced in p16 -null/ p53 -proficient, BAX -deficient, and BRCA1 -mutant cancer cells using mechanistically distinct TIS-inducing cancer therapeutics, including palbociclib, alisertib, doxorubicin, bleomycin, and olaparib. When the overall state of mitochondrial priming and competence was determined using activator peptides, the expected increase in overall mitochondrial priming was an exception rather than a generalizable feature across TIS phenotypes. A higher level of overall priming paralleled a higher sensitivity of competent TIS cancer cells to BCL-2/BCL-xL- and BCL-xL-targeted inhibitors when comparing TIS phenotypes among themselves. Unexpectedly, however, TIS cancer cells remained equally or even less overally primed than their proliferative counterparts. When sensitizing peptides were used to map dependencies on anti-apoptotic BCL-2 family proteins, competent TIS cancer cells appeared to share a dependency on BCL-xL. Furthermore, regardless of senescence-inducing therapeutic, stable/transient senescence acquisition, or genetic context, all TIS phenotypes shared a variable but significant senolytic response to the BCL-xL-selective BH3 mimetic A1331852. These findings may help to rethink the traditional assumption of the primed apoptotic landscape of TIS cancer cells. BCL-xL is a conserved anti-apoptotic effector of the TIS BCL2/BH3 interactome that can be exploited to maximize the efficacy of "one-two punch" senogenic-senolytic strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation

  • Donadeu, Laura|||0000-0002-5089-5047
  • Gómez-Ollés, Susana|||0000-0002-8935-7641
  • Casanova, Franc|||0000-0001-7427-1987
  • Torija, Alba
  • López-Meseguer, Manuel|||0000-0003-2650-9238
  • Boada Pérez, Meritxell|||0000-0002-8774-8593
  • Kervella, Delphine|||0000-0001-8069-6105
  • Crespo, Elena
  • Carrera-Muñoz, Claudia
  • Campos Varela, Isabel|||0000-0001-6597-3151
  • Castells, Lluís|||0000-0002-6672-5931
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Fernandez-Naval, Candela|||0000-0002-5584-3537
  • Quintero, Jesús|||0000-0002-6456-9031
  • Muñoz, Marina
  • Agüero, Fernando
  • González-Costello, José|||0000-0002-7437-3630
  • Lladó, Laura|||0000-0002-3717-3306
  • Favà, Alexandre|||0000-0003-1664-6001
  • Cañas, Laura
  • de la Hoz-Caballero, María del Mar
  • Meneghini, Maria|||0000-0001-7307-923X
  • Torres, Irina B.|||0000-0003-3304-0810
  • Juvé, Mariona|||0000-0001-8431-3757
  • Hafkamp, Florianne
  • Vila, Marta|||0000-0001-9303-5189
  • González Robles, Alba
  • Buzón, Maria José|||0000-0003-4427-9413
  • Toapanta, Néstor|||0000-0001-5983-6863
  • Zúñiga, José Miguel
  • Monforte, Víctor|||0000-0002-2918-7679
  • Sáez-Giménez, Berta|||0000-0002-9307-728X
  • Len, Oscar|||0000-0002-1819-3141
  • Los-Arcos, Ibai|||0000-0001-8835-2702
  • Miret Alomar, Enric|||0000-0002-6656-5050
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Pardo, Emma|||0000-0001-8703-5457
  • Martínez, Xavier
  • Moreso, Francesc|||0000-0002-7267-3963
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
Solid organ transplant (SOT) recipients display weak seroconversion and neutralizing antibody (NAb) responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and remain at risk of severe coronavirus disease 2019 (COVID-19). While B-cell memory is the hallmark of serological immunity, its role in driving successful vaccine responses and providing immune protection in SOT patients remains unclear. We investigated the function and interplay of SARS-CoV-2-specific memory B cells (mBc), different cytokineproducing T cells, and cross-reactive NAb in driving seroconversion and protection against COVID-19 in two cohorts. First, we studied a large cohort of 148 SOT recipients and 32 immunocompetent individuals who underwent several vaccinations. Subsequently, we assessed 25 SOT patients participating in a randomized controlled trial to compare two different immunosuppressive strategies for allowing successful seroconversion and memory-cell responses after booster vaccination. We corroborate previous findings that B- and T-cell memory responses are weaker and more delayed in SOT patients than in immunocompetent (IC) individuals; however, within the SOT cohort, we found that these responses are relatively stronger and more robust in patients not receiving mycophenolate mofetil (MMF)-based therapies. Anti- spike IgG titers strongly correlated with RBD-specific IgG-producing mBc, with both displaying broad viral cross reactivity. Prebooster SARS-CoV-2-specific mBc and IL-2- producing T cells accurately predicted Nab seroconversion (AUC, 0.828) and protection against severe COVID-19. While switching unresponsive SOT patients from calcineurin inhibitors (CNI)/MMF to a low-exposure CNI/mTOR-i regimen favored wider SARS-CoV-2-specific immune responses after a fourth booster vaccination, preformed RBD-specific mBc predicted NAb seroconversion. Our study adds new insights into the pathobiology of immune memory and highlights the pivotal role of SARS-CoV-2-specific mBc in promoting immune protection inSOT patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease

  • Martínez-Sánchez, Celia
  • Bassegoda, Octavi|||0000-0002-6036-6026
  • Deng, Hongping
  • Almodóvar, Xènia
  • Ibarzabal, Ainitze|||0000-0002-1220-6474
  • de Hollanda, Ana|||0000-0001-9114-8614
  • Martínez García de la Torre, Raquel-Adela
  • Blaya, Delia
  • Ariño, Silvia
  • Jiménez-Esquivel, Natalia
  • Aguilar-Bravo, Beatriz
  • Vallverdú, Julia
  • Montironi, Carla|||0000-0002-1453-2193
  • Osorio-Conles, Oscar
  • Fundora Suarez, Yiliam|||0000-0003-4950-6988
  • Sánchez Moreno, Francisco Javier
  • Gómez-Valadés, Alicia G.
  • Aguilar-Corominas, Laia
  • Soria, Anna|||0000-0001-5671-8343
  • Pose, Elisa|||0000-0002-0224-7686
  • Juanola, Adrià|||0000-0003-4832-5130
  • Cervera, Marta
  • Perez, Martina
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
  • Affò, Silvia
  • Swanson, Kelly S.
  • Ferrer-Fàbrega, Joana
  • Balibrea Del Castillo, José María|||0000-0002-0764-7179
  • Sancho-Bru, Pau|||0000-0001-5569-9259
  • Vidal, Josep|||0000-0002-4564-4518
  • Ginès, Pere|||0000-0003-4657-4504
  • Smith, Andrew M.
  • Graupera, Isabel|||0000-0001-9170-9784
  • Coll, Mar|||0000-0003-3726-0087
: The accumulation of adipose tissue macrophages (ATMs) in obesity has been associated with hepatic injury. However, the contribution of ATMs to hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD) remains to be elucidated. Herein, we investigate the relationship between ATMs and liver fibrosis in patients with patients with NAFLD and evaluate the impact of modulation of ATMs over hepatic fibrosis in an experimental non-alcoholic steatohepatitis (NASH) model. Adipose tissue and liver biopsies from 42 patients with NAFLD with different fibrosis stages were collected. ATMs were characterised by immunohistochemistry and flow cytometry and the correlation between ATMs and liver fibrosis stages was assessed. Selective modulation of the ATM phenotype was achieved by i.p. administration of dextran coupled with dexamethasone in diet-induced obesity and NASH murine models. Chronic administration effects were evaluated by histology and gene expression analysis in adipose tissue and liver samples. In vitro crosstalk between human ATMs and hepatic stellate cells (HSCs) and liver spheroids was performed. Patients with NAFLD presented an increased accumulation of pro-inflammatory ATMs that correlated with hepatic fibrosis. Long-term modulation of ATMs significantly reduced pro-inflammatory phenotype and ameliorated adipose tissue inflammation. Moreover, ATMs modulation was associated with an improvement in steatosis and hepatic inflammation and significantly reduced fibrosis progression in an experimental NASH model. In vitro, the reduction of the pro-inflammatory phenotype of human ATMs with dextran-dexamethasone treatment reduced the secretion of inflammatory chemokines and directly attenuated the pro-fibrogenic response in HSCs and liver spheroids. Pro-inflammatory ATMs increase in parallel with fibrosis degree in patients with NAFLD and their modulation in an experimental NASH model improves liver fibrosis, uncovering the potential of ATMs as a therapeutic target to mitigate liver fibrosis in NAFLD. We report that human adipose tissue pro-inflammatory macrophages correlate with hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD). Furthermore, the modulation of adipose tissue macrophages (ATMs) by dextran-nanocarrier conjugated with dexamethasone shifts the pro-inflammatory phenotype of ATMs to an anti-inflammatory phenotype in an experimental murine model of non-alcoholic steatohepatitis. This shift ameliorates adipose tissue inflammation, hepatic inflammation, and fibrosis. Our results highlight the relevance of adipose tissue in NAFLD pathophysiology and unveil ATMs as a potential target for NAFLD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Longitudinal trajectories of maternal TSH in healthy pregnant women in Catalonia

  • Soldevila i Madorell, Berta|||0000-0002-4582-4201
  • Velasco Lopez, Maria Ines|||0000-0002-6143-6970
  • Muñoz, Carla
  • Díaz, Yesika|||0000-0002-3727-7340
  • Egea Cortés, Laia|||0000-0003-4002-8254
  • Ferrer-Escopiñan, Laura
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Martínez-Mondejar, Raquel
  • Casabona-Barbarà, Jordi|||0000-0003-4816-5536
  • Puig Domingo, Manuel|||0000-0002-6744-7195
Longitudinal evaluation of thyroid function throughout pregnancy in the same subject could offer precise information about its dynamics as a physiological mechanism of adaption to the requirements. In this study, we evaluated longitudinal trajectories of maternal thyroid function during pregnancy by a latent class growth analysis and explored their association with maternal-fetal outcomes. A prospective observational study was carried out, including 414 healthy pregnant women, from the first trimester to delivery. Thyroid function and autoimmunity were measured in the three trimesters. Clinical data during pregnancy were obtained. Longitudinal mixed model techniques were performed to explore trajectories of gestational thyroid function. Three different longitudinal trajectories were obtained from maternal thyrotropin (TSH) levels: low-increasing TSH (class 1) in 86% of cases, high-increasing TSH (class 2) in 9.7%, and decreasing TSH (class 3) in 4.3%. No statistical differences in free thyroxine levels were found among the three classes. Differences in maternal age (P = 0.027) and initial maternal weight (P = 0.043) were observed among the groups. In logistic regression analysis, maternal age correlated with longitudinal trajectories. The three longitudinal classes remain when women with thyroid autoimmunity (TAI) are excluded. Multinomial logistic regression showed maternal age correlated with longitudinal trajectories independently of TAI status. Three differentiated TSH trajectories were found in healthy pregnant women living in Catalonia, as previously described. No association with obstetric outcomes was observed in these different chronological thyroid pathways, but maternal age might condition the longitudinal mechanism of thyroid function regulation throughout pregnancy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inflammation, The Link between Neural and Vascular Impairment in the Diabetic Retina and Therapeutic Implications

  • Ramos, Hugo|||0000-0001-6443-7576
  • Hernández, Cristina|||0000-0002-3109-1721
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Simó-Servat, Olga|||0000-0003-3483-652X
The etiology of diabetic retinopathy (DR) is complex, multifactorial and compromises all the elements of the retinal neurovascular unit (NVU). This diabetic complication has a chronic low-grade inflammatory component involving multiple inflammatory mediators and adhesion molecules. The diabetic milieu promotes reactive gliosis, pro-inflammatory cytokine production and leukocyte recruitment, which contribute to the disruption of the blood retinal barrier. The understanding and the continuous research of the mechanisms behind the strong inflammatory component of the disease allows the design of new therapeutic strategies to address this unmet medical need. In this context, the aim of this review article is to recapitulate the latest research on the role of inflammation in DR and to discuss the efficacy of currently administered anti-inflammatory treatments and those still under development.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

  • Bastard, Paul|||0000-0002-5926-8437
  • Gervais, A.
  • Taniguchi, M.
  • Saare, L.
  • Särekannu, K.
  • Voyer, T.L.
  • Philippot, Q.
  • Rosain, J.
  • Bizien, L.
  • Asano, T.
  • Garcia-Prat, Marina|||0000-0001-5387-1908
  • Parra-Martínez, Alba|||0000-0002-9564-8912
  • Migaud, M.
  • Tsumura, M.
  • Conti, F.
  • Belot, Alexandre|||0000-0003-4902-5332
  • Rivière, Jacques G.|||0000-0003-1055-2063
  • Morio, T.
  • Tanaka, J.
  • Javouhey, E.
  • Haerynck, F.
  • Duvlis, S.
  • Ozcelik, Tayfun|||0000-0001-5937-1082
  • Keles, S.
  • Tandjaoui-Lambiotte, Y.
  • Escoda, S.
  • Husain, M.
  • Pan-Hammarström, Q.
  • Hammarström, L.
  • Ahlijah, G.
  • Haidar, A.A.
  • Soudee, C.
  • Arseguel, V.
  • Abolhassani, Hassan|||0000-0002-4838-0407
  • Sahanic, S.
  • Tancevski, I.
  • Nukui, Y.
  • Hayakawa, S.
  • Chrousos, G.P.
  • Michos, A.
  • Tatsi, E.B.
  • Filippatos, F.
  • Rodriguez-Palmero, A.
  • Troya, Jesús|||0000-0001-7323-114X
  • Tipu, I.
  • Meyts, I.
  • Roussel, L.
  • Ostrowski, S.R.
  • Schidlowski, L.
  • Prando, C.
  • Condino-Neto, Antonio|||0000-0002-1069-3117
  • Cheikh, N.
  • Bousfiha, A.A.
  • Bakkouri, J.E.
  • Peterson, P.
  • Pujol, Aurora|||0000-0002-9606-0600
  • Lévy, R.
  • Quartier, P.
  • Vinh, D.C.
  • Boisson, Bertrand|||0000-0001-5240-3555
  • Béziat, V.
  • Zhang, S.Y.
  • Borghesi, A.
  • Pession, A.
  • Andreakos, E.
  • Marr, N.
  • Mentis, A.F.A.
  • H.mogensen, T.
  • Rodríguez-Gallego, C.
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
  • Tillmann, V.
  • Neven, B.
  • Trouillet-Assant, S.
  • Brodin, P.
  • Abel, Laurent|||0000-0001-7016-6493
  • Jouanguy, Emmanuelle|||0000-0002-7358-9157
  • Zhang, Q.
  • Martinón Torres, Federico|||0000-0002-9023-581X
  • Salas, A.
  • Gómez-Carballa, A.
  • Gonzalez-Granado, L.I.
  • Kisand, K.
  • Okada, S.
  • Puel, A.
  • Cobat, Aurélie|||0000-0001-7209-6257
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
  • Aguilera-Albesa, Sergio|||0000-0003-3540-1448
  • AlKhater, Suzan|||0000-0001-7315-6581
  • Alkan, G.
  • Castagnoli, R.
  • Cyrus, C.|||0000-0001-7333-6486
  • Bozdemir, S.E.
  • Emiroglu, M.
  • Gulhan, Belgin|||0000-0003-0839-1301
  • Erdeniz, E.H.
  • Hatipoglu, N.
  • Bayhan, G.I.|||0000-0002-1423-4348
  • Jabandziev, P.
  • Yuksek, S.K.
  • Karbuz, A.
  • Öz, Ş.K.T.
  • Marseglia, G.L.
  • Akcan, O.M.
  • Kılıç, A.O.
  • Parlakay, A.O.
  • Papadaki, M.
  • Slaba, K.
  • Sevketoglu, Esra|||0000-0002-8330-2877
  • Valencia-Ramos, J.
  • Yahşi, A.
  • Tuala, C.
  • Urbieta, A.I.D.
  • Esteban, B.D.
  • Santalla, M.J.D.
  • Pérez, C.F.
  • Villaverde, J.F.
  • Rodríguez, C.G.
  • Allut, J.L.G.
  • Vicente, L.G.
  • Vázquez, E.G.
  • Carballa, A.G.
  • Rial, J.G.
  • Barcala, F.J.G.
  • Liñares, B.G.
  • Iglesias, P.L.
  • Massa, B.L.
  • Fuentes, M.L.
  • Franco, M.L.
  • Lago, A.L.
  • Cruz, D.N.D.l
  • Masid, E.N.
  • Devesa, J.B.O.
  • Seco, J.P.
  • Núñez, M.P.
  • Bernal, M.P.D.M.
  • Freixo, H.P.
  • Rodríguez, L.P.
  • Pischedda, S.
  • Romero, M.P.
  • Reino, A.P.
  • Hervella, G.M.P.
  • Verdes, T.Q.
  • Redondo Collazo, Lorenzo|||0000-0002-3521-678X
  • Casuso, P.R.
  • García, S.R.
  • Vázquez, S.R.
  • Blanco, V.R.
  • Calle, I.R.
  • Velasco, C.R.
  • Núñez, N.R.
  • Sánchez, C.R.T.
  • Paz, E.S.
  • Orayyou, J.M.S.
  • Villanueva, C.S.
  • Fernández, S.S.
  • Sanmartín, P.S.
  • Muñiz, M.T.
  • Pena, R.T.
  • Castellano, M.T.
  • Cuadrado, L.V.
  • García, P.V.
  • Iglesias, M.S.V.
  • Lasheras, S.V.
  • Ferreiro Iglesias, Rocío|||0000-0002-0469-4332
  • Bastón-Rey, I.
  • Calviño-Suárez, C.
  • Aiuti, Alessandro|||0000-0002-5398-1717
  • Al-Muhsen, S.
  • Al-Mulla, F.
  • Amara, A.
  • Anderson, M.S.
  • Arias, A.A.
  • Arkin, L.M.
  • Feldman, H.B.
  • Biggs, C.M.
  • Bogunovic, Dusan|||0000-0002-9277-3232
  • Bolze, Alexandre|||0000-0001-7399-2766
  • Bondarenko, A.|||0000-0002-9737-2868
  • Bryceson, Y.
  • Butte, M.J.
  • Casari, G.
  • Christodoulou, J.
  • Constantinescu, S.N.
  • Cooper, M.A.
  • Dalgard, C.L.
  • Desai, M.
  • Drolet, B.A.
  • Duval, X.
  • Baghdadi, J.E.
  • Eloy, P.
  • Espinosa-Padilla, S.
  • Fellay, Jacques|||0000-0002-8240-939X
  • Flores, Carlos|||0000-0001-5352-069X
  • Franco, J.L.
  • Froidure, A.
  • Gorochov, G.
  • Gregersen, P.K.
  • Grimbacher, B.
  • Hagin, D.
  • Halwani, R.
  • Heath, J.R.
  • Hsieh, E.W.Y.
  • Husebye, Eystein Sverre|||0000-0002-7886-2976
  • Imai, K.
  • Itan, Yuval
  • Jarvis, E.D.
  • Kaja, E.
  • Karamitros, T.
  • Ku, C.L.
  • Lau, Y.L.
  • Ling, Y.
  • Lucas, C.L.
  • Mansouri, D.
  • Maródi, L.
  • Mentré, F.
  • Milner, J.D.
  • Mironska, K.
  • Mogensen, T.H.
  • Ng, L.F.P.
  • Notarangelo, L.D.
  • Novelli, A.
  • Novelli, G.
  • O'Farrelly, C.
  • Okamoto, K.
  • Pape, J.W.
  • Perez de Diego, Rebeca|||0000-0001-8426-8765
  • Perez-Tur, J.
  • Perlin, D.S.
  • Pesole, G.
  • Planas, A.M.
  • Quintana-Murci, L.
  • Ramaswamy, S.
  • Renia, L.
  • Resnick, I.
  • Sancho-Shimizu, V.
  • Sediva, A.
  • Seppänen, M.R.J.
  • Shahrooei, M.
  • Shcherbina, A.
  • Slaby, O.
  • Snow, A.L.
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Soumelis, V.
  • Spaan, A.N.
  • Su, H.C.
  • Tangye, S.G.
  • Tayoun, A.A.
  • Temel, Ş.G.
  • Thorball, C.
  • Tiberghien, P.
  • Turvey, S.E.
  • Uddin, K.M.F.
  • Uddin, M.J.
  • Beek, D.v.d
  • Bernuth, H.v
  • Wauters, J.
  • Zatz, Mayana|||0000-0003-3970-8025
  • Zawadzki, Pawel
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7-9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2-5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6-35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1-9.6]) of IFN-ω and/or IFN-α2.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands

  • Díaz-Tejedor, A.
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Ciudad, Laura|||0000-0002-5219-6792
  • Lorenzo-Mohamed, M.
  • González-Rodríguez, M.
  • Castellanos, B.
  • Sotolongo-Ravelo, J.
  • San-Segundo, L.
  • Corchete, L.A.
  • González-Méndez, L.
  • Martín Sánchez, Montserrat
  • Mateos, M. V.|||0000-0003-2390-1218
  • Ocio, Enrique M.|||0000-0002-5765-0085
  • Garayoa, M.
  • Paíno, T.
Multiple myeloma is a malignancy characterized by the accumulation of malignant plasma cells in bone marrow and the production of monoclonal immunoglobulin. A hallmark of cancer is the evasion of immune surveillance. Histone deacetylase inhibitors have been shown to promote the expression of silenced molecules and hold potential to increase the anti-MM efficacy of immunotherapy. The aim of the present work was to assess the potential effect of tinostamustine (EDO-S101), a first-in-class alkylating deacetylase inhibitor, in combination with daratumumab, an anti-CD38 monoclonal antibody (mAb), through different preclinical studies. Tinostamustine increases CD38 expression in myeloma cell lines, an effect that occurs in parallel with an increment in CD38 histone H3 acetylation levels. Also, the expression of MICA and MICB, ligands for the NK cell activating receptor NKG2D, augments after tinostamustine treatment in myeloma cell lines and primary myeloma cells. Pretreatment of myeloma cell lines with tinostamustine increased the sensitivity of these cells to daratumumab through its different cytotoxic mechanisms, and the combination of these two drugs showed a higher anti-myeloma effect than individual treatments in ex vivo cultures of myeloma patients' samples. In vivo data confirmed that tinostamustine pretreatment followed by daratumumab administration significantly delayed tumor growth and improved the survival of mice compared to individual treatments. In summary, our results suggest that tinostamustine could be a potential candidate to improve the efficacy of anti-CD38 mAbs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Repeat Expansions in PLIN4 Cause Autosomal Dominant Vacuolar Myopathy With Sarcolemmal Features

  • Llansó, Laura|||0000-0003-4950-7657
  • Stevanovski, Igor
  • Morís, Germán|||0000-0001-7608-2194
  • Collet Vidiella, Roger|||0000-0003-1668-1018
  • Segarra Casas, Alba|||0000-0001-5185-5031
  • González Quereda, Lidia|||0000-0003-0715-6414
  • Rodriguez Santiago, Benjamin|||0000-0003-1167-3852
  • Gallano, Pia|||0000-0001-8104-2197
  • Alvarez, Rodrigo
  • Vesperinas-Castro, Ana|||0000-0003-1919-9382
  • Blanco, Rosa
  • San-Millán, Beatriz
  • Navarro, Carmen|||0000-0003-4445-8585
  • Illa, Isabel|||0000-0002-2186-2684
  • Ravenscroft, Gianina|||0000-0003-3634-211X
  • W. Deveson, Ira
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
Objective: We aim to describe and characterize two unrelated Spanish families suffering from an autosomal dominant autophagic vacuolar myopathy caused by repeat expansions in PLIN4. Methods: We evaluated the clinical phenotype and muscle imaging, and performed a genetic workup that included exome sequencing, muscle RNAseq, and long-read genome sequencing. Muscle pathology was assessed by means of histochemistry, electron microscopy, PLIN4, p62, LC3, and NBR1 immunofluorescence and/or western blotting. Detailed characterization of autophagic vacuoles was performed. Results: Patients presented around the age of 30 with mild proximal weakness followed by prominent distal weakness in lower legs, eventually spreading to other muscle groups. Muscle biopsies showed unique pathological features characterized by numerous rimmed vacuoles that displayed sarcolemmal features and were located beneath the sarcolemma and within the cytoplasm. Ultrastructural studies showed autophagic vacuoles, replications, and loops of the basal lamina and tubulofilamentous sarcoplasmic inclusions. p62 and NBR1 co-localized with PLIN4 at the sarcolemma and vacuoles. LC3 immunoreactivity and other lysosomal markers were increased at the vacuoles. Targeted long-read sequencing of PLIN4 in affected individuals revealed a single expanded allele of 39 × 99 bp repeats in family 1 and of 37 × 99 bp repeats in family 2. Interpretation: We characterize two new families suffering from an autosomal dominant myopathy carrying repeat expansions in PLIN4. Subsarcolemmal p62 expression is a powerful although nonspecific marker of this disease. No correlation between the size of the expansion and clinical severity can be clearly established. PLIN4 expansions should be considered in the diagnosis of autosomal dominant vacuolar myopathies, especially when sarcolemmal features are present.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effectiveness of the FIBROWALK multicomponent therapy in online and outdoor formats for fibromyalgia, a randomized controlled trial (The On & Out study)

  • Serrat López, Mayte|||0000-0002-5591-9407
  • Royuela-Colomer, Estíbaliz|||0000-0001-9912-9610
  • Auer, William
  • Ferrés Puigdevall, Sònia|||0000-0001-5305-8386
  • Almirall, Míriam|||0000-0002-4874-8013
  • Neblett, Randy|||0000-0002-8620-2468
  • Nijs, Jo|||0000-0002-4976-6563
  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Borràs, Xavier|||0000-0003-3972-1385
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Feliu-Soler, Albert|||0000-0003-2810-7670
This study evaluated the effectiveness of FIBROWALK multicomponent intervention, delivered online (FIBRO-On) or outdoors (FIBRO-Out), compared to treatment as usual (TAU) in reducing fibromyalgia (FM) severity measured by FIQR, which assesses functional impairment, symptom intensity, and overall impact. A total of 225 individuals with FM were randomly assigned to 12 weeks of FIBRO-On (plus TAU), FIBRO-Out (plus TAU), or TAU alone. Assessments were conducted at baseline, mid-intervention (6 weeks), post-intervention (12 weeks), and 6-months (3 months post-intervention). Results from linear mixed-effects models indicated that FIBRO-On (ꞵ = -10.68, 95% CI = -15.13, -6.23) and FIBRO-Out (ꞵ = 9.91, 95% CI = -14.4, -5.42) were more effective than TAU in reducing FM severity at postintervention. FIBRO-On (ꞵ = -6.02, 95% CI = -10.78, -1.27) was more effective than TAU in reducing FM severity at 6 months, whereas FIBRO-Out showed no such advantage. No significant differences were observed between FIBRO-On and FIBRO-Out for any clinical measure at any time point. Clinically meaningful improvement was observed in 36.3% of FIBRO-On and 37.2% of FIBRO-Out post-intervention and ~20% at follow-up. Reductions in psychological inflexibility and kinesiophobia after the intervention mediated the effects of FIBROWALK on FM severity at 6-month follow-up, supporting the inclusion of acceptance and commitment therapy components in future versions. Low dropout rates, minimal adverse effects, and significant improvements across clinical outcomes highlight the feasibility and effectiveness of both formats. These findings support FIBROWALK, particularly FIBRO-On, as a scalable FM intervention. Future research should optimize long-term outcomes and explore personalized treatment delivery.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Efficacy of cognitive rehabilitation in cognition and brain networks, A randomised clinical trial in patients with multiple sclerosis

  • Lopez-Soley, Elisabet
  • Martinez-Heras, Eloy|||0000-0001-9937-3162
  • Vivó Pascual, Francesc|||0000-0002-6409-1197
  • Calvi, Alberto|||0000-0002-1953-2803
  • Alba-Arbalat, Salut|||0000-0003-1662-2317
  • Romero Pinel, Lucía|||0000-0001-8054-0565
  • Martínez Yélamos, Sergio|||0000-0001-9889-2040
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Munteis, Elvira|||0000-0002-6195-9106
  • Martínez-Rodríguez, José Enrique
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Anglada, E.|||0000-0001-5074-4970
  • Meza-Murillo, Edwin Roger|||0000-0001-6065-3546
  • Arévalo, María Jesús|||0000-0003-0626-5555
  • Sánchez Carrión, Rocío
  • Pelayo, Raúl|||0000-0002-1313-0686
  • Bernabeu Guitart, Montserrat|||0000-0003-2037-3069
  • Sola-Valls, Nuria
  • Hervas, M.
  • Sepúlveda, María
  • Saiz, Albert|||0000-0002-5793-8791
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Solana, Elisabeth|||0000-0001-7973-2439
  • Llufriu, Sara|||0000-0003-4273-9121
This study evaluated the efficacy of the computerised Guttmann, NeuroPersonalTrainer® (GNPT) cognitive rehabilitation (CR) and characterised the induced changes in cerebral networks in patients with multiple sclerosis (MS). This multicentre, double-blind, randomised clinical trial compared upward intensity training (active treatment) to low-intensity static training (static treatment). Cognition was assessed using the Brief Repeatable battery before and after 12 weeks of training and at 10-months follow-up, and patients were classified as having a mild or severe cognitive impairment (CI). Brain MRI pre- and post-CR were analysed using an advanced tractography algorithm, based on multishell diffusion MRI, to obtain node-based graph metrics (local efficiency and strength) from microscopic fractional anisotropy. Seventy MS patients completed the study (age 48.9 ± 8.8, disease duration 16.8 ± 9.0 years); active treatment: 36, static treatment: 34. Verbal memory improved significantly post-CR in both groups (55 % active; 34 % static treatment), accompanied by increases in local efficiency and strength in multimodal regions. At follow-up, verbal memory declined in both groups but remained above the pre-CR assessment (-25 % and -17 %, respectively). Patients with severe-CI (n = 36) showed improvement only with active treatment, while those with mild-CI (n = 34) improved regardless of intensity treatment. Network changes were more pronounced in patients in active treatment and in those with severe-CI. Quality of life did not change at post-CR, and cognitive improvement was influenced by cognitive reserve (p = 0.011). In MS, GNPT temporarily improves verbal memory and increases network connectivity, reinforcing the CR as a valuable tool for enhancing cognitive skills and promoting neuronal plasticity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evolving epidemiology of HCC in Spain

  • Sala Llinas, Margarita|||0000-0003-4879-1780
  • Pascual, Sonia|||0000-0002-4265-5019
  • Rota Roca, Maria Rosa
  • Matilla, Ana María
  • Campos, Marta
  • Delgado, Manuel
  • Ferrer, María Teresa
  • Montero, José Luís
  • González Santiago, Jesús M.|||0000-0003-4667-4492
  • Guerrero, Antonio
  • Aracil, Carlos|||0000-0002-8228-9041
  • Rodríguez Lope, Carlos|||0000-0002-6713-8800
  • Romero-Gutiérrez, Marta
  • Sogbe, Miguel|||0000-0002-2846-7812
  • Vázquez Rodríguez, Sergio|||0000-0001-6108-9449
  • Fuentes Olmo, Javier|||0000-0001-8637-510X
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Cortés-García, Luis|||0000-0003-3164-2703
  • Vallejo-Senra, N.
  • Rendón, Paloma|||0000-0002-6521-3766
  • Clos, Ariadna|||0000-0002-6414-2097
  • Díaz-Bethencourt, D.
  • García Sánchez, Araceli
  • Quiñones Castro, Raisa|||0000-0003-2446-9068
  • Bustamante, Javier|||0000-0002-5280-3038
  • Perelló, Christie|||0000-0003-0234-2330
  • Urquijo Ponce, J.J.
  • Andreu Serra, Hernán
  • Llamoza-Torres, Camilo J.|||0000-0001-8072-9413
  • Montoliu, Silvia|||0000-0002-3041-578X
  • Fernández Marcos, Cristina
  • Guiberteau, A.
  • Hernandez-Guerra, Manuel|||0000-0002-3478-9981
  • Vergara, Mercedes|||0000-0002-6971-8657
  • Fernández-López, A.M.
  • Valer López-Fando, M.P.
  • Gutiérrez-García, M.L.
  • Hernáez-Alsina, T.|||0000-0002-3734-2448
  • Coll, Susanna|||0000-0002-0395-9685
  • Cuyàs, Berta|||0000-0001-9988-7163
  • Morillas, M.J.
  • Rebolledo Olmedo, Susana
  • Fernández Bermejo, Miguel
  • Roget, Mercè
  • Calvo Ramos, Irina
  • Pacheco del Río, G.
  • Rifà, Raimon|||0000-0003-1911-3681
  • Conde Gacho, Pilar
  • Llorente Barrio, Mónica|||0000-0003-0267-989X
  • Gómez-Rubio, M.
  • Peñas, Irene
  • Serra Matamala, Isabel|||0000-0002-5694-9325
  • Cachero, Alba|||0000-0002-0010-4534
  • Reig, María|||0000-0002-5711-9534
  • Giráldez-Gallego, Álvaro|||0000-0001-6849-9272
  • Guerrero Misas, Marta
  • Segarra, J.X.|||0000-0002-7222-5191
  • Lledó, J.L.
  • Díaz-González, Álvaro|||0000-0003-3610-2263
  • Delgado, Carolina|||0000-0002-0808-4494
  • Iñarrairaegui, M.
  • Rodríguez-González, M.M.
  • Lázaro, M.
  • Bermúdez-Ramos, María|||0000-0002-5516-3902
  • Lué, A.|||0000-0002-9672-6038
  • Molina, E.
  • Macías-Rodríguez, M.A.|||0000-0003-2634-6125
  • Rodríguez, Manuel|||0000-0001-5763-7668
  • Chiminazzo, V.
  • Varela Calvo, Maria|||0000-0003-4288-2593
Background & Aims: The epidemiological landscape of hepatocellular carcinoma (HCC) in Europe is evolving. This study aims to provide an updated description of the current epidemiology of liver cancer in Spain. Methods: This multicenter prospective study collected demographic and clinical data on primary liver cancer between October 2022 and January 2023. We conducted descriptive and comparative analyses with data collected in 2008 and 2014. Results: Of the 767 cases of primary liver cancer collected from 52 centers, 91% were diagnosed as HCC. The majority of patients were male (83.3%), average age 68 years, 80.7% had cirrhosis. The primary causes were alcohol (29.9% alone, 55% combined with other etiologies), liver disease related to metabolic syndrome (LDrMS, 23%) and hepatitis C (17.3%). Treatments included ablation (15.7%), systemic therapy (14.7%), and chemoembolization (14.6%). Data from 29 centers (n = 1,351) across three registries revealed a significant increase in LDrMS (from 4.9% to 24%) and HCC in non-cirrhotic livers (from 4.2% to 7.9%). Meanwhile, hepatitis C decreased sharply (from 43% to 17.5%). Alcohol-related cases remained stable. There was a slight increase in male patients and hypertension, diabetes, and obesity. Patients with cirrhosis diagnosed outside of screening programs presented with larger tumors and more advanced disease. This led to fewer evaluations for curative treatments. Conclusions: Alcohol accounts for 30% of HCC cases and is the main etiology. The registry shows a decrease in hepatitis C-related HCC, an increase in LDrMS and HCC in non-cirrhotic livers. Surveillance was implemented in ∼80% of the recommended population. There is a need for improved screening and prevention strategies, particularly for alcohol abuse and LDrMS, to enhance HCC management. Impact and implications: Our study showcases the involvement of numerous reference centers across Spain and examines over 1,300 patients to track the changing epidemiology of hepatocellular carcinoma (HCC) over 14 years. In patients with known liver cirrhosis, more than 80% of HCC diagnoses were made through screening leading to early-stage identification and curative treatment opportunities. Notably, there has been a shift in HCC etiology within the registries from hepatitis C to liver disease related to metabolic syndrome, with an increase in cases without cirrhosis. Findings indicate a need for the prevention and early detection of HCC, particularly focusing on alcohol and liver disease related to metabolic syndrome, along with greater involvement of health authorities, to improve the participation of at-risk patients in screening programs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Critical Update of the Classification of Chiari and Chiari-like Malformations

  • Sahuquillo Barris, Juan|||0000-0003-0713-5875
  • Moncho, Dulce|||0000-0003-2877-8239
  • Ferré Masó, Alex|||0000-0002-3914-4154
  • López-Bermeo, Diego
  • Sahuquillo-Muxi, Aasma
  • Poca Pastor, María Antonia|||0000-0002-3831-0536
Chiari malformations are a group of craniovertebral junction anomalies characterized by the herniation of cerebellar tonsils below the foramen magnum, often accompanied by brainstem descent. The existing classification systems for Chiari malformations have expanded from the original four categories to nine, leading to debates about the need for a more descriptive and etiopathogenic terminology. This review aims to examine the various classification approaches employed and proposes a simplified scheme to differentiate between different types of tonsillar herniations. Furthermore, it explores the most appropriate terminology for acquired herniation of cerebellar tonsils and other secondary Chiari-like malformations. Recent advances in magnetic resonance imaging (MRI) have revealed a higher prevalence and incidence of Chiari malformation Type 1 (CM1) and identified similar cerebellar herniations in individuals unrelated to the classic phenotypes described by Chiari. As we reassess the existing classifications, it becomes crucial to establish a terminology that accurately reflects the diverse presentations and underlying causes of these conditions. This paper contributes to the ongoing discussion by offering insights into the evolving understanding of Chiari malformations and proposing a simplified classification and terminology system to enhance diagnosis and management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO)

  • Pizarro, David
  • Romero, Ignacio
  • Pérez-Mies, Belén
  • Redondo Sánchez, Andrés|||0000-0002-7257-5642
  • Caniego-Casas, Tamara
  • Carretero-Barrio, Irene|||0000-0003-1986-2965
  • Cristóbal, Eva
  • Gutiérrez-Pecharromán, Ana
  • Santaballa, Ana|||0000-0001-7763-320X
  • D'Angelo, Emanuela|||0000-0002-6173-1806
  • Hardisson, David|||0000-0002-2183-3699
  • Vieites, Begoña
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Estévez-García, Purificación
  • Guerra, Eva|||0000-0003-1910-4451
  • Prat, Jaime|||0000-0002-9787-3304
  • Poveda, Andrés
  • López Guerrero, José Antonio|||0000-0002-7369-8388
  • Palacios, José|||0000-0002-6730-5066
Early stages are under-represented in studies on the molecular and immune features of high-grade serous ovarian carcinoma (HGSOC), and specific studies focused on early-stage HGSOC are required for a better prognostic stratification and to personalize chemotherapy. The aim of this study was to determine the prognostic significance of CD8+ and CD4+ tumor-infiltrating lymphocytes (TILs), tumoral cell PD-L1 expression, BRCA mutational status and tumor mutation burden (TMB) in early-stage HGSOC. A retrospective study was performed on stage I and II HGSOC from the Molecular Reclassification of Early Stages of Ovarian Cancer (RECLAMO) cohort from the Spanish Group of Ovarian Cancer Research (GEICO). Centralized histological typing was performed based on morphological and immunohistochemical features. Intraepithelial (i) and stromal (s) CD8+ and CD4+ T cells and PD-L1 were evaluated on tissue microarrays by immunohistochemistry. BRCA1 and BRCA2 mutation status and TMB were analyzed in tumor DNA using next-generation sequencing. The study included 124 tumors. High iCD8+ (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Deep Sequencing Reveals Dual Evolution of SARS-CoV-2, Insights Into Defective Genomes From Wuhan-Hu-1 Variants to Omicron Subvariants

  • Campos, Carolina|||0000-0002-0132-7027
  • Ibañez Lligoña, Marta|||0000-0003-3428-2168
  • Colomer Castell, Sergi|||0000-0002-0307-7455
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Andrés, Cristina|||0000-0002-3200-0895
  • Piñana, Maria|||0000-0002-4766-2613
  • González Sánchez, Alejandra|||0000-0002-1809-3415
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Saubi, Narcis|||0000-0001-5493-1044
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Tabernero, David|||0000-0002-1146-4084
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Ferrer Costa, Roser|||0000-0002-8925-3172
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Kakze-van der Honing, Renate W.
  • Kampfraath, Andries A.
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • van der Poel, Wim H. M.
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Quer, Josep|||0000-0003-0014-084X
SARS-CoV-2 has evolved from early variants dominating the first (B.1.5, B.1.1) and second (B.1.177) pandemic waves, which exhibited a higher frequency of minority mutants with deletions leading to Defective Viral Genomes (DVGs) in the spike region near the S1/S2 cleavage site than the Alpha, Beta, and Delta variants. The emergence of Omicron has significantly altered the dominant variant profile, with Omicron subvariants now representing 100% of circulating viruses. To monitor the evolution and adaptation of Omicron in the human population, a deep-sequencing study was performed in RNA samples of BA.1, BA.1.1, BA.2, BA.5, BQ.1.1, XBB.1.5 and BA.2.86 Omicron subvariants. The findings reveal two occurrences of similar evolutionary patterns within SARS-CoV-2 characterized by a shift from a significant to a very low production of DVGs. This event suggests that DVGs might play a role in the virus's spread and adaptation for persistence in infected humans.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effectiveness of a psychoeducational intervention on myositis patients' quality of life and well-being, a randomized controlled trial

  • Armadans Tremolosa, Immaculada|||0000-0003-2690-0544
  • Palacin Lois, Maria Ramona|||0000-0001-7931-1466
  • Castrechini Trotta, Ángela|||0000-0003-3241-5254
  • Sanduvete-Chaves, Susana|||0000-0001-8568-6168
  • Chacón-Moscoso, Salvador|||0000-0002-6401-7384
  • Selva O'Callaghan, Albert|||0000-0003-2823-9761
Myositis is a rare disease associated with impaired health-related quality of life. A study evaluating the effectiveness of an intervention to improve the quality of life and well-being of myositis patients is presented. All myositis patients in a health district were contacted. Thirty-four eligible patients were randomly assigned to the experimental (n = 17) or control (n = 17) group. A psychoeducational intervention of 5 100-min sessions focusing on the disease as related to daily life was conducted only in experimental patients. Several reliable tools to measure quality of life and well-being were administered twice, before and after the intervention, to both groups. In the experimental group, post-test scores were higher than pre-test in quality of life, well-being, and self-efficacy to manage the disease. Improvements were more evident in the experimental group than controls in 70% of the variables studied. Specifically, sedentariness decreased and satisfaction with social relationships increased in the post-test evaluation to a greater degree in the experimental group than in controls. This randomized controlled trial on a representative sample of myositis patients in an extensive population provides evidence indicating the effectiveness of a psychoeducational intervention for improving HRQoL, well-being, and self-efficacy to manage the disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cerebrospinal fluid lipoprotein-mediated cholesterol delivery to neurons is impaired in Alzheimer's disease and involves APOE4

  • Borràs, Carla|||0000-0002-0998-7855
  • Canyelles, Marina|||0000-0002-0278-5337
  • Santos, David|||0000-0003-1157-4969
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Nuñez, Estefania|||0000-0002-0876-1264
  • Vázquez, Jesús|||0000-0003-1461-5092
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Zhao, Qi
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
In the central nervous system, apolipoprotein (APO)E-containing lipoprotein particles mediate the transport of glial-derived cholesterol to neurons, which is essential for neuronal membrane remodeling and maintenance of the myelin sheath. We aimed to examine cholesterol transport via lipoprotein particles in cerebrospinal fluid (CSF) of Alzheimer's disease (AD) patients compared to control individuals. Additionally, we explored the ability of reconstituted HDL containing different APOE isoforms to regulate cholesterol transport. We evaluated the capacity of CSF lipoprotein particles to facilitate radiolabeled unesterified cholesterol efflux from A172 human glioblastoma astrocytes and to deliver cholesterol to SH-SY5Y human neuronal cells. The CSF lipoprotein proteome was analyzed by LC-MS/MS. Reconstituted HDL nanoparticles were prepared by combining phospholipids and cholesterol with human APOE3 or APOE4, followed by radiolabeling with unesterified cholesterol. Our results showed that cholesterol efflux from astrocytes to CSF were similar between AD patients and controls, both under baseline conditions and after activation of ABCA1 and ABCG1. However, CSF lipoprotein-mediated neuronal cholesterol uptake was significantly reduced in the AD group. LC-MS/MS analysis identified 239 proteins associated with CSF lipoproteins in both groups, with no major alterations in proteins linked to cholesterol metabolism. However, 27 proteins involved in noncholesterol-related processes were differentially expressed. Notably, synthetic reconstituted HDL particles containing APOE4 exhibited reduced capacity to deliver cholesterol to neurons compared to those with APOE3. These findings indicate that CSF lipoproteins from patients with AD demonstrate impaired cholesterol delivery to neurons. Our study highlights APOE4 as a critical contributor to abnormal neuronal cholesterol uptake in AD pathophysiology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neural correlates of human fear conditioning and sources of variability in 2199 individuals

  • Radua, Joaquim|||0000-0003-1240-5438
  • Savage, Hannah S.
  • Vilajosana, Enric
  • Jamieson, Alec|||0000-0002-5598-0240
  • Abler, Birgit
  • Åhs, Fredrik
  • Beckers, Tom|||0000-0002-9581-1505
  • Cardoner, Narcís|||0000-0001-9633-0888
  • Cisler, Josh M.
  • Diniz, Juliana B.
  • Bach, Dominik R.|||0000-0003-3717-2036
  • Elsenbruch, Sigrid|||0000-0002-6528-2665
  • Greening, Steven G.|||0000-0003-4578-4139
  • Holt, Daphne J.
  • Kaczkurkin, Antonia N.|||0000-0002-0943-3094
  • Keil, Andreas|||0000-0002-4064-1924
  • Kindt, Merel|||0000-0001-7989-3195
  • Koch, Kathrin|||0000-0003-4664-8016
  • LaBar, Kevin S.|||0000-0002-8253-5417
  • Lam, Charlene L.
  • Larson, Christine L.|||0000-0002-1359-6080
  • Lonsdorf, Tina B.|||0000-0003-1501-4846
  • Merz, Christian J.|||0000-0001-5679-6595
  • McLaughlin, Katie A.|||0000-0002-1362-2410
  • Neria, Yuval
  • Pine, Daniel S.
  • van Reekum, Carien M.|||0000-0002-1516-1101
  • Shackman, Alexander J.|||0000-0002-3629-4704
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Spoormaker, Victor I.
  • Stout, Daniel M.
  • Straube, Benjamin|||0000-0002-9837-0944
  • Straube, Thomas
  • Tuominen, Lauri
  • Visser, Renée M.|||0000-0003-0376-8165
  • Ahumada, Laura|||0000-0002-9353-2457
  • Arolt, Volker|||0000-0002-2445-9778
  • Batistuzzo, Marcelo C.|||0000-0003-1347-8241
  • Bazán, Paulo R.|||0000-0003-2202-0494
  • Biggs, Emma E.
  • Cano, Marta|||0000-0003-0675-9483
  • Chavarría-Elizondo, Pamela|||0000-0002-8177-3771
  • Cooper, Samuel E.|||0000-0001-9563-1750
  • Dannlowski, Udo|||0000-0002-0623-3759
  • De la Peña-Arteaga, Víctor|||0000-0001-8627-2653
  • DeCross, Stephanie N.|||0000-0001-8993-4413
  • Domschke, Katharina|||0000-0002-2550-9132
  • Ehlers, Mana R.
  • Graner, John L.|||0000-0002-5465-7193
  • Hamm, Alfons O.
  • Herrmann, Martin J.|||0000-0001-9970-2122
  • Huggins, Ashley A.|||0000-0001-7936-2116
  • Icenhour, Adriane
  • Juaneda-Seguí, Asier
  • Junghoefer, Markus|||0000-0002-8532-2986
  • Kircher, Tilo|||0000-0002-2514-2625
  • Koelkebeck, Katja|||0000-0002-0469-3997
  • Kuhn, Manuel|||0000-0003-2210-9130
  • Labrenz, Franziska|||0000-0001-7284-3451
  • Lissek, Shmuel M.
  • Lotze, Martin|||0000-0003-4519-4956
  • Lueken, Ulrike|||0000-0003-1564-4012
  • Margraf, Jürgen|||0000-0001-5207-7016
  • Martínez-Zalacaín, Ignacio|||0000-0002-4036-0284
  • Moeck, Robert
  • Morriss, Jayne|||0000-0002-7928-9673
  • Ortuño, María|||0000-0002-7730-6054
  • Pittig, Andre|||0000-0003-3787-9576
  • Porta-Casteràs, Daniel|||0000-0002-3921-3607
  • Richter, Jan|||0000-0002-7127-6990
  • Ridderbusch, Isabelle C.
  • Rief, Winfried|||0000-0002-7019-2250
  • Roesmann, Kati|||0000-0001-6940-3551
  • Rosén, Jörgen|||0000-0002-3688-3859
  • Rußmann, Alena N.
  • Sjouwerman, Rachel
  • Spohrs, Jennifer
  • Ströhle, Andreas|||0000-0003-0935-3702
  • Suarez-Jimenez, Benjamin|||0000-0002-4765-2458
  • Ulrich, Martin|||0000-0002-1237-0426
  • Wittchen, Hans-Ulrich|||0000-0002-6311-7711
  • Zhu, Xi
  • Waller, Lea|||0000-0002-3239-6957
  • Walter, Henrik|||0000-0002-9403-6121
  • Thompson, Paul M.|||0000-0002-4720-8867
  • Bas-Hoogendam, Janna Marie|||0000-0001-8982-1670
  • Groenewold, Nynke A.|||0000-0002-0865-8427
  • Stein, Dan J.|||0000-0001-7218-7810
  • Van der Wee, Nic J.
  • Dunsmoor, Joseph E.|||0000-0002-5448-6873
  • Marquand, Andre F.|||0000-0001-5903-203X
  • Fullana, Miguel|||0000-0003-3863-5223
Pavlovian fear conditioning is a fundamental process in both health and disease. We investigate its neural correlates and sources of variability using harmonized functional magnetic resonance imaging data from 2199 individuals across nine countries, including 1888 healthy individuals and 311 with anxiety-related or depressive disorders. Using mega-analysis and normative modeling, we show that fear conditioning consistently engages brain regions within the "central autonomic-interoceptive" or "salience" network. Several task variables strongly modulate activity in these regions, contributing to variability in neural responses. Additionally, brain activation patterns differ between healthy individuals and those with anxiety-related or depressive disorders, with distinct profiles characterizing specific disorders such as post-traumatic stress disorder and obsessive-compulsive disorder. While the neural correlates of fear conditioning are highly generalizable at the population level, variability arises from differences in task design and clinical status, highlighting the importance of methodological diversity in capturing fear learning mechanisms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Alpha-synuclein co-pathology in Down syndrome-associated Alzheimer's disease

  • Bernhardt, Alexander Maximilian
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Longen, Sebastian
  • Trossbach, Svenja Verena
  • Giese, Armin
  • Matthias, Torsten
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Sanjuan, Aída
  • Fernández, Susana|||0000-0002-9777-1156
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Aranha, Mateus|||0000-0001-9594-292X
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Nübling, Georg|||0000-0003-4492-7302
  • Wagemann, Olivia
  • Stockbauer, Anna
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Fortea, Juan|||0000-0002-1340-638X
  • Levin, Johannes|||0000-0001-5092-4306
Alpha-synuclein (αSyn) seed amplification assay (SAA) enables in vivo study of αSyn but remains underexplored in Down syndrome-associated Alzheimer's disease (DSAD). We analyzed αSyn-SAA in cerebrospinal fluid (CSF) from 270 adults with Down syndrome, from the Down Alzheimer Barcelona Neuroimaging Initiative and from the AD21 cohort from the Department of Neurology at the University Hospital, Ludwig Maximilian University of Munich, Germany. Neuropathological examinations were conducted in 19 brain donors (five with ante mortem CSF). Participants were classified as asymptomatic or symptomatic (prodromal/dementia) Alzheimer's disease (AD). CSF Aβ1-42/1-40, CSF and plasma p-Tau181, and neurofilament light chain (NfL) levels were measured. Neuropathological evaluations assessed AD neuropathological changes and Lewy body pathology (LBP). ΑSyn-SAA was positive in 9.2% of cases, independent of age or cognitive status. Symptomatic αSyn-positive cases exhibited higher plasma NfL levels than αSyn-negative cases (31 vs 21 pg/mL, p = 0.027). LBP was observed in 47% of necropsies. The individual with severe neocortical LBP was αSyn-SAA-positive. These findings highlight LBP prevalence in DSAD but suggest current SAA may fail to detect limited αSyn deposition.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia

  • Medina-Gil, Daniel|||0000-0001-9421-949X
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Navarro Garcés, Víctor|||0000-0001-6925-4605
  • Lázaro, Gonzalo|||0000-0002-7548-114X
  • Martín-Mur, Beatriz|||0000-0002-6006-3295
  • Hernández Buñuel, Cristina
  • Castells, Oriol
  • Sánchez, Belén
  • Muñoz-Torres, Pau Marc|||0000-0002-0168-3224
  • Pagès Geli, Carlota|||0000-0001-9200-3943
  • Pujadas, Gemma|||0000-0002-3871-5883
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Cabirta, Alba|||0000-0001-7198-8894
  • Ferrá, Christelle|||0000-0003-4571-5125
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Terol, Maria Jose|||0000-0002-9467-932X
  • Andreu, Rafael|||0000-0002-9220-3352
  • Martí, Mercè|||0000-0002-1846-0043
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Crespo, Marta|||0000-0002-7732-7808
Continuous treatment with ibrutinib not only exerts tumor control but also enhances T-cell function in patients with chronic lymphocytic leukemia (CLL). We conducted longitudinal multi-omics analyses in samples from CLL patients receiving ibrutinib upfront to identify potential adaptive mechanisms to Bruton tyrosine kinase (BTK) inhibition during the first 12 months of continuous therapy. We found that ibrutinib induced a decrease in the expression of exhaustion markers and the proportion of regulatory T cells and T-follicular helper cells normalized to levels observed in healthy donors. Functionally, the expression of genes related to activation, proliferation, differentiation, and metabolism were downregulated in T cells; after in vitro stimulation, proliferation capacity was only slightly modified by ibrutinib treatment, while cytokine production was increased. In CLL cells, we observed a downregulation of immunosuppression, adhesion, and migration proteins. Adaptation at molecular level, characterized by an increase in cancer cell fraction of CLL cells with mutated driver genes, was observed in around half of the patients and was associated with retained migrative capacity towards CXCL12/CXCR4 axis. Interestingly, BTK C481S mutations were detected as early as after 6 months of treatment, particularly enriched in subsets of malignant cells retaining migrative capacity. These CLL cells with potential migrative capacity under ibrutinib also exhibited a distinct transcriptomic profile including upregulation of mTOR-AKT and MYC pathways. We identified the high expression of TMBIM6 as a potential novel independent poor prognostic factor. Of note, BIA, a TMBIM6 antagonist, induced CLL cell apoptosis and synergized with ibrutinib. In summary, our comprehensive multi-omics analysis of CLL patients undergoing ibrutinib therapy has unveiled early immunomodulatory effects on T cells and adaptative mechanisms in CLL cells. These findings can contribute to the identification of resistance mechanisms and the discovery of novel therapeutic targets.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Intraoperative Neurophysiological Monitoring in Syringomyelia Surgery, A Multimodal Approach

  • Sánchez Roldán, M. Ángeles|||0000-0002-7952-6755
  • Moncho, Dulce|||0000-0003-2877-8239
  • Rahnama Zand, Kimia|||0000-0002-6163-3405
  • Santa-Cruz, Daniela
  • Lainez, Elena|||0000-0003-0921-717X
  • Baiget, Daniel
  • Chocrón, Ivette
  • Gándara, Darío
  • Bescós Cabestre, Agustí|||0000-0002-9475-1969
  • Sahuquillo Barris, Juan|||0000-0003-0713-5875
  • Poca Pastor, María Antonia|||0000-0002-3831-0536
Syringomyelia can be associated with multiple etiologies. The treatment of the underlying causes is first-line therapy; however, a direct approach to the syrinx is accepted as rescue treatment. Any direct intervention on the syrinx requires a myelotomy, posing a significant risk of iatrogenic spinal cord (SC) injury. Intraoperative neurophysiological monitoring (IONM) is crucial to detect and prevent surgically induced damage in neural SC pathways. We retrospectively reviewed the perioperative and intraoperative neurophysiological data and perioperative neurological examinations in ten cases of syringomyelia surgery. All the monitored modalities remained stable throughout the surgery in six cases, correlating with no new postoperative neurological deficits. In two patients, significant transitory attenuation, or loss of motor evoked potentials (MEPs), were observed and recovered after a corrective surgical maneuver, with no new postoperative deficits. In two cases, a significant MEP decrement was noted, which lasted until the end of the surgery and was associated with postoperative weakness. A transitory train of neurotonic electromyography (EMG) discharges was reported in one case. The surgical plan was adjusted, and the patient showed no postoperative deficits. The dorsal nerve roots were stimulated and identified in the seven cases where the myelotomy was performed via the dorsal root entry zone. Dorsal column mapping guided the myelotomy entry zone in four of the cases. In conclusion, multimodal IONM is feasible and reliable and may help prevent iatrogenic SC injury during syringomyelia surgery.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dimensiones y dominios para evaluar la exposición al humo ambiental de tabaco, conclusiones de un estudio Delphi, Dimensions and domains to assess secondhand tobacco smoke exposure

  • Blanco-Ferreiro, A.
  • Rey-Brandariz, J.
  • Ahluwalia, J.S.
  • Varela-Lema, L.
  • Galán, I.
  • Santiago-Pérez, M.I.
  • Sureda, Xisca|||0000-0002-6262-2257
  • Fu, Marcela|||0000-0002-4962-0927
  • Schiaffino, Anna|||0000-0001-8787-2634
  • López Medina, María José|||0000-0003-4402-2239
  • Continente, Xavier|||0000-0003-4888-2754
  • Candal Pedreira, Cristina
  • Mahabee-Gittens, M.
  • Pérez-Ríos, M.
Objetivo: Identificar las dimensiones y los dominios que deben incluirse en los cuestionarios para evaluar la exposición al humo ambiental de tabaco (HAT) autodeclarada en estudios etiológicos y en encuestas de salud poblacionales. Método: Se realizó un estudio cualitativo en dos etapas. En la primera, basada en un estudio Delphi, 16 expertos en epidemiología del tabaquismo completaron dos cuestionarios y participaron en una sesión grupal. En la segunda, se realizaron entrevistas triangulares con seis expertos del estudio Delphi para una reflexión más profunda sobre los dominios identificados en la primera etapa. Las transcripciones grabadas se analizaron utilizando un enfoque temático. Resultados: Los expertos discutieron la importancia de evaluar la exposición al HAT en escenarios específicos, destacando el hogar, el lugar de trabajo, los lugares de ocio y el transporte privado. Además, consideraron la inclusión de preguntas sobre la convivencia con fumadores al evaluar la exposición en el hogar. Los expertos enfatizaron la importancia de diferenciar entre espacios de ocio, priorizando los cerrados sobre los abiertos. Para encuestas de salud poblacionales recomendaron que el tiempo de recuerdo fuera reciente, refiriéndose a los últimos 7 días. Para estudios etiológicos sugirieron explorar las exposiciones a lo largo de la vida. Conclusiones: Este estudio representa un primer paso para identificar las dimensiones y los dominios en la evaluación de la exposición al HAT autodeclarada. La estandarización de las preguntas es clave para facilitar la comparación entre estudios y analizar las tendencias en la evolución de la exposición al HAT., Objective: To identify the dimensions and domains to be included in questionnaires when assessing self-reported secondhand tobacco smoke (SHS) exposure in etiological studies and in population health surveys. Method: A qualitative study was conducted in two stages. In stage one, based on a Delphi methodology, 16 experts in tobacco epidemiology completed two questionnaires and attended a group session. In stage two, triangulation interviews were conducted with six experts from the Delphi study to provided in-depth reflection on the domains identified in stage one. The recorded transcriptions were analyzed using a thematic approach. Results: The experts discussed the importance of assessing SHS exposure in specific scenarios, highlighting the home, workplace, leisure venues, and private transport. They discussed the importance of asking about cohabiting with smokers when assessing exposure at home. The experts stressed the importance of differentiating between leisure venues, by prioritizing closed over open spaces. In population-based health surveys, the experts recommended that the recall time should be recent, referring to the last seven days. In etiological studies, they suggested that lifetime exposures should be explored. Conclusions: This study marks the first step toward identifying the dimensions and domains for assessing self-reported SHS exposure. Question standardization when ascertaining SHS exposure is critical to permit cross study comparisons and to analyze trends in the evolution of SHS exposure.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass

  • Hernández-Montoliu, Laura
  • Rodríguez-Peña, M.Mar
  • Puig, Rocío
  • Astiarraga, Brenno|||0000-0003-2216-8974
  • Guerrero-Pérez, Fernando
  • Virgili, Nuria
  • López-Urdiales, Rafael|||0000-0002-2355-3041
  • Osorio, Javier|||0000-0002-0889-4585
  • Monseny, Rosa
  • Lazzara, Claudia
  • Sobrino, Lucía
  • Pérez-Maraver, Manuel|||0000-0003-4427-7581
  • Pérez-Prieto, María
  • Pellitero, Silvia|||0000-0002-9510-7251
  • Fernández-Veledo, Sonia|||0000-0003-2906-3788
  • Vendrell, Joan|||0000-0002-6994-6115
  • Vilarrasa, Nuria|||0000-0003-3188-1990
Objective: To determine changes in incretins, systemic inflammation, intestinal permeability and microbiome modifications 12 months after metabolic RYGB (mRYGB) in patients with type 2 diabetes (T2D) and their relationship with metabolic improvement. Materials and methods: Prospective single-center non-randomized controlled study, including patients with class II-III obesity and T2D undergoing mRYGB. At baseline and one year after surgery we performed body composition measurements, biochemical analysis, a meal tolerance test (MTT) and lipid test (LT) with determination of the area under the curve (AUC) for insulin, C-peptide, GLP-1, GLP-2, and fasting determinations of succinate, zonulin, IL-6 and study of gut microbiota. Results: Thirteen patients aged 52.6 ± 6.5 years, BMI 39.3 ± 1.4 kg/m, HbA 7.62 ± 1.5% were evaluated. After mRYGB, zonulin decreased and an increase in AUC after MTT was observed for GLP-1 (pre 9371 ± 5973 vs post 15788 ± 8021 pM, P<0.05), GLP-2 (pre 732 ± 182 vs post 1190 ± 447 ng/ml, P<0.001) and C- peptide, as well as after LT. Species belonging to Streptococaceae, Akkermansiacea, Rickenellaceae, Sutterellaceae, Enterobacteriaceae, Oscillospiraceae, Veillonellaceae, Enterobacterales_uc, and Fusobacteriaceae families increased after intervention and correlated positively with AUC of GLP-1 and GLP-2, and negatively with glucose, HbA, triglycerides and adiposity markers. Clostridium perfringens and Roseburia sp. 40_7 behaved similarly. In contrast, some species belonging to Lachnospiraceae, Erysipelotricaceae, and Rumnicocaceae families decreased and showed opposite correlations. Higher initial C-peptide was the only predictor for T2D remission, which was achieved in 69% of patients. Conclusions: Patients with obesity and T2D submitted to mRYGB show an enhanced incretin response, a reduced gut permeability and a metabolic improvement, associated with a specific microbiota signature.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparison of Extracellular Vesicle Isolation Methods for miRNA Sequencing

  • Llorens-Revull, Meritxell|||0000-0002-8671-8907
  • Martínez-González, Brenda|||0000-0002-4482-5181
  • Quer, Josep|||0000-0003-0014-084X
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Núñez-Moreno, Gonzalo|||0000-0001-5982-570X
  • Minguez, Pablo|||0000-0003-4099-9421
  • Burgui, Idoia
  • Ramos-Ruiz, Ricardo|||0000-0002-6331-9786
  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • Rico, Angie
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Sauleda, Silvia|||0000-0001-7343-9557
  • Piron, Maria|||0000-0001-6858-9374
  • Corrales Insa, Irene|||0000-0002-0647-0340
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Ramírez Serra, Clara|||0000-0001-8971-1711
  • Camós Anguila, Sílvia|||0000-0002-0478-8494
  • Domingo, Esteban
  • Bes, Marta|||0000-0001-6103-072X
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Costafreda Salvany, Maria Isabel|||0000-0002-3114-3034
MicroRNAs (miRNAs) encapsulated in extracellular vesicles (EVs) are potential diagnostic and prognostic biomarkers. However, discrepancies in miRNA patterns and their validation are still frequent due to differences in sample origin, EV isolation, and miRNA sequencing methods. The aim of the present study is to find a reliable EV isolation method for miRNA sequencing, adequate for clinical application. To this aim, two comparative studies were performed in parallel with the same human plasma sample: (i) isolation and characterization of EVs obtained using three procedures: size exclusion chromatography (SEC), iodixanol gradient (GRAD), and its combination (SEC+GRAD) and (ii) evaluation of the yield of miRNA sequences obtained using NextSeq 500 (Illumina) and three miRNA library preparation protocols: NEBNext, NEXTFlex, and SMARTer smRNA-seq. The conclusion of comparison (i) is that recovery of the largest amount of EVs and reproducibility were attained with SEC, but GRAD and SEC+GRAD yielded purer EV preparations. The conclusion of (ii) is that the NEBNext library showed the highest reproducibility in the number of miRNAs recovered and the highest diversity of miRNAs. These results render the combination of GRAD EV isolation and NEBNext library preparation for miRNA retrieval as adequate for clinical applications using plasma samples.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Temporal trends and social inequities in adolescent and young adult mental health disorders in Catalonia, Spain, a 2008-2022 primary care cohort study

  • Lozano-Sánchez, Ana
  • Aragonès, Enric|||0000-0002-5245-4667
  • López Jiménez, Tomàs|||0000-0001-8255-4936
  • Bennett, Matthew|||0000-0002-8309-8191
  • Evangelidou, Stella|||0000-0002-7107-3229
  • Francisco, Esther|||0000-0001-8086-0817
  • García, Myriam|||0000-0002-4896-9772
  • Malgosa Gasol, Estel|||0000-0003-0727-5392
  • Codern-Bové, Núria|||0000-0003-0210-7488
  • Guzmán-Molina, Claudia|||0000-0002-8083-4368
  • Jacques-Aviñó, Constanza|||0000-0001-8506-780X
The prevalence of mental health disorders in children, teens, and young adults is rising at an alarming rate. This study aims to explore time trends in the incidence of mental disorders among young people in Catalonia, Spain from 2008 to 2022, focusing on the effects of the COVID-19 pandemic and from the perspective of social inequities. A cohort study using primary care records from the SIDIAP database was conducted. It included 2,088,641 individuals aged 10 to 24 years. We examined the incidence of depressive, anxiety, eating, and attention deficit/hyperactivity disorders, stratified by sex, age, deprivation, and nationality. All disorders reflected an increasing trend throughout the study period: depressive disorders (IRR: 2.44, 95% CI: 2.31-2.59), anxiety disorders (IRR: 2.33, 95% CI: 2.27-2.39), ADHD (IRR: 2.33, 95%CI: 2.17-2.50), and eating disorders (IRR: 3.29, 95% CI: 3.01-3.59). A significant increase in incidence was observed after the outbreak of the COVID-19 pandemic. In 2022, anxiety disorders were most frequent, with an incidence rate (IR) of 2,537 per 100,000 persons-year (95% CI: 2,503-2,571). Depressive disorders followed with an IR of 471 (95% CI: 458-486), ADHD with an IR of 306 (95% CI: 295-317) and eating disorders with an IR of 249 (95% CI: 239-259). Significant associations were reported with sex, age, deprivation, and nationality. The incidence of all studied disorders has steadily increased, reaching unprecedented levels during the pandemic. Understanding these trends is essential for an appropriate healthcare response, while addressing the non-medical determinants, requires action across all sectors of society. The online version contains supplementary material available at 10.1186/s13034-024-00849-2.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Novel Splicing Variant in Atypical Presentation of Familial Frontotemporal Lobar Degeneration

  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Bernal, Sara|||0000-0003-4427-0574
  • Almenta Gallego, David|||0000-0001-9069-8948
  • Perez Blanco, Josefina|||0000-0002-6489-8871
  • Camacho, Valle|||0000-0003-0748-0847
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
C-truncating variants in the charged multivesicular body protein 2B (CHMP2B) gene are a rare cause of frontotemporal lobar degeneration (FTLD), previously identified only in Denmark, Belgium, and China. We report a novel CHMP2B splice-site variant (c.35-1G>A) associated with familial FTLD in Spain. The cases were two monozygotic male twins who presented at ages 62 and 66 years with a slowly progressive behavioral variant of frontotemporal dementia and a syndrome mimicking dementia with Lewy bodies, respectively. Functional and in silico analyses supported the pathogenicity of this variant. Our findings contribute new insights into the genetic landscape and clinical heterogeneity of FTLD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography

  • Wicklein, Rebecca|||0000-0002-6661-6081
  • Yam, Charmaine
  • Noll, Christina
  • Aly, Lilian|||0000-0002-7051-124X
  • Banze, Nicolas
  • Romahn, Eva Feodora
  • Wolf, Elisabeth
  • Hemmer, Bernhard|||0000-0001-5985-6784
  • Oertel, Frederike Cosima|||0000-0003-4906-5983
  • Zimmermann, Hanna G.|||0000-0002-0276-8051
  • Albrecht, Philipp|||0000-0001-7987-658X
  • Ringelstein, Marius|||0000-0003-3618-8407
  • Baumann, Carmen
  • Feucht, Nikolaus
  • Penkava, Josef
  • Havla, Joachim|||0000-0002-4386-1340
  • Gernert, Jonathan A.
  • Mardin, Christian
  • Vasileiou, Eleni S.|||0000-0002-8639-8405
  • van der Walt, Anneke|||0000-0002-4278-7003
  • Al-Louzi, Omar|||0000-0003-2260-5660
  • Cabello, Sergio
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Krämer, Julia
  • Wiendl, Heinz|||0000-0003-4310-3432
  • Preiningerova, Jana Lizrova|||0000-0003-0337-3462
  • Ciccarelli, Olga|||0000-0001-7485-1367
  • Garcia-Martin, Elena|||0000-0001-6258-2489
  • Kana, Veronika
  • Calabresi, Peter A.|||0000-0002-7776-6472
  • Paul, Friedemann|||0000-0002-6378-0070
  • Saidha, Shiv|||0000-0001-6387-0714
  • Petzold, Axel|||0000-0002-0344-9749
  • Toosy, Ahmed T.|||0000-0002-4441-3750
  • Knier, Benjamin|||0000-0003-4187-9472
Optical coherence tomography angiography (OCTA) is a noninvasive high-resolution imaging technique for assessing the retinal vasculature and is increasingly used in various ophthalmologic, neuro-ophthalmologic, and neurologic diseases. To date, there are no validated consensus criteria for quality control (QC) of OCTA. Our study aimed to develop criteria for OCTA quality assessment. To establish criteria through (1) extensive literature review on OCTA artifacts and image quality to generate standardized and easy-to-apply OCTA QC criteria, (2) application of OCTA QC criteria to evaluate interrater agreement, (3) identification of reasons for interrater disagreement, revision of OCTA QC criteria, development of OCTA QC scoring guide and training set, and (4) validation of QC criteria in an international, interdisciplinary multicenter study. We identified 7 major aspects that affect OCTA quality: (O) obvious problems, (S) signal strength, (C) centration, (A) algorithm failure, (R) retinal pathology, (M) motion artifacts, and (P) projection artifacts. Seven independent raters applied the OSCAR-MP criteria to a set of 40 OCTA scans from people with MS, Sjogren syndrome, and uveitis and healthy individuals. The interrater kappa was substantial (κ 0.67). Projection artifacts were the main reason for interrater disagreement. Because artifacts can affect only parts of OCTA images, we agreed that prior definition of a specific region of interest (ROI) is crucial for subsequent OCTA quality assessment. To enhance artifact recognition and interrater agreement on reduced image quality, we designed a scoring guide and OCTA training set. Using these educational tools, 23 raters from 14 different centers reached an almost perfect agreement (κ 0.92) for the rejection of poor-quality OCTA images using the OSCAR-MP criteria. We propose a 3-step approach for standardized quality control: (1) To define a specific ROI, (2) to assess the occurrence of OCTA artifacts according to the OSCAR-MP criteria, and (3) to evaluate OCTA quality based on the occurrence of different artifacts within the ROI. OSCAR-MP OCTA QC criteria achieved high interrater agreement in an international multicenter study and is a promising QC protocol for application in the context of future clinical trials and studies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Solved the enigma of pediatric severe acute hepatitis of unknown origin?

  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Quer, Josep|||0000-0003-0014-084X
Hepatitis is an inflammation of the liver whose etiology is very heterogeneous. The most common cause of hepatitis is viral infections from hepatotropic viruses, including hepatitis A, B, C, D and E. However, other factors such as infections from other agents, metabolic disorders, or autoimmune reactions can also contribute to hepatitis, albeit to a lesser extent. On April 5, 2022, the United Kingdom Health Security Agency alerted the World Health Organization (WHO) on the increased incidence of severe acute hepatitis of unknown causes (not A-E) in previously healthy young children, with symptoms of liver failure that in some cases required liver transplantation. By July 2022, 1,296 cases were reported in 37 countries. Acute hepatitis of unknown causes is not an exceptional phenomenon: in fact, it represents more than 30% of cases of acute hepatitis in children, however in the present instance the large proportion of severe cases was surprising and alarming (6% of liver transplants and almost 3% mortality). Multiple hypotheses have been proposed to explain the etiology of such higher proportion of acute hepatitis, including their co-occurrence in the context of COVID-19 pandemic. This is a review of the history of a clinical threat that has put in check a world health care system highly sensitized by the current COVID-19 pandemics, and that it looks like has ended with the arguments that the severe acute pediatric hepatitis is caused by Adeno-associated virus 2 (AAV2) infection associated with a coinfection with a helper virus (human Adenovirus HAdV or human herpesvirus 6) in susceptible children carrying HLA-class II antigen HLA-DRB1*04:01.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early-Stage Breast Cancer Detection in Breast Milk

  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Ortiz, Carolina|||0000-0002-5523-829X
  • Matito, Judit|||0000-0001-7560-7737
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Suñol Camas, Anna
  • Martín, Ágatha|||0000-0003-4818-6433
  • Cordoba Cardona, Octavi|||0000-0002-9591-7430
  • Martínez-Sabadell, Alex|||0000-0002-9477-1396
  • Garcia-Ruiz, Itziar|||0000-0002-0717-7795
  • Miranda, Ignacio|||0000-0002-4813-5946
  • Morales-Comas, Clara|||0000-0001-6771-6749
  • Carrasco, Estela|||0000-0003-1964-7675
  • Viaplana, Cristina|||0000-0001-8904-4330
  • Peg, Vicente|||0000-0002-5203-6166
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Bayó-Puxan, Neus|||0000-0001-9909-1499
  • González Medina, Alberto, 1990-|||0000-0002-2819-9053
  • Miquel, Josep M.|||0000-0002-9262-4464
  • Gómez-Rey, Marina|||0000-0002-9636-3281
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Arévalo, Silvia|||0000-0001-8169-1322
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Tabernero, Josep|||0000-0002-2495-8139
  • Vivancos, Ana|||0000-0003-2888-6512
  • Sansó, Miriam|||0000-0001-7155-4041
The presence of cell-free tumor DNA was reported in breast milk from patients with breast cancer, and its use as a screening method surpassed plasma liquid biopsy in terms of detecting and molecularly profiling early-stage tumors, even prior to diagnosis. For the first time, we show that BM obtained from patients with breast cancer carries ctDNA, surpassing plasma-based liquid biopsy for detection and molecular profiling of early-stage breast cancer, even prior to diagnosis by image.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment

  • Bolsewig, K.
  • Willemse, E.A.J.
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Rábano, Alberto|||0000-0001-9320-6566
  • Martínez, Minerva|||0000-0002-9036-2595
  • Doecke, J.D.|||0000-0003-2863-0293
  • Bellomo, Giovanni|||0000-0003-0456-5650
  • Vermunt, L.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Halbgebauer, S.
  • in 't Veld, S.
  • Mattsson-Carlgren, N.
  • Veverova, K.
  • Fowler, C.J.
  • Boonkamp, L.
  • Koel-Simmelink, M.
  • Hussainali, Z.
  • Ruiters, D.N.
  • Gaetani, L.
  • Toja, A.
  • Fortea, Juan|||0000-0002-1340-638X
  • Pijnenburg, Y.
  • Lemstra, A.W.
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Hort, J.
  • Otto, M.|||0000-0003-4273-4267
  • Hansson, Oskar|||0000-0001-8467-7286
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Masters, C.L.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Teunissen, C.E.
  • Campo Milán, Marta del|||0000-0003-2808-3699
DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson's disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Testing a bifactor model of the comprehensive assessment of acceptance and Commitment Therapy Processes (CompACT) in Finnish and British populations

  • Gallego, Ana|||0000-0002-8060-2495
  • Navarrete Hidalgo, Jaime|||0000-0002-9482-4822
  • Gorinelli, Simone
  • Brandolin, Francesca|||0000-0003-4079-3669
  • Lappalainen, Päivi|||0000-0001-9038-894X
  • Golijani-Moghaddam, Nima
  • Dawson, David L.
  • Lappalainen, Raimo|||0000-0001-6683-134X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
Introduction: Psychological flexibility is a core concept in Acceptance and Commitment Therapy, with several self-report instruments developed to measure it. One multidimensional measure is the Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT). This study is the first to test a bifactor structure of the CompACT providing new insights into its dimensional structure and how scores should be computed. Additionally, the study validates the Finnish version of the instrument. Methods: Data from five distinct non-clinical Finnish (n = 281) and British samples (n = 690) were obtained. The internal structure of the CompACT was examined through confirmatory factor analysis. For the Finnish samples, reliability, construct validity, and sensitivity to change were also performed. Results: The bifactor structure was the best-fitting model across Finnish and British samples, supporting both a general psychological flexibility factor and three specific subcomponents: openness to experience, behavioral awareness, and valued action. The Finnish version of the CompACT demonstrated good internal consistency, strong construct validity, and significant correlations with mindfulness, well-being, stress, and depression measures. Additionally, the measure was sensitive to change in psychological flexibility following ACT-based interventions, with moderate-to-large effect sizes. Discussion: This study represents a significant advancement in the psychometric evaluation of the CompACT, providing the first empirical evidence that a bifactor model offers the optimal structural representation of the measure. The bifactor structure supports, for the first time, the computation of both an overarching psychological f lexibility score and subscale scores in the CompACT, reinforcing the theoretical conceptualization of psychological flexibility. These findings contribute to the refinement of psychological flexibility measurement and offer valuable insights for both research and clinical applications. Future studies should further investigate the bifactor model's added value over other established measures of psychological flexibility.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnosis, management and treatment of the Alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN

  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Lipska-Ziętkiewicz, Beata S.|||0000-0002-4169-9685
  • Acke, Frederic|||0000-0001-6312-4260
  • Antignac, Corinne|||0000-0002-9934-4940
  • Becker, Jan Ulrich|||0000-0003-2929-8085
  • Cornec-Le Gall, Emilie|||0000-0003-1958-4459
  • van Eerde, Albertien M.|||0000-0001-5953-5956
  • Feltgen, Nicolas|||0000-0002-6857-3003
  • Ferrari, Rossella
  • Gale, Daniel|||0000-0002-9170-1579
  • Gear, Susie
  • Gross, Oliver|||0000-0002-8390-8852
  • Haeberle, Stefanie
  • Heidet, Laurence|||0000-0002-1362-5515
  • Lennon, Rachel|||0000-0001-6400-0227
  • Massella, Laura|||0000-0001-5796-3965
  • Pfau, Kristina|||0000-0002-3642-3502
  • Venegas, María del Prado|||0000-0001-9048-4501
  • Topaloglu, Rezan|||0000-0002-6423-0927
  • Wlodkowski, Tanja
  • Zealey, Heidi
Glomerular nephropathy resulting from the genetic defects in COL4A3/4/5 genes including the classical Alport syndrome is the second most common hereditary kidney disease characterized by persistent haematuria progressing to the need for kidney replacement therapy, frequently associated with sensorineural deafness, and occasionally with ocular anomalies. Diagnosis and management of COL4A3/4/5 glomerulopathy is a great challenge due to its phenotypic heterogeneity, multiple modes of inheritance, variable expressivity, and disease penetrance of individual variants as well as imperfect prognostic and progression factors and scarce and limited clinical trials, especially in children. As a joint initiative of the European Rare Kidney disease reference Network (ERKNet), European Renal Association (ERA Genes&Kidney), and European Society for Paediatric Nephrology (ESPN) Inherited renal disorders working group, a team of experts including adult and paediatric nephrologists, kidney geneticists, audiologists, ophthalmologists, and a kidney pathologist were selected to perform a systematic literature review on 21 clinically relevant PICO (Patient or Population covered, Intervention, Comparator, Outcome) questions. The experts formulated recommendations and formally graded them at a consensus meeting with input from patient representatives and a voting panel of nephrologists representing all regions of the world. Genetic diagnostics comprising joint analysis of COL4A3/4/5 genes is already the key diagnostic test during the initial evaluation of an individual presenting with persistent haematuria, proteinuria, kidney failure of unknown origin, focal segmental sclerosis of unknown origin, and possibly cystic kidney disease. Early renin-angiotensin system blockade is the standard of care therapy; sodium-glucose cotransporter-2 inhibitors may be added in adults with proteinuria and chronic kidney disease. Relatives with heterozygous COL4A3/4/5 variants should only be considered as the last possible resource for living kidney donation. This guideline provides guidance for the diagnosis and management of individuals with pathogenic variants in COL4A3/4/5 genes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Relationship of cognitive decline with glucocerebrosidase activity and amyloid-beta 42 in and

  • Gonzalez, Maria Camila|||0000-0003-1061-4164
  • Oftedal, Linn
  • Lange, Johannes
  • Tovar-Rios, Diego Alejandro
  • Tysnes, Ole-Bjørn
  • Paquet, Claire|||0000-0002-2273-7316
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Rejdak, Konrad
  • Papuc, Ewa
  • Hort, Jakub|||0000-0002-1080-3726
  • Falup-Pecurariu, Cristian
  • Aarsland, Dag|||0000-0001-6314-216X
  • Alves, Guido
  • Maple-Grødem, Jodi
Dementia with Lewy bodies (DLB) and Parkinson's disease (PD) share clinical, pathological, and genetic risk factors, including GBA1 and APOEε4 mutations. Biomarkers associated with the pathways of these mutations, such as glucocerebrosidase enzyme (GCase) activity and amyloid-beta 42 (Aβ42) levels, may hold potential as predictive indicators, providing valuable insights into the likelihood of cognitive decline within these diagnoses. Our objective was to determine their association with cognitive decline in DLB and PD. A total of 121 DLB patients from the European-DLB Consortium and 117 PD patients from the Norwegian ParkWest Study were included in this study. The four most commonly associated variants of GBA1 mutations (E326K, T369M, N370S, L444P), APOEε4 status, and cerebrospinal fluid (CSF) Aβ42 levels and GCase activity were assessed, as well as global cognition using the Mini-Mental State Examination. Linear mixed-effects regression models were used to evaluate the association of CSF biomarkers with cognitive decline in each diagnostic group, adjusted for age, sex, education, and genetic mutation profile. Low CSF Aβ42 levels were associated with accelerated cognitive decline in DLB, whereas reduced CSF GCase activity predicted faster cognitive decline in PD. These associations were independent of GBA1 gene mutations or APOEε4 status. Our study provides important evidence on the relationship between brain Aβ deposition and GCase activity in the Lewy body disease spectrum independent of their genetic mutation profile. This information could be relevant for designing future clinical trials targeting these pathways.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia

  • Delaby, Constance|||0000-0002-8606-6814
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Busto, G.
  • Gabelle, A.
  • Ayrignac, X.
  • Bennys, K.
  • Muiño, Elena|||0000-0001-5839-7328
  • Villatoro-González, Paula|||0009-0001-0287-4073
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Pradeilles, N.
  • Bounasri, Shaima El
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Hirtz, C.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Lehmann, Sylvain|||0000-0001-6117-562X
Background: Blood-based assays are expected to be integrated into clinical routines across various contexts, including Alzheimer's disease (AD). Vascular dementia (VaD), which is the second most common cause leading to dementia after AD, could also significantly benefit from this advancement. However, no informative fluid biomarker has been identified for VaD. Given the disruption of iron homeostasis in both AD and VaD, this study aims to characterize the potential of the iron-related hormone Hepcidin as a biomarker for these two conditions. We will compare its added value to established AT(N) blood biomarkers. Methods: Blood biomarkers (amyloid-composite, p-Tau, Neurofilament Light Chain [NfL] and Hepcidin) levels in blood were analyzed in two independent cohorts and compared between AD patients and non-AD individuals. Additionally, blood Hepcidin and NfL were evaluated in the contexts of VaD and CADASIL, with their relative diagnostic value assessed. Results: Blood Hepcidin and NfL do not significantly increase the AUC obtained with both p-Tau and amyloid composite in the context of AD. In contrast, AUC for VaD diagnosis is significantly higher when combining these two blood biomarkers compared to NfL alone. Hepcidin was not significantly modified in CADASIL patients compared to control subjects. Conclusion: Blood Hepcidin and NfL have limited interest in the clinical context of AD but determination of these biomarkers shows to be highly informative for the diagnosis of VaD. This result could have important implications for diagnosis and implementation of clinical trials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer's pathophysiological biomarkers

  • Cervantes González, Alba|||0000-0003-1006-6719
  • Goossens, J.
  • Campuzano, E.V.
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Lidón Gil, Laia|||0000-0002-2083-3515
  • Perlaza, D.
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Haapasalo, A.
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Vanmechelen, E.
  • Belbin, Olivia|||0000-0002-6109-6371
Background: Synaptic protein levels in cerebrospinal fluid (CSF) may represent much-needed objective biomarkers of cognitive impairment, disease progression and drug efficacy in patients with dementia with Lewy bodies (DLB). Soluble N-ethylmaleimide-sensitive factor attachment proteins receptors (SNARE) proteins, such as VAMP-2 and SNAP-25, are implicated in α-synuclein pathophysiology and CSF levels of these proteins are associated with pathophysiological biomarkers and cognitive decline in Alzheimer's disease (AD). The aim of the study was to compare CSF levels of VAMP-2 and SNAP-25 in patients with DLB to cognitively unimpaired controls and AD patients and study their association with cognitive performance and AD and neurodegeneration biomarkers. Methods: VAMP-2 and SNAP-25 were quantified in CSF from cognitively normal controls (n = 62), DLB (n = 44) and AD (n = 114) patients from the Sant Pau Initiative for Neurodegeneration (SPIN) cohort using homebrew Single Molecule Array assays (Simoa). The DLB group was stratified into two groups with ("DLB + AD", n = 28) or without AD co-pathology ("pure DLB", n = 16) using our validated cut-off for the CSF phosphorylated tau (p-tau)/Aβ42 ratio. We used linear regression to test for group differences (adjusting for age) and association with AD biomarkers. We used standardized w-scores of the cognitive tests to analyze the association of the synaptic markers with cognitive performance. Results: CSF VAMP-2 and SNAP-25 levels correlated across all groups (r = 0.71-0.9, p < 0.001). Both proteins were decreased in pure DLB (p < 0.001, p = 0.01) but increased in DLB + AD (p = 0.01, p = 0.02) compared to controls and showed good accuracy to discriminate pure DLB from DLB + AD (AUC = 0.84, 0.85). Both proteins were associated with CSF p-tau and total tau (t-tau) across all groups (r = 0.49-0.88, p < 0.001), with the Aβ42/40 ratio in DLB + AD (r = 0.29-0.36, p < 0.001) and in AD (r = 0.12-0.23, p < 0.001) and with CSF neurofilament-light chain (NfL) in controls (r²=0.10-0.11, p < 0.001-0.01) and AD patients (r²=0.01-0.08, p = 0.01 - 0.001). SNAP-25 was associated with CSF NfL in the DLB + AD group (r²=0.15, p = 0.02). CSF VAMP-2 and SNAP-25 were associated with phonemic fluency in pure DLB (r = 0.39 - 0.28, p = 0.01-0.03) and SNAP-25 with the Clock drawing test and the MMSE in DLB + AD (adj.r = 0.15 - 0.14, p = 0.03-0.03) and DLB (adj.r = 0.12 - 0.08, p = 0.02-0.04) groups. Conclusions: CSF VAMP-2 and SNAP-25 are promising surrogate markers of synapse degeneration in DLB. However, care should be taken when interpreting CSF levels of these synaptic markers in DLB in light of the confounding effect of AD pathophysiological markers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Generational effects in Down syndrome, Enriched environment enhances functionality without reducing Alzheimer's disease risk

  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Sanjuan, Aída
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Arenaza-Urquijo, Eider|||0000-0001-7016-7576
  • Lleó, Alberto|||0000-0002-2568-5478
  • Bartrés-Faz, David|||0000-0001-6020-4118
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
Down syndrome (DS) is the leading cause of intellectual disability (ID) and a genetic form of Alzheimer's disease (AD). We wanted to assess whether generational changes have induced (1) milder ID with greater independence and (2) delayed AD diagnosis. We analyzed 681 asymptomatic DS to test generational effects on ID, functionality, and cognition. In 353 DS individuals with AD, we compared clinical diagnosis age by ID using analysis of variance. In addition, dementia diagnosis age was examined through a published meta-analysis. Our results indicate a generational shift toward a higher proportion of individuals with mild/moderate ID, greater intelligence, and autonomy. However, it was not paralleled by an ID-related delay in the age at AD onset in our cohort, or by generational delays reported over the past 35 years. The findings highlight notable generational improvements in DS, but no effects on the age at AD dementia diagnosis. OrderedDict([(u'list', OrderedDict([(u'@list-type', u'bullet'), (u'@id', u'alz70447-list-0001'), (u'list-item', [OrderedDict([(u'p', u'A generational effect has reduced the severity of intellectual disability in Down syndrome (DS).')]), OrderedDict([(u'p', u'Individuals with DS have increased autonomy and improved intellectual milestones.')]), OrderedDict([(u'p', u"The enriched environment has not delayed the age at Alzheimer's disease (AD) dementia in DS.")]), OrderedDict([(u'p', u'Further studies should confirm if cognitive reserve might delay AD in DS.'.